

4-(1,1,3,3-テトラメチルブチル)フェノールの rasH2 マウスを用いた  
強制経口投与による中期がん原性試験報告書

試験番号：0900, 0901

CAS No. 140 - 66 - 9

2019年3月5日

独立行政法人 労働者健康安全機構  
日本バイオアッセイ研究センター

目 次

標題	.....	i
試験目的	.....	i
試験法	.....	i
GLP 対応	.....	i
拡散防止措置及び動物福祉	.....	i
厚生労働省担当課	.....	ii
試験施設及び運営管理者	.....	ii
試験日程	.....	ii
試験関係者一覧	.....	iii
試資料の保管	.....	iii
試験責任者（最終報告書作成者）の署名、捺印及び日付	.....	iii
陳述書	.....	iv
信頼性保証証明書	.....	v
本文	.....	vi
TABLES	A 1~A 36、B 1~B 36	
FIGURES	A 1~A 6、B 1~B 6	
PHOTOGRAPHS	1~12	
APPENDICES	1-1~6	

## 標題

4-(1,1,3,3-テトラメチルブチル)フェノールの rasH2 マウスを用いた強制経口投与による中期がん原性試験

## 試験目的

4-(1,1,3,3-テトラメチルブチル)フェノールを遺伝子改変マウス (rasH2 マウス) に 26 週間強制経口投与し、そのがん原性を検索した。

## 試験法

本試験は「遺伝子改変動物を用いたがん原性試験による調査の基準」(平成 28 年度第 3 回発がん性評価ワーキンググループ: 2017 年 3 月 1 日厚生労働省) に準拠して実施した。

## GLP 対応

本試験は、「労働安全衛生規則第 34 条の 3 第 2 項の規定に基づく試験施設等が具備すべき基準 (安衛法 GLP)」(昭和 63 年 9 月 1 日労働省告示第 76 号、最終改正 平成 28 年 4 月 18 日厚生労働省告示第 208 号) に準拠し、OECD GLP (1997 年 11 月 26 日採択) を参考にして実施した。

## 拡散防止措置及び動物福祉

本試験は、「日本バイオアッセイ研究センターにおける遺伝子組換え生物使用実験安全管理規程」(平成 26 年 9 月 3 日制定、最終改正平成 28 年 4 月 1 日) 及び「実験動物の飼養及び保管並びに苦痛の軽減に関する基準」(平成 18 年 4 月 28 日環境省告示第 88 号、最終改正平成 25 年 8 月 30 日環境省告示第 84 号)、「厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針」(平成 18 年 6 月 1 日厚生労働省大臣官房厚生科学課長通知、最終改正平成 27 年 2 月 20 日厚生労働省大臣官房厚生科学課長通知)、「日本バイオアッセイ研究センターにおける動物実験等に関する規程」(平成 24 年 4 月 25 日制定、最終改正平成 28 年 4 月 1 日) を遵守した。

また、本試験は、日本バイオアッセイ研究センターの遺伝子組換え生物使用実験安全委員会 (承認番号 2017-04) 及び日本バイオアッセイ研究センターの動物実験委員会で審査された (承認番号 0183)。

厚生労働省担当課

厚生労働省労働基準局安全衛生部化学物質対策課  
東京都千代田区霞が関 1-2-2

試験施設及び運営管理者

独立行政法人 労働者健康安全機構  
日本バイオアッセイ研究センター  
所長 菅野 純  
神奈川県秦野市平沢 2445

試験日程

本試験は、動物導入日より雄を試験番号 0900、雌を試験番号 0901 として実施した。

試験開始日	2017年 9月 8日
動物導入日	2017年 9月 15日
群分け日	2017年 9月 25日 (0900) 2017年 9月 27日 (0901)
被験物質投与開始日	2017年 9月 26日 (0900) 2017年 9月 28日 (0901)
被験物質投与終了日	2018年 3月 26日、27日 (0900) 2018年 3月 28日、29日 (0901)
定期解剖日	2018年 3月 27日、28日 (0900) 2018年 3月 29日、30日 (0901)
試験終了日	2019年 3月 5日

4-(1,1,3,3-テトラメチルブチル)フェノールの rasH2 マウスを用いた  
強制経口投与による中期がん原性試験報告書

試験番号：0900, 0901

本文

## 本文目次

	頁
要約 .....	1
I 試験材料 .....	4
I-1 被験物質及び調製媒体 .....	4
I-1-1 被験物質の名称等 .....	4
I-1-2 被験物質の構造式及び分子量 .....	4
I-1-3 被験物質の物理化学的性状等 .....	4
I-1-4 被験物質の使用ロット等 .....	4
I-1-5 被験物質の製造量等 .....	5
I-1-6 被験物質の主な用途 .....	5
I-1-7 許容濃度等 .....	5
I-1-8 被験物質の調製媒体 .....	5
I-1-9 被験物質の同一性・安定性 .....	5
(1) 同一性 .....	5
(2) 安定性 .....	5
I-2 陽性対照物質及び調製媒体 .....	6
I-2-1 陽性対照物質の名称等 .....	6
I-2-2 陽性対照物質の構造式及び分子量 .....	6
I-2-3 陽性対照物質の物理化学的性状等 .....	6
I-2-4 陽性対照物質の使用ロット等 .....	6
I-2-5 陽性対照物質の調製媒体 .....	6
I-2-6 陽性対照物質の同一性・安定性 .....	7
(1) 同一性 .....	7
(2) 安定性 .....	7
I-3 試験動物 .....	7
II 試験方法 .....	8
II-1 投与 .....	8
II-1-1 投与経路 .....	8
II-1-2 投与方法及び投与期間 .....	8
II-1-3 投与用量 .....	8
II-1-4 投与方法、投与期間及び投与用量の設定理由 .....	8

II-1-5	被験物質及び陽性対照物質投与液の調製	10
II-1-6	被験物質及び陽性対照物質調製液の濃度及び均一性確認	10
II-1-7	被験物質及び陽性対照物質調製液の濃度安定性確認	10
II-2	動物管理	11
II-2-1	各群の使用動物数	11
II-2-2	群分け及び個体識別方法	11
II-2-3	飼育条件	11
(1)	飼育環境	11
(2)	飼料	12
(3)	飲水	12
II-3	観察・検査項目及び方法	12
II-3-1	動物の生死及び一般状態の観察	12
II-3-2	体重測定	12
II-3-3	摂餌量測定	12
II-3-4	尿検査	13
II-3-5	血液学的検査	13
II-3-6	血液生化学的検査	13
II-3-7	病理学的検査	13
(1)	肉眼的観察	13
(2)	臓器重量	13
(3)	病理組織学的検査	14
II-4	数値処理と統計方法	14
II-4-1	数値の取り扱いと表示	14
II-4-2	統計処理	14
III	試験成績-1 (被験物質投与群)	16
III-1	生死状況	16
III-2	一般状態	16
III-3	体重	16
III-4	摂餌量	17
III-5	尿検査	17
III-6	血液学的検査	17
III-7	血液生化学的検査	17
III-8	病理学的検査	18
III-8-1	肉眼的観察	18

III-8-2	臓器重量	18
III-8-3	病理組織学的検査	19
III-8-4	死因	20
IV	試験成績-2 (陽性対照物質投与群)	21
IV-1	生死状況	21
IV-2	一般状態	21
IV-3	体重	21
IV-4	摂餌量	21
IV-5	尿検査	22
IV-6	血液学的検査	22
IV-7	血液生化学的検査	22
IV-8	病理学的検査	23
IV-8-1	肉眼的観察	23
IV-8-2	臓器重量	23
IV-8-3	病理組織学的検査	23
IV-8-4	死因	25
V	考察及びまとめ	26
V-1	生存率、一般状態、体重、摂餌量	26
V-2	腫瘍性及び腫瘍関連病変	26
V-3	その他の影響	27
V-4	陽性対照物質投与群 ( <i>N</i> -Nitroso- <i>N</i> -methylurea: MNU) の評価	28
VI	結論	29
VII	文献	30
VIII	予見することのできなかつた試験の信頼性に影響を及ぼす疑いのある事態 及び試験計画書に従わなかつたこと	32



## 要約

4-(1,1,3,3-テトラメチルブチル)フェノールのがん原性を検索する目的で、遺伝子改変マウス (rasH2 マウス) を用いた強制経口投与による 26 週間の試験を実施した。

本試験は、媒体対照群、被験物質投与群 3 群及び陽性対照群 (*N*-Nitroso-*N*-methylurea) の計 5 群の構成で、媒体対照群と被験物質投与群は雌雄とも各 25 匹/群、陽性対照群は 15 匹/群 (計 230 匹) とした。被験物質は毎日 1 回の強制経口投与 (26 週間)、陽性対照物質は単回腹腔内投与とした。投与用量は、雌雄とも、0 (オリブ油)、50、100 及び 200 mg/kg BW とし、陽性対照物質は、雌雄とも 75 mg/kg BW とした。観察、検査として、一般状態の観察、体重及び摂餌量の測定、血液学的検査、血液生化学的検査、尿検査、解剖時の肉眼的観察、臓器重量測定及び病理組織学的検査を行った。

被験物質投与の結果、生存率は、雌雄とも媒体対照群と比較して差を認めなかった。一般状態では、雌雄とも被験物質投与の影響と考えられる異常所見は認められず、体重及び摂餌量も投与期間を通して媒体対照群との間に顕著な差は認めなかった。

腫瘍の発生は、雄で胃 (前胃) の扁平上皮乳頭腫の発生が、媒体対照群、50 mg/kg 群及び 100 mg/kg 群で 0 匹 (0%) に対し、200 mg/kg 群で 2 匹 (8%) にみられ、Peto 検定と Cochran-Armitage 検定で有意な増加を示した。扁平上皮癌は 200 mg/kg 群で 1 匹 (4%) に発生がみられ、扁平上皮乳頭腫と扁平上皮癌を合わせた発生 (200 mg/kg 群 3 匹、12%) は、Peto 検定と Cochran-Armitage 検定で有意な増加を示した。本試験における統計検定結果に加え、本試験に先立って実施した背景データ (無処置、50 匹) 及び文献データを参考に比較した結果、扁平上皮乳頭腫の試験単位での最大発生率 6.7% であり、200 mg/kg 群の扁平上皮乳頭腫の発生率 (8%) は、最大発生率を超えていた。また、扁平上皮癌の発生率 (4%) は、この範囲内であるものの試験単位での上限に近い発生率であった。以上の結果から、雄に認められた胃の扁平上皮乳頭腫、及び扁平上皮乳頭腫と扁平上皮癌を合わせた発生増加は、rasH2 マウスに対するがん原性を示す証拠 (some evidence) と考えられた。一方、雌では腫瘍の発生増加は認められなかった。

非腫瘍性病変は、雌雄の腎臓と雄の肝臓に影響がみられた。腎臓では慢性腎炎の発生増加が雄の 200 mg/kg 群、雌の 100 mg/kg 以上の群で認められ、その程度は雌で強かった。また、肝臓では、小葉中心性の肝細胞肥大の発生増加が雄の 200 mg/kg 群で認められた。

陽性対照物質投与群では、雄に皮膚の扁平上皮乳頭腫、肺の細気管支-肺胞上皮腺腫と細気管支-肺胞上皮癌を合わせた発生、胸腺の悪性リンパ腫、胃の扁平上皮乳頭腫、及び扁平上皮癌の発生がそれぞれ有意な増加を示した。雌では、胃の扁平上皮乳頭腫、及び扁平上皮乳頭腫と扁平上皮癌を合わせた発生、胸腺、脾臓及び全臓器の悪性リンパ腫の発生が有意な増加を示した。雌雄とも陽性対照物質投与による明らかな腫瘍の発生増加が認められ、本試験系の有効性が確認された。

以上のように、rasH2 マウスを用いて、4-(1,1,3,3-テトラメチルブチル)フェノールの 26 週間にわたる強制経口投与によるがん原性試験を行った結果、1) 雄 rasH2 マウスに対するがん原性を示す証拠が得られた (some evidence of carcinogenic activity)、2) 雌 rasH2 マウスに対するがん原性を示す証拠は得られなかった (no evidence of carcinogenic activity) と結論された。

4-(1,1,3,3-テトラメチルブチル)フェノールの中期がん原性試験における主な腫瘍発生  
(rasH2 マウス 雄)

投与用量 (mg/kg)		0	50	100	200	Peto 検定	Cochran- Armitage 検定
検査動物数		25	25	25	25		
肺 胃 (前胃)	細気管支-肺胞上皮腺腫	1	4	1	1		
	扁平上皮乳頭腫	0	0	0	2	↑	↑
	扁平上皮癌 <sup>#</sup>	0	0	0	1		
	扁平上皮乳頭腫 +扁平上皮癌 <sup>#</sup>	0	0	0	3	↑↑	↑↑
鼻腔 脾臓	血管腫	0	1	0	0		
	血管腫	1	0	0	0		
	血管肉腫 <sup>#</sup>	0	1	0	2		
	血管腫+血管肉腫 <sup>#</sup>	1	1	0	2		
小腸 膀胱	血管肉腫 <sup>#</sup>	0	0	0	1		
	血管腫	0	1	0	0		
胸膜	血管腫	0	0	0	1		
	血管肉腫 <sup>#</sup>	0	1	0	0		
	血管腫+血管肉腫 <sup>#</sup>	0	1	0	1		
全臓器	血管腫	1	2	0	1		
	血管肉腫 <sup>#</sup>	0	2	0	3		

4-(1,1,3,3-テトラメチルブチル)フェノールの中期がん原性試験における主な腫瘍発生  
(rasH2 マウス 雌)

投与用量 (mg/kg)		0	50	100	200	Peto 検定	Cochran- Armitage 検定
検査動物数		25	25	25	25		
肺	細気管支-肺胞上皮腺腫	3	3	2	0		
	細気管支-肺胞上皮癌 <sup>#</sup>	0	0	1	0		
	細気管支-肺胞上皮腺腫 +細気管支-肺胞上皮癌 <sup>#</sup>	3	3	3	0		
胃 (前胃)	扁平上皮癌 <sup>#</sup>	0	0	0	1		
鼻腔	血管腫	0	0	1	0		
脾臓	血管肉腫 <sup>#</sup>	0	0	1	0		
唾液腺	血管腫	1	0	0	0		
子宮	血管腫	0	0	1	0		
筋肉	血管腫	0	0	0	1		
腹膜	血管肉腫 <sup>#</sup>	0	1	0	0		
全臓器	血管腫	1	0	2	1		
	血管肉腫 <sup>#</sup>	0	1	1	0		

上段：上皮系腫瘍      下段：非上皮系腫瘍

#：悪性腫瘍

\*： $p \leq 0.05$  で有意

\*\*： $p \leq 0.01$  で有意

(Fisher 検定)

↑： $p \leq 0.05$  で有意増加

↑↑： $p \leq 0.01$  で有意増加

(Peto, Cochran-Armitage 検定)

↓： $p \leq 0.05$  で有意減少

↓↓： $p \leq 0.01$  で有意減少

(Cochran-Armitage 検定)

陽性対照 (*N*-Nitroso-*N*-methylurea) の中期がん原性試験における主な腫瘍発生  
(rasH2 マウス 雄)

投与用量 (mg/kg)		媒体対照 0	陽性対照 (MNU) 75
検査動物数		25	15
皮膚	扁平上皮乳頭腫	0	3 *
	肺		
	細気管支-肺胞上皮腺腫	1	4
	細気管支-肺胞上皮癌 <sup>#</sup>	0	1
	細気管支-肺胞上皮腺腫 +細気管支-肺胞上皮癌 <sup>#</sup>	1	5 *
胃 (前胃)	扁平上皮乳頭腫	0	15 **
	扁平上皮癌 <sup>#</sup>	0	4 *
	扁平上皮乳頭腫 +扁平上皮癌 <sup>#</sup>	0	15 **
胸腺	悪性リンパ腫 <sup>#</sup>	0	8 **

陽性対照 (*N*-Nitroso-*N*-methylurea) の中期がん原性試験における主な腫瘍発生  
(rasH2 マウス 雌)

投与用量 (mg/kg)		媒体対照 0	陽性対照 (MNU) 75
検査動物数		25	15
胃 (前胃)	扁平上皮乳頭腫	0	13 **
	扁平上皮癌 <sup>#</sup>	0	2
	扁平上皮乳頭腫 +扁平上皮癌 <sup>#</sup>	0	13 **
リンパ節	悪性リンパ腫 <sup>#</sup>	0	2
胸腺	悪性リンパ腫 <sup>#</sup>	0	6 **
脾臓	悪性リンパ腫 <sup>#</sup>	0	3 *
全臓器	悪性リンパ腫 <sup>#</sup>	0	11 **

上段：上皮系腫瘍

下段：非上皮系腫瘍

<sup>#</sup>：悪性腫瘍

\*：p ≤ 0.05 で有意

\*\*：p ≤ 0.01 で有意

(Fisher 検定)

## I 試験材料

## I-1 被験物質及び調製媒体

## I-1-1 被験物質の名称等 (文献 1)

名 称 : 4-(1,1,3,3-テトラメチルブチル)フェノール  
(4-(1,1,3,3-Tetramethylbutyl) phenol)


別 名 : 4-*tert*-Octylphenol

CAS No. : 140-66-9

被験物質番号 : 1238

## I-1-2 被験物質の構造式及び分子量 (文献 1)

構 造 式 :



化 学 式 : C<sub>14</sub>H<sub>22</sub>O

分 子 量 : 206.33

## I-1-3 被験物質の物理化学的性状等 (文献 1、2)

性 状 : 白色～ほとんど白色、結晶～粉末

融 点 : 83°C

沸 点 : 279°C

溶 解 性 : 水にほとんど溶けない、エタノール及びアセトンに溶けやすい

保 管 条 件 : 室温かつ遮光

## I-1-4 被験物質の使用ロット等

製 造 元 : 東京化成工業(株)

純 度 : 95.8% (東京化成工業(株) 試験成績書データ)

ロット番号 : Y8LQL

I-1-5 被験物質の製造量等（文献3）

製造、輸入量：22,524 t（平成28年度）

I-1-6 被験物質の主な用途（文献1）

樹脂、非イオン界面活性剤及びゴム添加剤の製造の中間体

I-1-7 許容濃度等

管理濃度：未設定

日本産業衛生学会：未設定

米国産業衛生専門家会議（ACGIH）：未設定

国際がん研究機関（IARC）：情報なし

ドイツ研究振興協会（DFG）：MAK value 0.5 ml/m<sup>3</sup>(ppm) (4.3 mg/m<sup>3</sup>)（文献4）

I-1-8 被験物質の調製媒体

名 称：オリーブ油（日本薬局方）

製 造 元：丸石製薬(株)

ロット番号：76121

保 管 条 件：室温かつ遮光

I-1-9 被験物質の同一性・安定性

(1) 同一性

被験物質の同一性は、赤外吸収スペクトルを赤外分光光度計（(株)島津製作所 IRAffinity-1）を用いて測定し、文献値（文献5）と比較することにより確認した。

被験物質の赤外吸収スペクトルは文献値と同じ波数にピークを示したことから、被験物質は4-(1,1,3,3-テトラメチルブチル)フェノールであることを確認した。

その結果は APPENDIX 1-1 に示す。

(2) 安定性

被験物質の安定性は、使用開始前及び使用終了後に赤外吸収スペクトルを赤外分光光度計（(株)島津製作所 IRAffinity-1）を用いて測定し、それぞれのデータを比較することにより確認した。

使用開始前と使用終了後の赤外吸収スペクトルに差はみられず、使用期間中の被験物質は安定であることを確認した。

その結果は APPENDIX 1-2 に示す。


## I-2 陽性対照物質及び調製媒体

### I-2-1 陽性対照物質の名称等 (文献 6)

名 称 : *N*-Nitroso-*N*-methylurea  
別 名 : *N*-Methyl-*N*-nitrosourea, MNU  
CAS No. : 684-93-5

### I-2-2 陽性対照物質の構造式及び分子量 (文献 6)

構 造 式 :



化 学 式 :  $C_2H_5N_3O_2$   
分 子 量 : 103.08

### I-2-3 陽性対照物質の物理化学的性状等 (文献 6, 7)

性 状 : 薄黄色固体  
融 点 : 119~124°C  
溶 解 性 : 水に可溶 (14400 mg/L, 24°C)  
保 管 条 件 : 冷蔵 (約 4°C) かつ遮光

### I-2-4 陽性対照物質の使用ロット等

製 造 元 : Sigma-Aldrich Co. LLC.  
ロット番号 : MKBQ7120V

### I-2-5 陽性対照物質の調製媒体

名 称 : 0.1M ぐえん酸緩衝液 pH4.5  
製 造 元 : 武藤化学(株)  
ロット番号 : 170829  
保 管 条 件 : 室温かつ遮光

## I-2-6 陽性対照物質の同一性・安定性

### (1) 同一性

陽性対照物質の同一性は、赤外吸収スペクトルを赤外分光光度計（(株)島津製作所 IRAffinity-1）を用いて測定し、文献値（文献 8, 9）と比較することにより確認した。

陽性対照物質の赤外吸収スペクトルパターンと主な結合官能基の吸収帯は文献値（文献 8）と一致した。また、確認のため、他の文献値（文献 9）との比較では、同じ各波数にピークを示したことから、陽性対照物質は *N*-Nitroso-*N*-methylurea であることを確認した。

その結果は APPENDIX 2-1 に示す。

### (2) 安定性

陽性対照物質の安定性は、使用開始前及び使用終了後に赤外吸収スペクトルを赤外分光光度計（(株)島津製作所 IRAffinity-1）を用いて測定し、それぞれのデータを比較することにより確認した。

使用開始前と使用終了後の赤外吸収スペクトルに差はみられず、使用期間中の陽性対照物質は安定であることを確認した。

その結果は APPENDIX 2-2 に示す。

## I-3 試験動物

動物は、日本クレア(株)（富士生育場）の Jic:CB6F1-Tg rasH2@Jcl マウス（SPF）の雌雄を使用した。

雌雄各 120 匹を 6 週齢で導入し、7 日間を検疫と馴化を兼ねて飼育し、その後群分けまで待機飼育した。発育順調で一般状態に異常を認めなかった動物から、体重値の中央値に近い雌雄各 115 匹（群分け時体重範囲、雄：22.3～27.2 g、雌：17.6～22.6 g）を選別し、試験に用いた。

中期がん原性試験に rasH2 マウスを選択した理由は、中期発がん性試験としての有用性が検証されていることによる（文献 10）。

## II 試験方法

### II-1 投与

#### II-1-1 投与経路

投与経路は経口投与とした。

#### II-1-2 投与方法及び投与期間

1日当たりの解剖可能な動物数を限定する理由から、媒体対照群及び被験物質投与群は、各群の先頭動物番号より14匹(A)と残り11匹(B)の2グループに分けた。

被験物質はオリブ油に溶解し、ディスポーザブル注射筒(ニプロ(株)製、1 mL)及びフレキシブル経口ゾンデ((有)フチガミ器械製、No.5202)を用いて、1日1回、26週間(雄:2017年9月26日~2018年3月26日(A)、27日(B)、雌:2017年9月28日~2018年3月28日(A)、29日(B))、毎日、12時から16時の時間帯に強制経口投与した。投与液量は5 mL/kg BWとし、直前に測定した体重に基づいて個体別に算出した。

陽性対照物質は0.1Mくえん酸緩衝液(pH 4.5)に溶解し、26Gまたは27G注射針を装着したディスポーザブル注射筒(ニプロ(株)製、1 mL)を用いて、群分け翌日(雄:2017年9月26日、雌:2017年9月28日)の12時から16時の時間帯に単回腹腔内投与した。投与液量は10 mL/kg BWとし、投与日の体重に基づいて個体別に算出した。

#### II-1-3 投与用量

被験物質は、雌雄ともに、50、100及び200 mg/kg BWの3段階(公比2)に設定した。また、媒体対照群としてオリブ油を投与する群を設けた。

陽性対照物質の投与用量は、雌雄ともに75 mg/kg BWとした。

#### II-1-4 投与方法、投与期間及び投与用量の設定理由

被験物質の投与方法を決定するために、C57BL/6Jマウスを用いて2週間混餌投与試験(試験番号4592)を実施した。その結果、混餌投与方法では対照群を含む全群に多量の餌こぼしがあり、高用量では摂餌忌避が認められた。一方、被験物質はオリブ油に溶解し、投与液中で8日間安定であることから、投与方法はオリブ油を媒体とする強制経口投与方法を選択した。

投与期間は、「遺伝子改変動物を用いたがん原性試験による調査の基準」(文献11)に従い、26週間とした。

本試験の投与用量は、4週間毒性試験(試験番号0890)の結果を基に設定した。4週間毒性試験では、雌雄のrasH2マウス(non-Tg)を用いて、1群当たり各10匹の動物に



0 (オリブ油)、30、100、200 及び 300 mg/kg BW の用量で、毎日、4 週間強制経口投与した。

その結果、雌雄とも全群で動物の死亡及び一般状態に毒性症状はみられなかったが、雌雄の 300 mg/kg 群では 2~3 週目にかけて餌こぼしが多い傾向が観察された。体重は媒体対照群と比較し、雌雄とも投与群でやや高値傾向で推移した。被験物質投与による影響は、主に腎臓と肝臓に認められ、造血系への影響も示唆された。

腎臓への影響として、剖検観察では 300 mg/kg 群の雌雄に腎臓の淡色化が各 4 例みられ、200 mg/kg 以上の群の雌で腎臓実重量と体重比が高値であった。病理組織学的検査では、近位尿細管の再生が 200 mg/kg 以上の群の雌雄（全例）、100 mg/kg 群の雄（3 例）に認められ、その程度は投与用量に対応して広範囲にみられた。また、尿細管腔内には顆粒状円柱の形成が 200 mg/kg 以上の群の雌雄、100 mg/kg 群の雄にみられた。血液生化学検査では、尿素窒素の高値が雄の 300 mg/kg 群で認められた。

肝臓への影響として、100 mg/kg 以上の群の雌雄で肝臓実重量と体重比の高値がみられ、病理組織学的検査では、雄の 200 mg/kg 以上の群に小葉中心性の肝細胞肥大及び単細胞壊死が認められた。また、血液生化学検査では、肝臓の障害性変化、脂質代謝等への影響を示唆する変化（雌雄に総コレステロール、トリグリセライド、リン脂質及び  $\gamma$ -GTP の高値、雄に ALT、LDH 及び ALP の高値等）認められた。これらの影響は雌雄とも概ね 100 mg/kg 以上の群でみられた。

造血系への影響を示唆する変化として、血液学的検査では 200 mg/kg 以上の群の雌雄に網赤血球比の高値、雄に血小板数の高値、雌に好中球比の低値とリンパ球比の高値が認められた。また、雌の 300 mg/kg 群では白血球数が高値であった。200 mg/kg 以上の群の雄と 300 mg/kg 群の雌に脾臓実重量と体重比の高値がみられ、病理組織学的検査では、200 mg/kg 以上の群の雌雄で髄外造血の亢進がみられた。

以上の結果から、4-(1,1,3,3-テトラメチルブチル)フェノールの毒性標的器官は主に腎臓、肝臓及び造血系であると考えられた。この中で腎臓の雌雄 300 mg/kg 群に認められた近位尿細管の再生像は広範囲に認められ、尿細管への傷害も広範囲に起きたと判断できることから、300 mg/kg は 26 週間の投与には耐えられないと考えられる。一方、近位尿細管の再生像は 200 mg/kg 群でも全例にみられるものの、その程度は減弱していることから、200 mg/kg は 26 週間の投与に耐えうる用量であると判断した。したがって、本試験では、高用量を 200 mg/kg BW に設定し、公比 2 で除して中用量を 100 mg/kg BW、低用量を 50 mg/kg BW とした。

陽性対照物質の投与用量は、ILSI/HESI 国際共同検証試験（文献 10）の方法を参考に、雌雄ともに 75 mg/kg BW とした。

## II-1-5 被験物質及び陽性対照物質投与液の調製

被験物質投与液の調製は、秤量した被験物質にオリブ油を加え、マグネチックスターラーで攪拌・混合して溶解し、10、20 及び 40 mg/mL の濃度の投与液を調製した。調製した投与液は、調製液中の被験物質濃度の安定性が確認された 8 日間以内に使用した。調製後の投与液は、投与日まで冷蔵庫（約 4℃、遮光）内で保管した。

陽性対照物質投与液の調製は、秤量した陽性対照物質に 0.1M くえん酸緩衝液（pH 4.5）を加え、マグネチックスターラーで攪拌・混合して溶解し、7.5 mg/mL の濃度の投与液を調製した。なお、調製は投与日に用時調製とした。

## II-1-6 被験物質及び陽性対照物質調製液の濃度及び均一性確認

被験物質調製液は、調製時の濃度及び均一性確認を全調製濃度について行った。初回調製時及び 13 週目に調製容器内から各 7 点サンプリングし、高速液体クロマトグラフ（(株)島津製作所 LC-10）を用いて被験物質濃度を測定することで確認した。

陽性対照物質調製液は、調製時の濃度確認を行った。初回調製時に調製容器内から 3 点サンプリングし、高速液体クロマトグラフ（(株)島津製作所 LC-10）を用いて陽性対照物質濃度を測定することで確認した。

被験物質調製液の濃度は APPENDIX 3-1、均一性は APPENDIX 3-2 に示す。また、陽性対照物質調製液の濃度は APPENDIX 4 示す。

被験物質調製液の平均濃度は、設定濃度に対して 95.8～100%の範囲にあった。また、均一性は各調製濃度ともばらつきが少なかった。従って、被験物質調製液は設定濃度に対して正確に調製されたことを確認した。

陽性対照物質調製液の平均濃度は、設定濃度に対して 106%及び 99.9%であり、陽性対照物質調製液は設定濃度に対して正確に調製されたことを確認した。

## II-1-7 被験物質及び陽性対照物質調製液の濃度安定性確認

被験物質調製液の濃度安定性は、被験物質調製液（0.6 mg/mL 及び 60 mg/mL：投与用量として 3 mg/kg BW 及び 300 mg/kg BW に相当）を冷蔵保管（約 4℃）し、調製後 8 日間の濃度は安定であることを確認した（試験番号：8042）。本試験はその濃度範囲で実施するため濃度安定性確認は行わなかった。

陽性対照物質調製液の濃度安定性は、投与日に用時調製するため行わなかった。

濃度安定性確認の結果は APPENDIX 5 に示す。

## II-2 動物管理

### II-2-1 各群の使用動物数

媒体対照群 1 群、被験物質投与群 3 群及び陽性対照群の計 5 群を設け、1 群当たりの動物数は、媒体対照群と被験物質投与群は雌雄各 25 匹、陽性対照群は雌雄各 15 匹の動物を用いた。

群名称	動物数 (動物番号)	
	雄	雌
媒体対照群	25 匹 (1001~1025)	25 匹 (2001~2025)
50 mg/kg 群	25 匹 (1101~1125)	25 匹 (2101~2125)
100 mg/kg 群	25 匹 (1201~1225)	25 匹 (2201~2225)
200 mg/kg 群	25 匹 (1301~1325)	25 匹 (2301~2325)
陽性対照群	15 匹 (1401~1415)	15 匹 (2401~2415)

### II-2-2 群分け及び個体識別方法

供試動物の各群への割り当ては、一般状態及び体重の推移に異常を認めなかった動物を体重の重い順より各群に 1 匹ずつ割り当て、二巡目からは各群の動物の体重の合計を比較して、小さい群より順に体重の重い動物を割り当てることにより、群間の体重の偏りを小さくする群分け方法 (適正層別方式) により実施した (文献 12)。

動物の個体識別は、検疫期間及び馴化期間では尾に油性マーカーによる色素塗布、投与期間では耳パンチにより行った。また、ケージには個体識別番号を記したラベルを付した。

なお、動物はバリア区域内の独立した室 (雄 202 室、雌 203 室) に収容し、室の扉に試験番号、試験動物、飼育期間及び遺伝子改変動物飼育中を表示し、他試験及び異種動物と区別した。

### II-2-3 飼育条件

#### (1) 飼育環境

飼育室の環境条件及び使用したケージ等を以下に示した。飼育室の温度と湿度は、実測値 (平均値±標準偏差) を < > 内に示した。

温度： 23±2℃ <202 室：22.8±0.2℃、203 室：22.6±0.3℃>

湿度： 55±15% <202 室：54±2%、203 室：56±1%>

明暗サイクル： 12 時間点灯(8:00~20:00)/12 時間消灯(20:00~8:00)

換気回数： 15~17 回/時

ケージへの動物の収容方法： 個別飼育

ケージの材質・形状・寸法等：

ステンレス製 2 連網ケージ (112(W)×212(D)×120(H) mm/匹)

飼育器材の滅菌方法： 飼育器材（ラック、ケージ、餌箱、給水ノズル、作業台車、トレイ等）は、オートクレーブを用いて滅菌（約 120℃、15 分以上）した。

## (2) 飼料

飼料は、全飼育期間を通して、オリエンタル酵母工業(株) 製造の CRF-1 固型（30kGy- $\gamma$  線照射滅菌飼料）を自由摂取させた。ただし、定期解剖前日（投与最終日）の夕方からは絶食させた。

試験に使用した飼料中の栄養成分と夾雑物については、オリエンタル酵母工業(株) から分析データを入手し、確認後保管した。

## (3) 飲水

飲水は、全飼育期間を通して、市水（神奈川県秦野市水道局供給）をフィルターろ過した後、紫外線照射し、自動給水ノズルから自由摂取させた。

飲水の水質は、動物試験施設として定期的（年 2 回）に実施している水道水の検査において、水道法に定められている水質基準に適合していることを確認した。

## II-3 観察・検査項目及び方法

### II-3-1 動物の生死及び一般状態の観察

全動物について、毎日、投与前及び投与後に生死及び一般状態を観察した。また、定期解剖日は飼育室からの搬出時に一般状態を観察した。

### II-3-2 体重測定

全動物について、週 1 回、投与前に体重測定を行った。また、定期解剖日には絶食後の体重（搬出時体重）を測定した。

死亡及び瀕死状態の動物は、飼育室からの搬出時に体重を測定した。

### II-3-3 摂餌量測定

全動物について、週 1 回、給餌量及び残餌量を測定し、その値から 1 匹 1 日当たりの摂餌量を算出した。

#### II-3-4 尿検査

投与最終週に生存した動物のうち自然排尿した動物の新鮮尿について、尿試験紙（ウロラブスティックス、シーメンスヘルスケア・ダイアグノスティクス社）を用いて、下記の項目について検査を行った。

検査項目：pH、蛋白、グルコース、ケトン体、潜血、ウロビリノーゲン

#### II-3-5 血液学的検査

定期解剖時に生存していた採血可能な動物について、剖検直前にイソフルラン麻酔下で開腹し、腹大動脈から EDTA-2 カリウム入り採血管に採血した血液を用いて、下記の項目について検査を行った。検査方法は APPENDIX 6 に示す。

検査項目：赤血球数、ヘモグロビン濃度、ヘマトクリット値、平均赤血球容積(MCV)、平均赤血球ヘモグロビン量(MCH)、平均赤血球ヘモグロビン濃度(MCHC)、血小板数、網赤血球比、白血球数、白血球分類

#### II-3-6 血液生化学的検査

定期解剖時に生存していた採血可能な動物について、剖検直前にイソフルラン麻酔下で開腹し、腹大動脈よりヘパリンリチウム入り採血管に採血した血液を遠心分離し、得られた血漿を用いて、下記の項目について検査を行った。検査方法は APPENDIX 6 に示す。

検査項目：総蛋白、アルブミン、A/G 比、総ビリルビン、グルコース、総コレステロール、トリグリセライド、リン脂質、AST、ALT、LDH、ALP、 $\gamma$ -GTP、CK、尿素窒素、ナトリウム、カリウム、クロール、カルシウム、無機リン

#### II-3-7 病理学的検査

##### (1) 肉眼的観察

全動物について肉眼的に観察を行った。なお、定期解剖動物はイソフルラン麻酔下で腹大動脈より採血後、腹大動脈を切断し、放血することで安楽死させた。

##### (2) 臓器重量

定期解剖時まで生存した動物について、下記に示した臓器の湿重量（臓器実重量）を測定した。また、各臓器の湿重量の搬出時体重に対する百分率（臓器重量体重比）を算出した。

測定臓器：胸腺、副腎、精巣、卵巣、心臓、肺、腎臓、脾臓、肝臓、脳

### (3) 病理組織学的検査

全動物について下記に示した器官、組織を摘出し、10%中性リン酸緩衝ホルマリン溶液で固定後、パラフィン包埋、薄切、ヘマトキシリン・エオジン染色を行い、光学顕微鏡で病理組織学的に検査した。

なお、鼻腔については切歯の後端（レベル1）、切歯乳頭（レベル2）、第一臼歯の前端（レベル3）の3ヶ所（文献13）で切り出し（横断）、検査した。

検査器官・組織：皮膚、鼻腔、鼻咽頭、喉頭、気管、肺、骨髄（大腿骨）、リンパ節（腋窩、鼠径等）、胸腺、脾臓、心臓、舌、唾液腺、食道、胃、小腸（十二指腸を含む）、大腸、肝臓、胆嚢、膵臓、腎臓、膀胱、下垂体、甲状腺、上皮小体、副腎、精巣、精巣上体、精嚢、前立腺、卵巣、子宮、膣、乳腺、脳、脊髄、末梢神経（坐骨神経）、眼球、ハーダー腺、筋肉、骨（胸骨、大腿骨）、肉眼的に変化のみられた器官及び組織

## II-4 数値処理と統計方法

### II-4-1 数値の取り扱いと表示

各数値データは測定機器の精度に合わせて表示した。

体重はgを単位とし、小数点以下第1位まで測定し、表示した。

摂餌量はgを単位とし、給餌量及び残餌量を小数点以下第1位まで測定し、給餌量値から残餌量値を減じて摂餌量とした。この値を測定期間の日数で除し、1日当たりの平均摂餌量を算出し、小数点以下第2位を四捨五入して小数点以下第1位までを表示した。

臓器実重量はgを単位とし、小数点以下第3位まで測定し、表示した。臓器重量体重比は臓器実重量値を搬出時体重で除し、パーセント単位で小数点以下第4位を四捨五入し、小数点以下第3位までを表示した。

血液学的検査、血液生化学的検査はAPPENDIX 6に示した単位と桁数により表示した。

なお、各数値データの平均値及び標準偏差は、上記に示した桁数と同様になるよう四捨五入を行い表示した。

### II-4-2 統計処理

各群の有効動物数は、供試動物より事故等の理由で外された動物数を減じた動物数とした。

病理組織学的検査は、臓器ごとに検査不能臓器を除いた臓器数、その他の検査及び測定は、実施できた動物数を検査（測定）数とした。

体重、摂餌量、血液学的検査、血液生化学的検査及び臓器重量の測定値は、媒体対照群を基準群として、まずBartlett法により等分散の予備検定を行い、その結果が等分散の場合には一元配置分散分析を行い、群間に有意差が認められた場合はDunnnettの多重比較により平均値の検定を行った。また、分散の等しくない場合には各群を通して測定値を順位化し

て、Kruskal-Wallis の順位検定を行い、群間に有意差が認められた場合には Dunnett 型の多重比較を行った。

なお、媒体対照群と陽性対照群間の有意差検定は、まず F 検定を用い、等分散である場合は Student の  $t$  検定を行い、等分散でない場合は Aspin-Welch の  $t$  検定を行った。

病理組織学的検査のうち非腫瘍性病変については、所見のみられなかった動物をグレード 0、所見のみられた動物は、その所見の程度及び範囲などを基準にしてグレード 1~4 に分け、 $\chi^2$  検定を行った。また、尿検査についても媒体対照群と各投与群間で  $\chi^2$  検定を行った。

腫瘍性病変については、各臓器の腫瘍ごとに、各群ごとの総担腫瘍臓器数について、Peto 検定、Cochran-Armitage 検定、Fisher 検定を行った。なお、媒体対照群と陽性対照群間は、各群の総担腫瘍臓器数について Fisher 検定を行った。

各検定は 5%の有意水準で両側検定を行い、検定結果を表示する場合には 5%及び 1%の有意水準の表示を行った。

### Ⅲ 試験成績-1 (被験物質投与群)

#### Ⅲ-1 生死状況

生死状況を TABLE A 1, 2 及び FIGURE A 1, 2 に示す。

—雄—

被験物質投与による生存率への影響は認められなかった。

各群の 26 週における生存動物数 (生存率) は、媒体対照群 : 25 匹 (100%)、50 mg/kg 群 : 24 匹 (96%)、100 mg/kg 群 : 25 匹 (100%)、200 mg/kg 群 : 23 匹 (92%) であった。

—雌—

被験物質投与による生存率への影響は認められなかった。

各群の 26 週における生存動物数 (生存率) は、媒体対照群 : 23 匹 (92%)、50 mg/kg 群 : 24 匹 (96%)、100 mg/kg 群 : 25 匹 (100%)、200 mg/kg 群 : 24 匹 (96%) であった。

#### Ⅲ-2 一般状態

一般状態の観察結果を TABLE A 3, 4 に示す。

—雌雄—

投与期間を通して、被験物質投与の影響と考えられる異常所見は認められなかった。

#### Ⅲ-3 体重

体重の推移を TABLE A 5~8 及び FIGURE A 3, 4 に示す。

—雄—

投与期間を通して媒体対照群との間に顕著な差は認められなかった。

投与群の最終体重は媒体対照群に対して、50 mg/kg 群 : 98 %、100 mg/kg 群 : 101 %、200 mg/kg 群 : 101 %であった。

—雌—

投与期間を通して媒体対照群との間に顕著な差は認められなかった。

投与群の最終体重は媒体対照群に対して、50 mg/kg 群 : 97 %、100 mg/kg 群 : 99 %、200 mg/kg 群 : 97 %であった。



### Ⅲ-4 摂餌量

摂餌量の推移を TABLE A 9~12 及び FIGURE A 5, 6 に示す。

—雄—

投与期間を通して媒体対照群との間に顕著な差は認められなかった。

投与期間を通しての1匹当たりの1日平均摂餌量は、媒体対照群：3.3 g、50 mg/kg 群：3.1 g、100 mg/kg 群：3.3 g、200 mg/kg 群：3.4 g であった。

—雌—

投与期間を通して媒体対照群との間に顕著な差は認められなかった。

投与期間を通しての1匹当たりの1日平均摂餌量は、媒体対照群：2.9 g、50 mg/kg 群：2.9 g、100 mg/kg 群：2.9 g、200 mg/kg 群：2.9 g であった。

### Ⅲ-5 尿検査

尿検査の結果を TABLE A 13, 14 に示す。

—雌雄—

100 mg/kg 以上の群で尿蛋白の陽性度の減少、及びケトン体の陽性例の減少が認められた。

### Ⅲ-6 血液学的検査

血液学的検査の結果を TABLE A 15, 16 に示す。

—雄—

被験物質投与の影響と考えられる影響は認められなかった。

なお、200 mg/kg 群で MCV、網赤血球比及び好塩基球比が、統計学的に有意な高値を示したが、ごく軽度の変化であり、毒性学的意義は乏しいと考えられた。

—雌—

100 mg/kg 以上の群でヘモグロビン濃度の低値、200 mg/kg 群で赤血球数、ヘマトクリット値、MCH 及び MCHC の低値が認められた。

なお、100 mg/kg 群で単球比が統計学的に有意な高値を示したが、投与用量に対応した変化ではないことから、偶発的変動と考えられた。

### Ⅲ-7 血液生化学的検査

血液生化学的検査の結果を TABLE A 17, 18 に示す。

—雄—

50 mg/kg 以上の群で総コレステロール、トリグリセライド、リン脂質及び ALP の高値、100 mg/kg 以上の群でグルコースの高値、並びに A/G 比の低値、200 mg/kg 群で尿素窒素

及びカルシウムの高値、並びにアルブミン及び総ビリルビンの低値が認められた。

—雌—

50 mg/kg 以上の群で ALP 及び CK の高値、100 mg/kg 以上の群で総コレステロール及びリン脂質の高値、並びに A/G 比の低値、200 mg/kg 群で総蛋白、アルブミン、トリグリセライド、 $\gamma$ -GTP、尿素窒素、カルシウム及び無機リンの高値、並びに総ビリルビン、ナトリウム及びクロールの低値が認められた。

### III-8 病理学的検査

#### III-8-1 肉眼的観察

解剖時の剖検観察所見を TABLE A 19, 20 に示す。

—雄—

前胃の結節が媒体対照群 0 匹に対して 200 mg/kg 群で 3 匹に認められた。また、腎臓の顆粒状変化が媒体対照群 0 匹に対して 200 mg/kg 群で 3 匹に認められた。

—雌—

前胃の結節が媒体対照群 0 匹に対して 200 mg/kg 群で 1 匹に認められた。また、腎臓の淡色化が媒体対照群 0 匹に対して 200 mg/kg 群で 16 匹に、腎臓の顆粒状変化が媒体対照群 0 匹に対して 200 mg/kg 群で 10 匹に認められた。

#### III-8-2 臓器重量

定期解剖時に測定した臓器の実重量を TABLE A 21, 22 に、体重比を TABLE A 23, 24 に示す。

—雄—

50 mg/kg 以上の群で肝臓の体重比の高値、100 mg/kg 以上の群で肝臓の実重量の高値、200 mg/kg 群で脾臓の実重量と体重比の高値、並びに胸腺の実重量と体重比の低値が認められた。なお、腎臓の体重比が 100 mg/kg 群で低値を示したが、投与用量に対応した変化ではなかった。

—雌—

50 mg/kg 以上の群で胸腺の実重量の低値あるいは低値傾向、100 mg/kg 以上の群で腎臓の体重比の高値、200 mg/kg 群で脾臓の実重量と体重比、肝臓の体重比の高値が認められた。

その他、200 mg/kg 群で心臓の実重量の低値及び脳の体重比の高値がみられたが、200 mg/kg 群の搬出時体重は媒体対照群と比較して低値であり、それに起因するものと考えられた。

### Ⅲ-8-3 病理組織学的検査

腫瘍性病変は、腫瘍の種類別の発生数を TABLE A 25, 26 に、統計解析 (Peto 検定、Cochran-Armitage 検定、Fisher 検定) の結果を TABLE A 27, 28 に、担腫瘍動物数と発生腫瘍数を TABLE A 29, 30 に、転移性病変を TABLE A 31, 32 に示す。また、非腫瘍性病変は TABLE A 33, 34 に示す。さらに、病理組織所見の代表例を PHOTOGRAPH 1~6 に示す。

—雄—

#### 1) 腫瘍性病変

<胃 (前胃) >

扁平上皮乳頭腫の発生は、媒体対照群、50 mg/kg 群及び 100 mg/kg 群で 0 匹 (0%) に対し、200 mg/kg 群で 2 匹 (8%) に認められ、Peto 検定 (有病率法) と Cochran-Armitage 検定で有意な増加を示した。扁平上皮癌の発生は、200 mg/kg 群で 1 匹 (4%) にのみ発生がみられた。さらに、扁平上皮乳頭腫と扁平上皮癌を合わせた発生は、媒体対照群、50 mg/kg 群及び 100 mg/kg 群で 0 匹 (0%) に対し、200 mg/kg 群で 3 匹 (12%) に認められ、Peto 検定 (有病率法、死亡率法+有病率法) と Cochran-Armitage 検定で有意な増加を示した。

担腫瘍動物数は、媒体対照群 2 匹 (8%) に対し、50 mg/kg 群 7 匹 (28%)、100 mg/kg 群 1 匹 (4%)、200 mg/kg 群 7 匹 (28%) であった。

#### 2) 非腫瘍性病変

<腎臓>

慢性腎炎の発生増加が 200 mg/kg 群で認められ、病変の程度は軽度から中等度であった。なお、100 mg/kg 群でも 1 匹に発生がみられた。慢性腎炎は、ネフロン単位で変性・壊死が認められ、尿細管の再生や線維化が認められた。

<肝臓>

小葉中心性の肝細胞肥大の発生増加が 200 mg/kg 群で認められ、病変の程度はいずれも軽度であった。なお、100 mg/kg 群でも 1 匹に発生がみられた。

—雌—

#### 1) 腫瘍性病変

被験物質投与による腫瘍の発生増加は認められなかった。

担腫瘍動物数は、媒体対照群 5 匹 (20%) に対し、50 mg/kg 群 4 匹 (16%)、100 mg/kg 群 6 匹 (24%)、200 mg/kg 群 2 匹 (8%) であった。

2) 非腫瘍性病変

<腎臓>

慢性腎炎の発生増加と程度の増強が 100 mg/kg 群と 200 mg/kg 群で認められ、病変の程度は 100 mg/kg 群が軽度から中等度、200 mg/kg 群が中等度から重度であった。慢性腎炎は、ネフロン単位で変性・壊死が認められ、尿細管の再生や線維化が認められた。

III-8-4 死因

病理学的にみた死亡／瀕死の原因を TABLE A 35, 36 に示す。

—雌雄—

投与群に特定の病変あるいは腫瘍による死亡の増加は認められなかった。

#### IV 試験成績-2 (陽性対照物質投与群)

##### IV-1 生死状況

生死状況を TABLE B 1, 2 及び FIGURE B 1, 2 に示す。

—雄—

陽性対照群の死亡は 7 匹みられ、媒体対照群と比較して生存率の低下が認められた。

26 週における生存動物数 (生存率) は、媒体対照群 : 25 匹 (100%)、陽性対照群 : 8 匹 (53.3%) であった。

—雌—

陽性対照群の死亡は 11 匹みられ、媒体対照群と比較して生存率の低下が認められた。

26 週における生存動物数 (生存率) は、媒体対照群 : 23 匹 (92%)、陽性対照群 : 4 匹 (26.7%) であった。

##### IV-2 一般状態

一般状態の観察結果を TABLE B 3, 4 に示す。

—雌雄—

投与期間を通して、陽性対照物質投与の影響と考えられる異常所見の増加は認められなかった。

##### IV-3 体重

体重の推移を TABLE B 5~8 及び FIGURE B 3, 4 に示す。

—雄—

陽性対照群では、飼育 5 週目以降多くの週で体重の高値が認められた。

陽性対照群の最終体重は媒体対照群に対して 104 % であった。

—雌—

陽性対照群では、飼育 5 週目以降多くの週で体重の高値が認められた。

陽性対照群の最終体重は媒体対照群に対して 104 % であった。

##### IV-4 摂餌量

摂餌量の推移を TABLE B 9~12 及び FIGURE B 5, 6 に示す。

—雄—

陽性対照群では、投与期間を通して摂餌量の高値が認められた。

投与期間を通しての 1 匹当たりの 1 日平均摂餌量は、媒体対照群 : 3.3 g、陽性対照群 : 4.0 g であった。

—雌—

陽性対照群では、投与期間を通して摂餌量の高値が認められた。

投与期間を通しての1匹当たりの1日平均摂餌量は、媒体対照群：2.9 g、陽性対照群：3.6 gであった。

#### IV-5 尿検査

尿検査の結果を TABLE B 13, 14 に示す。

—雄—

陽性対照物質投与による影響は認められなかった。

—雌—

尿蛋白の陽性例の増加が認められた。

#### IV-6 血液学的検査

血液学的検査の結果を TABLE B 15, 16 に示す。

—雄—

陽性対照群で好中球比の高値、並びにリンパ球比の低値が認められた。

—雌—

陽性対照群でリンパ球比の低値が認められた。

#### IV-7 血液生化学的検査

血液生化学的検査の結果を TABLE B 17, 18 に示す。

—雄—

陽性対照群で AST、ALT、LDH、尿素窒素、カルシウム及び無機リンの高値が認められた。

なお、ALP が統計学的に有意な低値を示したが、低下性の変化であることから毒性学的意義は乏しいと考えられた。

—雌—

陽性対照群で無機リンの高値、並びに A/G 比の低値が認められた。

なお、ALP が統計学的に有意な低値を示したが、低下性の変化であることから毒性学的意義は乏しいと考えられた。

#### IV-8 病理学的検査

##### IV-8-1 肉眼的観察

解剖時の剖検観察所見を TABLE B 19, 20 に示す。

—雄—

媒体対照群と比較して、皮膚及び前胃の結節、リンパ節及び脾臓の腫大、胸腔の胸水貯留の発生が多く認められた。

—雌—

媒体対照群と比較して、前胃の結節、リンパ節、脾臓及び肝臓の腫大、縦隔の腫瘤、肺の赤色斑の発生が多く認められた。

##### IV-8-2 臓器重量

定期解剖時に測定した臓器の実重量を TABLE B 21, 22 に、体重比を TABLE B 23, 24 に示す。

—雄—

陽性対照群で肝臓の実重量と体重比、心臓の実重量の高値が認められた。

—雌—

陽性対照群で心臓及び腎臓の体重比の高値が認められた。

##### IV-8-3 病理組織学的検査

腫瘍性病変は、腫瘍の種類別の発生数を TABLE B 25, 26 に、統計解析 (Fisher 検定) の結果を TABLE B 27, 28 に、担腫瘍動物数と発生腫瘍数を TABLE B 29, 30 に、転移性病変を TABLE B 31, 32 に示す。また、非腫瘍性病変は TABLE B 33, 34 に示す。さらに、病理組織所見の代表例を PHOTOGRAPH 7~12 に示す。

—雄—

###### 1) 腫瘍性病変

<皮膚>

扁平上皮乳頭腫の発生は、媒体対照群で 0 匹 (0%) に対し、陽性対照群で 3 匹 (20%) に認められ、Fisher 検定で有意な増加を示した。

<肺>

細気管支-肺胞上皮腺腫と細気管支-肺胞上皮癌を合わせた発生は、媒体対照群で 1 匹 (4%) に対し、陽性対照群で 5 匹 (33.3%) に認められ、Fisher 検定で有意な増加を示した。

<胸腺>

悪性リンパ腫の発生は、媒体対照群で 0 匹 (0%) に対し、陽性対照群で 8 匹 (53.3%)

に認められ、Fisher 検定で有意な増加を示した。

<胃（前胃）>

扁平上皮乳頭腫の発生は、媒体対照群で 0 匹 (0%) に対し、陽性対照群で 15 匹 (100%)、扁平上皮癌の発生は、媒体対照群で 0 匹 (0%) に対し、陽性対照群で 4 匹 (26.7%) に認められ、それぞれ Fisher 検定で有意な増加を示した。

その他、白血病細胞浸潤（悪性リンパ腫転移）が多くの臓器に認められた。なお、担腫瘍動物数は、媒体対照群 2 匹 (8%) に対し、陽性対照群 15 匹 (100%) であった。

## 2) 非腫瘍性病変

<胃（前胃）>

統計学的に有意でないものの、前胃の扁平上皮過形成の発生が陽性対照群で増加し、病変の程度はいずれも軽度であった。

—雌—

### 1) 腫瘍性病変

<胃（前胃）>

扁平上皮乳頭腫の発生は、媒体対照群で 0 匹 (0%) に対し、陽性対照群で 13 匹 (86.7%)、扁平上皮癌の発生は、媒体対照群で 0 匹 (0%) に対し、陽性対照群で 2 匹 (13.3%) に認められた。扁平上皮乳頭腫、及び扁平上皮乳頭腫と扁平上皮癌を合わせた発生は Fisher 検定で有意な増加を示した。

<リンパ節、胸腺、脾臓>

悪性リンパ腫の発生は、いずれも媒体対照群で 0 匹 (0%) に対し、陽性対照群でリンパ節に 2 匹 (13.3%)、胸腺に 6 匹 (40.0%)、脾臓に 3 匹 (20.0%)、全臓器では 11 匹 (73.3%) に認められた。そのうち、胸腺、脾臓及び全臓器の発生が Fisher 検定で有意な増加を示した。

その他、白血病細胞浸潤（悪性リンパ腫転移）が多くの臓器に認められた。なお、担腫瘍動物数は、媒体対照群 5 匹 (20%) に対し、陽性対照群 15 匹 (100%) であった。

## 2) 非腫瘍性病変

<胃（前胃）>

前胃の扁平上皮過形成の発生増加が陽性対照群で認められ、病変の程度はいずれも軽度であった。

<副腎>

紡錘形細胞過形成の発生減少が陽性対照群で認められた。



#### IV-8-4 死因

病理学的にみた死亡／瀕死の原因を TABLE B 35, 36 に示す。

—雄—

陽性対照群では 7 匹の死亡がみられ、死因は全て悪性リンパ腫であった。

—雌—

陽性対照群では 11 匹の死亡がみられ、死因は 10 匹が悪性リンパ腫、1 匹が胃の腫瘍であった。

## V 考察及びまとめ

4-(1,1,3,3-テトラメチルブチル)フェノールの rasH2 マウスを用いた強制経口投与による中期がん原性試験（投与用量：0（媒体対照）、50、100 及び 200 mg/kg）を行った結果、雄に前胃腫瘍（扁平上皮乳頭腫、扁平上皮乳頭腫と扁平上皮癌を合わせた発生）の発生増加がみられた。

### V-1 生存率、一般状態、体重、摂餌量

動物の生存率は、雌雄とも媒体対照群と比較して差を認めなかった。一般状態では、雌雄とも被験物質投与の影響と考えられる異常所見は認められず、体重及び摂餌量も投与期間を通して媒体対照群との間に顕著な差は認めなかった。

### V-2 腫瘍性及び腫瘍関連病変

本試験は rasH2 マウスを用いた 26 週間がん原性試験の初回報告であり、当センターで行った対照群の蓄積データがないため、rasH2 マウスの背景データを取得する目的で、本試験に先立って実施した無処置動物 50 匹のデータをがん原性評価の参考とした。また、文献（文献 14, 15, 16）のヒストリカルコントロールデータ（雌雄 rasH2 マウス）もがん原性評価の参考とした。

雄では胃（前胃）の扁平上皮乳頭腫の発生が、媒体対照群、50 mg/kg 群及び 100 mg/kg 群で 0 匹（0%）に対し、200 mg/kg 群で 2 匹（8%）みられ、Peto 検定（有病率法）と Cochran-Armitage 検定で有意な増加を示した。扁平上皮癌の発生（200 mg/kg 群 1 匹、4%）は有意な増加は示さなかったが、扁平上皮乳頭腫と扁平上皮癌を合わせた発生（200 mg/kg 群 3 匹、12%）は、Peto 検定（有病率法、死亡率法+有病率法）と Cochran-Armitage 検定で有意な増加を示した。

雄の胃の扁平上皮乳頭腫は、発生が極めて稀な腫瘍であり、当センターの雄 rasH2 マウス（無処置動物）50 匹の発生率は 2%（1/50 匹）であった。また、文献のヒストリカルコントロールデータでは、Paranjpe ら（文献 14）は平均 0.28%（26 試験、710 匹、最小 0%～最大 4%）、Nambiar ら（文献 15）は平均 0.6%（10 試験、333 匹、最小 0%～最大 4%）、Takaoka ら（文献 16）は平均 0.6%（12 試験、180 匹、最小 0%～最大 6.7%）と報告されている。これらの報告の試験単位での最大発生率は 6.7%であり、本試験の 200 mg/kg 群の扁平上皮乳頭腫の発生（2/25 匹、8%）は、試験単位での最大発生率を超えていることから、被験物質投与による影響と考えた。

扁平上皮癌も発生が極めて稀な腫瘍であり、当センターの背景データの発生率は 2%（1/50

匹)であった。文献データでは、Paranjpeらは平均0.56% (26試験、710匹、最小0%～最大4%)、Nambiarらは平均0.3% (10試験、333匹、最小0%～最大4%)、Takaokaらは平均0.6% (12試験、180匹、最小0%～最大6.7%)と報告されている。これらの報告の試験単位での最大発生率は6.7%であり、本試験の200 mg/kg群の扁平上皮癌の発生(1/25匹、4%)は、この範囲内であるものの試験単位での上限に近い発生率であった。これらのことを考慮し、扁平上皮乳頭腫と扁平上皮癌を合わせた発生(3/25匹、12%)も被験物質投与による影響と考えた。

従って、雄に認められた胃の扁平上皮乳頭腫、及び扁平上皮乳頭腫と扁平上皮癌を合わせた発生増加は、rasH2マウスに対するがん原性を示す証拠と考えられた。

一方、雌では腫瘍の発生増加は認められず、雌 rasH2マウスに対するがん原性を示す証拠は得られなかった。

### V-3 その他の影響

病理組織学的検査では、雌雄の腎臓と雄の肝臓に影響がみられた。

腎臓では、慢性腎炎の発生増加が雄の200 mg/kg群で認められ、1例だが100 mg/kg群でも発生がみられた。雌では慢性腎炎の発生増加が100 mg/kg以上の群で認められ、その程度は雌で強かった。また、腎重量(体重比)は雌の100 mg/kg以上の群で高値であり、血漿中尿素窒素が雌雄の200 mg/kg群で高値を示した。

肝臓では、小葉中心性の肝細胞肥大の発生増加が雄の200 mg/kg群で認められ、100 mg/kg群でも1例に発生がみられた。また、肝の実重量が雄の100 mg/kg以上の群、体重比が雄の50 mg/kg以上の群と雌の200 mg/kg群で高値であり、血液生化学的検査で、雌雄の50 mg/kg以上の群でALPの高値、雌の200 mg/kg群で $\gamma$ -GTPが高値を示した。

臓器重量では、胸腺重量(実重量・体重比)が雄の200 mg/kg群で低値を示し、雌では実重量が50 mg/kg以上の群で低値あるいは低値傾向を示したが、病理組織所見では変化はみられなかった。脾重量(実重量・体重比)は雌雄の200 mg/kg群で軽度の高値を示したが、病理組織所見に所見の増加はみられなかった。

血液学的検査では、雌の200 mg/kg群で軽度の貧血傾向(赤血球、ヘモグロビン濃度、ヘマトクリット値、MCH及びMCHCの低値)が認められた。

その他、血液生化学的検査で脂質代謝への影響を示唆する変化として、総コレステロール、トリグリセライド及びリン脂質の高値が、雄では50 mg/kg以上、雌では100 mg/kg以上ないし200 mg/kg群でみられた。

V-4 陽性対照物質投与群 (*N*-Nitroso-*N*-methylurea: MNU) の評価

陽性対照物質として、MNU を単回腹腔内投与（雌雄 15 匹、75 mg/kg BW）し、26 週間飼育した。

その結果、陽性対照群の生存動物数（生存率）は、雄 8 匹（53.3%）、雌 4 匹（26.7%）であった。体重は媒体対照群に比較して、雌雄とも飼育 5 週目以降に高値が認められ、摂餌量も投与期間を通して高値が認められた。

腫瘍性病変の発生は、雄では皮膚の扁平上皮乳頭腫、肺の細気管支-肺胞上皮腺腫と細気管支-肺胞上皮癌を合わせた発生、胸腺の悪性リンパ腫、胃の扁平上皮乳頭腫、及び扁平上皮癌の発生が、それぞれ Fisher 検定で有意な増加を示した。7 匹の途中死亡動物の死因は全て悪性リンパ腫であり、担腫瘍動物数は、媒体対照群 2 匹（8%）に対し、陽性対照群 15 匹（100%）であった。

雌では、胃の扁平上皮乳頭腫、及び扁平上皮乳頭腫と扁平上皮癌を合わせた発生、胸腺、脾臓及び全臓器の悪性リンパ腫の発生が Fisher 検定で有意な増加を示した。11 匹の途中死亡動物の死因は 10 匹が悪性リンパ腫、1 匹が胃の腫瘍であり、担腫瘍動物数は、媒体対照群 5 匹（20%）に対し、陽性対照群 15 匹（100%）であった。

以上の結果より、雌雄とも陽性対照物質（MNU）投与による明らかな腫瘍の発生増加が認められ、本試験系の有効性が確認された。

## VI 結論

rasH2 マウスを用いて、4-(1,1,3,3-テトラメチルブチル)フェノールの26週間にわたる強制経口投与によるがん原性試験を行った結果、

1. 雄 rasH2 マウスに対するがん原性を示す証拠が得られた (some evidence of carcinogenic activity) と結論された。
2. 雌 rasH2 マウスに対するがん原性を示す証拠は得られなかった (no evidence of carcinogenic activity) と結論された。

## VII 文献

- 1) Organisation for Economic Co-operation and Development (OECD). 1995. OECD SIDS. PHENOL, 4-(1,1,3,3-TETRAMETHYLBUTYL)-. SIDS Initial Assessment Report for SIAM3. <http://www.inchem.org/documents/sids/sids/140669.pdf> [accessed 2017/04/26]
- 2) 東京化成工業(株). 2017. 4-(1,1,3,3-Tetramethylbutyl)phenol 安全データシート.
- 3) 経済産業省. 2018. 優先評価化学物質の製造・輸入数量 (28年度実績) [http://www.meti.go.jp/policy/chemical\\_management/kasinhou/files/information/volume/priority/Volume\\_priority\\_h28.xlsx](http://www.meti.go.jp/policy/chemical_management/kasinhou/files/information/volume/priority/Volume_priority_h28.xlsx) [accessed 2018/11/16]
- 4) Deutsche Forschungsgemeinschaft (DFG) 2018. 4-tert-Octylphenol: MAK Value Documentation. The MAK Collection for Occupational Health and Safety 2018, Vol 3, No 3 pp1137-1150. <https://onlinelibrary.wiley.com/doi/pdf/10.1002/3527600418.mb14066kske6318> [accessed 2018/11/16]
- 5) 国立研究開発法人 産業技術総合研究所 有機化合物スペクトルデータベース(SDBS). p-(1,1,3,3-tetramethylbutyl)phenol. [accessed 2017/04/26].
- 6) シグマ アルドリッチ ジャパン合同会社. 2017. N-Nitroso-N-methylurea 安全データシート.
- 7) U.S. National Library of Medicine. 2003. N-NITROSO-N-METHYLUREA. Chemical/Physical Properties. Hazardous Substances Data Bank (HSDB). <https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB> [accessed 2017/09/06]
- 8) 国立研究開発法人 産業技術総合研究所 有機化合物スペクトルデータベース(SDBS). 1-methyl-1-nitrosourea. [accessed 2017/08/07].
- 9) National Institute of Standards and Technology (NIST). 2017. N-NITROSO-N-METHYLUREA. NIST Chemistry WebBook, SRD 69. <https://webbook.nist.gov/cgi/cbook.cgi?Name=684-93-5&Units=SI&cIR=on#IR-Spec> [accessed 2017/9/20]

- 10) Robinson DE, MacDonald JS. 2001. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. *Toxicol Pathol* 29 (Suppl.): 13-19.
- 11) 「遺伝子改変動物を用いたがん原性試験による調査の基準」 2017. 平成 28 年度第 3 回発がん性評価ワーキンググループ（平成 29 年 3 月 1 日厚生労働省）資料.
- 12) 阿部正信. 1986. 長期毒性試験に用いるラット、マウスの体重変化の解析による群分けの適正層別方式の確立. *薬理と治療* 14: 7285-7302.
- 13) Nagano K, Katagiri T, Aiso S, Senoh H, Sakura Y, Takeuchi T. 1997. Spontaneous lesions of nasal cavity in aging F344 rats and BDF1 mice. *Exp Toxic Pathol.* 49: 97-104.
- 14) Paranjpe MG, Elbekaei RH, Shah SA, Hickman M, Wenk ML, Zahalka EA. 2013. Historical control data of spontaneous tumors in transgenic CByB6F1-Tg (HRAS)<sup>2Jic</sup> (Tg. rasH2) mice. *Int. J. Toxicol.* 32: 48-57.
- 15) Nambiar PR, Turnquist SE, Morton D. 2012. Spontaneous tumor incidence in rasH2 mice: review of internal data and published literature. *Toxicol. Pathol.* 40: 614-623.
- 16) Takaoka M, Sehata S, Maejima, T, Imai T, Torii M, Satoh H, et al. 2003. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice. *Toxicol. Pathol.* 31: 191-199.

VIII 予見することのできなかつた試験の信頼性に影響を及ぼす疑いのある事態及び試験計画書に従わなかつたこと

1. 陽性対照物質 (*N*-Nitroso-*N*-methylurea) の同一性確認

試験計画書では、「陽性対照物質の同一性は、赤外吸収スペクトルを赤外分光光度計 ((株) 島津製作所 IRAffinity-1) を用いて測定し、文献値 (文献 8) と比較することにより確認する。」と記載されていたが、文献 (文献 9) を追加し、陽性対照物質の同一性を確認した。

赤外吸収スペクトルパターンと主な結合官能基の吸収帯は文献値 (文献 8) と一致することを確認したが、更に、文献 (文献 9) との比較で、同じ各波数にピークを示すことを確認し、陽性対照物質は *N*-Nitroso-*N*-methylurea であることを確認した。

2. 媒体対照群と陽性対照群間の腫瘍性病変の統計検定

媒体対照群と陽性対照群間の腫瘍性病変の統計検定は、両群間の Fisher 検定の結果のみを用いて評価を行った。

上記変更は、いずれも試験結果の評価の信頼性に影響を及ぼすものではない。



4-(1,1,3,3-テトラメチルブチル)フェノールの rasH2 マウスを用いた  
強制経口投与による中期がん原性試験報告書

試験番号 : 0900, 0901

# TABLES

## TABLES

(Test substance-treated group)

TABLE A 1	SURVIVAL ANIMAL NUMBERS: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 2	SURVIVAL ANIMAL NUMBERS: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 3	CLINICAL OBSERVATION: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 4	CLINICAL OBSERVATION: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 5	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 6	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 7	BODY WEIGHT CHANGES: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 8	BODY WEIGHT CHANGES: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 9	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 10	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 11	FOOD CONSUMPTION CHANGES: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 12	FOOD CONSUMPTION CHANGES: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 13	URINALYSIS: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 14	URINALYSIS: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 15	HEMATOLOGY: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 16	HEMATOLOGY: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 17	BIOCHEMISTRY: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE A 18	BIOCHEMISTRY: FEMALE (Control, 50, 100 and 200 mg/kg groups)

**TABLES (CONTINUED)**  
**(Test substance-treated group)**

TABLE	A 19	GROSS FINDINGS: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 20	GROSS FINDINGS: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 21	ORGAN WEIGHT, ABSOLUTE: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 22	ORGAN WEIGHT, ABSOLUTE: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 23	ORGAN WEIGHT, RELATIVE: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 24	ORGAN WEIGHT, RELATIVE: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 25	HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 26	HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 27	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 28	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 29	NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 30	NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 31	HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 32	HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: FEMALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 33	HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : MALE (Control, 50, 100 and 200 mg/kg groups)
TABLE	A 34	HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS : FEMALE (Control, 50, 100 and 200 mg/kg groups)

**TABLES (CONTINUED)**  
**(Test substance-treated group)**

TABLE A 35 CAUSE OF DEATH: MALE (Control, 50, 100 and 200 mg/kg groups)

TABLE A 36 CAUSE OF DEATH: FEMALE (Control, 50, 100 and 200 mg/kg groups)

## TABLES (Positive control group)

- TABLE B 1 SURVIVAL ANIMAL NUMBERS: MALE  
(Control and Positive control group)
- TABLE B 2 SURVIVAL ANIMAL NUMBERS: FEMALE  
(Control and Positive control group)
- TABLE B 3 CLINICAL OBSERVATION: MALE  
(Control and Positive control group)
- TABLE B 4 CLINICAL OBSERVATION: FEMALE  
(Control and Positive control group)
- TABLE B 5 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS  
: MALE (Control and Positive control group)
- TABLE B 6 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS  
: FEMALE (Control and Positive control group)
- TABLE B 7 BODY WEIGHT CHANGES: MALE  
(Control and Positive control group)
- TABLE B 8 BODY WEIGHT CHANGES: FEMALE  
(Control and Positive control group)
- TABLE B 9 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL  
NUMBERS: MALE (Control and Positive control group)
- TABLE B 10 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL  
NUMBERS: FEMALE (Control and Positive control group)
- TABLE B 11 FOOD CONSUMPTION CHANGES: MALE  
(Control and Positive control group)
- TABLE B 12 FOOD CONSUMPTION CHANGES: FEMALE  
(Control and Positive control group)
- TABLE B 13 URINALYSIS: MALE (Control and Positive control group)
- TABLE B 14 URINALYSIS: FEMALE (Control and Positive control group)
- TABLE B 15 HEMATOLOGY: MALE (Control and Positive control group)
- TABLE B 16 HEMATOLOGY: FEMALE (Control and Positive control group)

**TABLES (CONTINUED)**  
**(Positive control group)**

TABLE	B 17	BIOCHEMISTRY: MALE (Control and Positive control group)
TABLE	B 18	BIOCHEMISTRY: FEMALE (Control and Positive control group)
TABLE	B 19	GROSS FINDINGS: MALE (Control and Positive control group)
TABLE	B 20	GROSS FINDINGS: FEMALE (Control and Positive control group)
TABLE	B 21	ORGAN WEIGHT, ABSOLUTE: MALE (Control and Positive control group)
TABLE	B 22	ORGAN WEIGHT, ABSOLUTE: FEMALE (Control and Positive control group)
TABLE	B 23	ORGAN WEIGHT, RELATIVE: MALE (Control and Positive control group)
TABLE	B 24	ORGAN WEIGHT, RELATIVE: FEMALE (Control and Positive control group)
TABLE	B 25	HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: MALE (Control and Positive control group)
TABLE	B 26	HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: FEMALE (Control and Positive control group)
TABLE	B 27	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: MALE (Control and Positive control group)
TABLE	B 28	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: FEMALE (Control and Positive control group)
TABLE	B 29	NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED: MALE (Control and Positive control group)
TABLE	B 30	NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED: FEMALE (Control and Positive control group)
TABLE	B 31	HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: MALE (Control and Positive control group)
TABLE	B 32	HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR: FEMALE (Control and Positive control group)

**TABLES (CONTINUED)**  
**(Positive control group)**

TABLE B 33 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS  
: MALE (Control and Positive control group)

TABLE B 34 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS  
: FEMALE (Control and Positive control group)

TABLE B 35 CAUSE OF DEATH: MALE (Control and Positive control group)

TABLE B 36 CAUSE OF DEATH: FEMALE (Control and Positive control group)

TABLE A 1

SURVIVAL ANIMAL NUMBERS : MALE

(Control, 50, 100 and 200 mg/kg groups)



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 26  
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
50 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
200 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BA155

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 26  
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)												
		14	15	16	17	18	19	20	21	22	23	24	25	26
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
50 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
100 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
200 mg/kg	25	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	23/25 92.0	23/25 92.0	23/25 92.0	23/25 92.0
		Number of survival/ Number of effective animals Survival rate(%)												

TABLE A 2

SURVIVAL ANIMAL NUMBERS : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901

ANIMAL : Jic:CB6F1-Tg rash2@Jcl

REPORT TYPE : A1 26

SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

PAGE : 1

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
50 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
100 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
200 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 26  
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		14	15	16	17	18	19	20	21	22	23	24	25	26	
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	23/25 92.0	23/25 92.0
50 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
100 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
200 mg/kg	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0

Number of survival/ Number of effective animals  
 Survival rate(%)

TABLE A 3

CLINICAL OBSERVATION : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27'

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-1 1	1-1 2	1-2 1	1-2 2	1-3 1	1-3 2	1-4 1	1-4 2	1-5 1	1-5 2	1-6 1	1-6 2	1-7 1	1-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day													
		2-1 1	2-1 2	2-2 1	2-2 2	2-3 1	2-3 2	2-4 1	2-4 2	2-5 1	2-5 2	2-6 1	2-6 2	2-7 1	2-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		3-1 1	3-1 2	3-2 1	3-2 2	3-3 1	3-3 2	3-4 1	3-4 2	3-5 1	3-5 2	3-6 1	3-6 2	3-7 1	3-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day													
		4-1 1	4-1 2	4-2 1	4-2 2	4-3 1	4-3 2	4-4 1	4-4 2	4-5 1	4-5 2	4-6 1	4-6 2	4-7 1	4-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day													
		5-1 1	5-1 2	5-2 1	5-2 2	5-3 1	5-3 2	5-4 1	5-4 2	5-5 1	5-5 2	5-6 1	5-6 2	5-7 1	5-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day													
		6-1 1	6-1 2	6-2 1	6-2 2	6-3 1	6-3 2	6-4 1	6-4 2	6-5 1	6-5 2	6-6 1	6-6 2	6-7 1	6-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HANT90)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 7

Clinical sign	Group Name	Administration Week-day													
		7-1 1	7-1 2	7-2 1	7-2 2	7-3 1	7-3 2	7-4 1	7-4 2	7-5 1	7-5 2	7-6 1	7-6 2	7-7 1	7-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 8

Clinical sign	Group Name	Administration Week-day													
		8-1 1	8-1 2	8-2 1	8-2 2	8-3 1	8-3 2	8-4 1	8-4 2	8-5 1	8-5 2	8-6 1	8-6 2	8-7 1	8-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 9

Clinical sign	Group Name	Administration Week-day													
		9-1 1	9-1 2	9-2 1	9-2 2	9-3 1	9-3 2	9-4 1	9-4 2	9-5 1	9-5 2	9-6 1	9-6 2	9-7 1	9-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BA155

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 10

Clinical sign	Group Name	Administration Week-day													
		10-1 1	10-1 2	10-2 1	10-2 2	10-3 1	10-3 2	10-4 1	10-4 2	10-5 1	10-5 2	10-6 1	10-6 2	10-7 1	10-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 11

Clinical sign	Group Name	Administration Week-day													
		11-1 1	11-1 2	11-2 1	11-2 2	11-3 1	11-3 2	11-4 1	11-4 2	11-5 1	11-5 2	11-6 1	11-6 2	11-7 1	11-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 12

Clinical sign	Group Name	Administration Week-day													
		12-1 1	12-1 2	12-2 1	12-2 2	12-3 1	12-3 2	12-4 1	12-4 2	12-5 1	12-5 2	12-6 1	12-6 2	12-7 1	12-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 13

Clinical sign	Group Name	Administration Week-day													
		13-1 1	13-1 2	13-2 1	13-2 2	13-3 1	13-3 2	13-4 1	13-4 2	13-5 1	13-5 2	13-6 1	13-6 2	13-7 1	13-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 14

Clinical sign	Group Name	Administration Week-day													
		14-1 1	14-1 2	14-2 1	14-2 2	14-3 1	14-3 2	14-4 1	14-4 2	14-5 1	14-5 2	14-6 1	14-6 2	14-7 1	14-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 15

Clinical sign	Group Name	Administration Week-day													
		15-1 1	15-1 2	15-2 1	15-2 2	15-3 1	15-3 2	15-4 1	15-4 2	15-5 1	15-5 2	15-6 1	15-6 2	15-7 1	15-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24

(HAN190)

BA155

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 16

Clinical sign	Group Name	Administration Week-day													
		16-1 1	16-1 2	16-2 1	16-2 2	16-3 1	16-3 2	16-4 1	16-4 2	16-5 1	16-5 2	16-6 1	16-6 2	16-7 1	16-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 17

Clinical sign	Group Name	Administration Week-day													
		17-1 1	17-1 2	17-2 1	17-2 2	17-3 1	17-3 2	17-4 1	17-4 2	17-5 1	17-5 2	17-6 1	17-6 2	17-7 1	17-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24

(HANT90)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 18

Clinical sign	Group Name	Administration Week-day													
		18-1 1	18-1 2	18-2 1	18-2 2	18-3 1	18-3 2	18-4 1	18-4 2	18-5 1	18-5 2	18-6 1	18-6 2	18-7 1	18-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24

(HAN190)

BAIS 5



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 19

Clinical sign	Group Name	Administration Week-day													
		19-1 1	19-1 2	19-2 1	19-2 2	19-3 1	19-3 2	19-4 1	19-4 2	19-5 1	19-5 2	19-6 1	19-6 2	19-7 1	19-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 20

Clinical sign	Group Name	Administration Week-day													
		20-1 1	20-1 2	20-2 1	20-2 2	20-3 1	20-3 2	20-4 1	20-4 2	20-5 1	20-5 2	20-6 1	20-6 2	20-7 1	20-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 21

Clinical sign	Group Name	Administration Week-day													
		21-1 1	21-1 2	21-2 1	21-2 2	21-3 1	21-3 2	21-4 1	21-4 2	21-5 1	21-5 2	21-6 1	21-6 2	21-7 1	21-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 22

Clinical sign	Group Name	Administration Week-day													
		22-1 1	22-1 2	22-2 1	22-2 2	22-3 1	22-3 2	22-4 1	22-4 2	22-5 1	22-5 2	22-6 1	22-6 2	22-7 1	22-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 23

Clinical sign	Group Name	Administration Week-day													
		23-1 1	23-1 2	23-2 1	23-2 2	23-3 1	23-3 2	23-4 1	23-4 2	23-5 1	23-5 2	23-6 1	23-6 2	23-7 1	23-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	2	2	2	2	2	2	2	2	2	2	2	2
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	24	24	23	23	23	23	23	23	23	23	23	23	23	23

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 24

Clinical sign	Group Name	Administration Week-day													
		24-1 1	24-1 2	24-2 1	24-2 2	24-3 1	24-3 2	24-4 1	24-4 2	24-5 1	24-5 2	24-6 1	24-6 2	24-7 1	24-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	2	2	2	2	2	2	2	2	2	2	2	2	2	2
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	23	23	23	23	23	23	23	23	23	23	23	23	23	23

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 25

Clinical sign	Group Name	Administration Week-day													
		25-1 1	25-1 2	25-2 1	25-2 2	25-3 1	25-3 2	25-4 1	25-4 2	25-5 1	25-5 2	25-6 1	25-6 2	25-7 1	25-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	2	2	2	2	2	2	2	2	2	2	2	2	2	2
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	23	23	23	23	23	23	23	23	23	23	23	23	23	23

(HAN190)

BA155

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 26

Clinical sign	Group Name	Administration Week-day													
		26-1 1	26-1 2	26-2 1	26-2 2	26-3 1	26-3 2	26-4 1	26-4 2	26-5 1	26-5 2	26-6 1	26-6 2	26-7 1	26-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	2	2	2	2	2	2	2	2	2	2	2	2	2	2
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	23	23	23	23	23	23	23	23	23	23	23	23	23	23

(HAN190)

BAIS 5



STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : MALE

PAGE : 27

Clinical sign	Group Name	Administration Week-day	
		27-1	27-1
		1	2
DEATH	Control	0	0
	50 mg/kg	1	1
	100 mg/kg	0	0
	200 mg/kg	2	2
NON REMARKABLE	Control	25	11
	50 mg/kg	24	11
	100 mg/kg	25	11
	200 mg/kg	23	10

(HAN190)

BAIS 5

TABLE A 4

CLINICAL OBSERVATION : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-1 1	1-1 2	1-2 1	1-2 2	1-3 1	1-3 2	1-4 1	1-4 2	1-5 1	1-5 2	1-6 1	1-6 2	1-7 1	1-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day													
		2-1 1	2-1 2	2-2 1	2-2 2	2-3 1	2-3 2	2-4 1	2-4 2	2-5 1	2-5 2	2-6 1	2-6 2	2-7 1	2-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		3-1 1	3-1 2	3-2 1	3-2 2	3-3 1	3-3 2	3-4 1	3-4 2	3-5 1	3-5 2	3-6 1	3-6 2	3-7 1	3-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day													
		4-1 1	4-1 2	4-2 1	4-2 2	4-3 1	4-3 2	4-4 1	4-4 2	4-5 1	4-5 2	4-6 1	4-6 2	4-7 1	4-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1-27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day													
		5-1 1	5-1 2	5-2 1	5-2 2	5-3 1	5-3 2	5-4 1	5-4 2	5-5 1	5-5 2	5-6 1	5-6 2	5-7 1	5-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day													
		6-1 1	6-1 2	6-2 1	6-2 2	6-3 1	6-3 2	6-4 1	6-4 2	6-5 1	6-5 2	6-6 1	6-6 2	6-7 1	6-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 7

Clinical sign	Group Name	Administration Week-day													
		7-1 1	7-1 2	7-2 1	7-2 2	7-3 1	7-3 2	7-4 1	7-4 2	7-5 1	7-5 2	7-6 1	7-6 2	7-7 1	7-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 8

Clinical sign	Group Name	Administration Week-day													
		8-1 1	8-1 2	8-2 1	8-2 2	8-3 1	8-3 2	8-4 1	8-4 2	8-5 1	8-5 2	8-6 1	8-6 2	8-7 1	8-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 9

Clinical sign	Group Name	Administration Week-day													
		9-1 1	9-1 2	9-2 1	9-2 2	9-3 1	9-3 2	9-4 1	9-4 2	9-5 1	9-5 2	9-6 1	9-6 2	9-7 1	9-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 10

Clinical sign	Group Name	Administration Week-day													
		10-1 1	10-1 2	10-2 1	10-2 2	10-3 1	10-3 2	10-4 1	10-4 2	10-5 1	10-5 2	10-6 1	10-6 2	10-7 1	10-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 11

Clinical sign	Group Name	Administration Week-day													
		11-1 1	11-1 2	11-2 1	11-2 2	11-3 1	11-3 2	11-4 1	11-4 2	11-5 1	11-5 2	11-6 1	11-6 2	11-7 1	11-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 12

Clinical sign	Group Name	Administration Week-day													
		12-1 1	12-1 2	12-2 1	12-2 2	12-3 1	12-3 2	12-4 1	12-4 2	12-5 1	12-5 2	12-6 1	12-6 2	12-7 1	12-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 13

Clinical sign	Group Name	Administration Week-day													
		13-1 1	13-1 2	13-2 1	13-2 2	13-3 1	13-3 2	13-4 1	13-4 2	13-5 1	13-5 2	13-6 1	13-6 2	13-7 1	13-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 14

Clinical sign	Group Name	Administration Week-day													
		14-1 1	14-1 2	14-2 1	14-2 2	14-3 1	14-3 2	14-4 1	14-4 2	14-5 1	14-5 2	14-6 1	14-6 2	14-7 1	14-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 15

Clinical sign	Group Name	Administration Week-day													
		15-1 1	15-1 2	15-2 1	15-2 2	15-3 1	15-3 2	15-4 1	15-4 2	15-5 1	15-5 2	15-6 1	15-6 2	15-7 1	15-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 16

Clinical sign	Group Name	Administration Week-day													
		16-1 1	16-1 2	16-2 1	16-2 2	16-3 1	16-3 2	16-4 1	16-4 2	16-5 1	16-5 2	16-6 1	16-6 2	16-7 1	16-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 17

Clinical sign	Group Name	Administration Week-day													
		17-1 1	17-1 2	17-2 1	17-2 2	17-3 1	17-3 2	17-4 1	17-4 2	17-5 1	17-5 2	17-6 1	17-6 2	17-7 1	17-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 18

Clinical sign	Group Name	Administration Week-day													
		18-1 1	18-1 2	18-2 1	18-2 2	18-3 1	18-3 2	18-4 1	18-4 2	18-5 1	18-5 2	18-6 1	18-6 2	18-7 1	18-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 19

Clinical sign	Group Name	Administration Week-day													
		19-1 1	19-1 2	19-2 1	19-2 2	19-3 1	19-3 2	19-4 1	19-4 2	19-5 1	19-5 2	19-6 1	19-6 2	19-7 1	19-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 20

Clinical sign	Group Name	Administration Week-day													
		20-1 1	20-1 2	20-2 1	20-2 2	20-3 1	20-3 2	20-4 1	20-4 2	20-5 1	20-5 2	20-6 1	20-6 2	20-7 1	20-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 21

Clinical sign	Group Name	Administration Week-day													
		21-1 1	21-1 2	21-2 1	21-2 2	21-3 1	21-3 2	21-4 1	21-4 2	21-5 1	21-5 2	21-6 1	21-6 2	21-7 1	21-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 22

Clinical sign	Group Name	Administration Week-day													
		22-1 1	22-1 2	22-2 1	22-2 2	22-3 1	22-3 2	22-4 1	22-4 2	22-5 1	22-5 2	22-6 1	22-6 2	22-7 1	22-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 23

Clinical sign	Group Name	Administration Week-day													
		23-1 1	23-1 2	23-2 1	23-2 2	23-3 1	23-3 2	23-4 1	23-4 2	23-5 1	23-5 2	23-6 1	23-6 2	23-7 1	23-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 24

Clinical sign	Group Name	Administration Week-day													
		24-1 1	24-1 2	24-2 1	24-2 2	24-3 1	24-3 2	24-4 1	24-4 2	24-5 1	24-5 2	24-6 1	24-6 2	24-7 1	24-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 25

Clinical sign	Group Name	Administration Week-day													
		25-1 1	25-1 2	25-2 1	25-2 2	25-3 1	25-3 2	25-4 1	25-4 2	25-5 1	25-5 2	25-6 1	25-6 2	25-7 1	25-7 2
DEATH	Control	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	1	1	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	1	0	0	0	0
PARALYTIC GAIT	Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 26

Clinical sign	Group Name	Administration Week-day													
		26-1 1	26-1 2	26-2 1	26-2 2	26-3 1	26-3 2	26-4 1	26-4 2	26-5 1	26-5 2	26-6 1	26-6 2	26-7 1	26-7 2
DEATH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 27

Clinical sign	Group Name	Administration Week-day	
		27-1 1	27-1 2
DEATH	Control	1	1
	50 mg/kg	0	0
	100 mg/kg	0	0
	200 mg/kg	0	0
MORIBUND SACRIFICE	Control	1	1
	50 mg/kg	1	1
	100 mg/kg	0	0
	200 mg/kg	1	1
LOCOMOTOR MOVEMENT DECR	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	0	0
	200 mg/kg	0	0
PARALYTIC GAIT	Control	0	0
	50 mg/kg	1	1
	100 mg/kg	0	0
	200 mg/kg	0	0
A LOT OF SPILLED FOOD	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	0	0
	200 mg/kg	0	0
SOILED PERI-GENITALIA	Control	0	0
	50 mg/kg	1	1
	100 mg/kg	0	0
	200 mg/kg	0	0
EXTERNAL MASS	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	1	1
	200 mg/kg	0	0
M. NOSE	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	1	1
	200 mg/kg	0	0
M. PERI-MOUTH	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	0	0
	200 mg/kg	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 28

Clinical sign	Group Name	Administration Week-day													
		1-1 1	1-1 2	1-2 1	1-2 2	1-3 1	1-3 2	1-4 1	1-4 2	1-5 1	1-5 2	1-6 1	1-6 2	1-7 1	1-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 29

Clinical sign	Group Name	Administration Week-day													
		2-1 1	2-1 2	2-2 1	2-2 2	2-3 1	2-3 2	2-4 1	2-4 2	2-5 1	2-5 2	2-6 1	2-6 2	2-7 1	2-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	1	1	1	1	1	1	1	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	24	24	24	24	24	24	24	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 30

Clinical sign	Group Name	Administration Week-day													
		3-1 1	3-1 2	3-2 1	3-2 2	3-3 1	3-3 2	3-4 1	3-4 2	3-5 1	3-5 2	3-6 1	3-6 2	3-7 1	3-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 31

Clinical sign	Group Name	Administration Week-day													
		4-1 1	4-1 2	4-2 1	4-2 2	4-3 1	4-3 2	4-4 1	4-4 2	4-5 1	4-5 2	4-6 1	4-6 2	4-7 1	4-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 32

Clinical sign	Group Name	Administration Week-day													
		5-1 1	5-1 2	5-2 1	5-2 2	5-3 1	5-3 2	5-4 1	5-4 2	5-5 1	5-5 2	5-6 1	5-6 2	5-7 1	5-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901

ANIMAL : Jic:CB6F1-Tg rasH20Jcl

REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)

ALL ANIMALS

SEX : FEMALE

PAGE : 33

Clinical sign	Group Name	Administration Week-day													
		6-1 1	6-1 2	6-2 1	6-2 2	6-3 1	6-3 2	6-4 1	6-4 2	6-5 1	6-5 2	6-6 1	6-6 2	6-7 1	6-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 34

Clinical sign	Group Name	Administration Week-day													
		7-1 1	7-1 2	7-2 1	7-2 2	7-3 1	7-3 2	7-4 1	7-4 2	7-5 1	7-5 2	7-6 1	7-6 2	7-7 1	7-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 35

Clinical sign	Group Name	Administration Week-day													
		8-1 1	8-1 2	8-2 1	8-2 2	8-3 1	8-3 2	8-4 1	8-4 2	8-5 1	8-5 2	8-6 1	8-6 2	8-7 1	8-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 36

Clinical sign	Group Name	Administration Week-day													
		9-1 1	9-1 2	9-2 1	9-2 2	9-3 1	9-3 2	9-4 1	9-4 2	9-5 1	9-5 2	9-6 1	9-6 2	9-7 1	9-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 37

Clinical sign	Group Name	Administration Week-day													
		10-1 1	10-1 2	10-2 1	10-2 2	10-3 1	10-3 2	10-4 1	10-4 2	10-5 1	10-5 2	10-6 1	10-6 2	10-7 1	10-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 38

Clinical sign	Group Name	Administration Week-day													
		11-1 1	11-1 2	11-2 1	11-2 2	11-3 1	11-3 2	11-4 1	11-4 2	11-5 1	11-5 2	11-6 1	11-6 2	11-7 1	11-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 39

Clinical sign	Group Name	Administration Week-day													
		12-1 1	12-1 2	12-2 1	12-2 2	12-3 1	12-3 2	12-4 1	12-4 2	12-5 1	12-5 2	12-6 1	12-6 2	12-7 1	12-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 40

Clinical sign	Group Name	Administration Week-day													
		13-1 1	13-1 2	13-2 1	13-2 2	13-3 1	13-3 2	13-4 1	13-4 2	13-5 1	13-5 2	13-6 1	13-6 2	13-7 1	13-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 41

Clinical sign	Group Name	Administration Week-day													
		14-1 1	14-1 2	14-2 1	14-2 2	14-3 1	14-3 2	14-4 1	14-4 2	14-5 1	14-5 2	14-6 1	14-6 2	14-7 1	14-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 42

Clinical sign	Group Name	Administration Week-day													
		15-1 1	15-1 2	15-2 1	15-2 2	15-3 1	15-3 2	15-4 1	15-4 2	15-5 1	15-5 2	15-6 1	15-6 2	15-7 1	15-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 43

Clinical sign	Group Name	Administration Week-day													
		16-1 1	16-1 2	16-2 1	16-2 2	16-3 1	16-3 2	16-4 1	16-4 2	16-5 1	16-5 2	16-6 1	16-6 2	16-7 1	16-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 44

Clinical sign	Group Name	Administration Week-day													
		17-1 1	17-1 2	17-2 1	17-2 2	17-3 1	17-3 2	17-4 1	17-4 2	17-5 1	17-5 2	17-6 1	17-6 2	17-7 1	17-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 45

Clinical sign	Group Name	Administration Week-day													
		18-1 1	18-1 2	18-2 1	18-2 2	18-3 1	18-3 2	18-4 1	18-4 2	18-5 1	18-5 2	18-6 1	18-6 2	18-7 1	18-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HANT90)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 46

Clinical sign	Group Name	Administration Week-day													
		19-1 1	19-1 2	19-2 1	19-2 2	19-3 1	19-3 2	19-4 1	19-4 2	19-5 1	19-5 2	19-6 1	19-6 2	19-7 1	19-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 47

Clinical sign	Group Name	Administration Week-day													
		20-1 1	20-1 2	20-2 1	20-2 2	20-3 1	20-3 2	20-4 1	20-4 2	20-5 1	20-5 2	20-6 1	20-6 2	20-7 1	20-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 48

Clinical sign	Group Name	Administration Week-day													
		21-1 1	21-1 2	21-2 1	21-2 2	21-3 1	21-3 2	21-4 1	21-4 2	21-5 1	21-5 2	21-6 1	21-6 2	21-7 1	21-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	25	25	25	25	25	25	25	25	25	25	25	24	24	24
	100 mg/kg	25	25	25	25	25	25	25	25	25	25	25	24	24	24
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 49

Clinical sign	Group Name	Administration Week-day													
		22-1 1	22-1 2	22-2 1	22-2 2	22-3 1	22-3 2	22-4 1	22-4 2	22-5 1	22-5 2	22-6 1	22-6 2	22-7 1	22-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 50

Clinical sign	Group Name	Administration Week-day													
		23-1 1	23-1 2	23-2 1	23-2 2	23-3 1	23-3 2	23-4 1	23-4 2	23-5 1	23-5 2	23-6 1	23-6 2	23-7 1	23-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 51

Clinical sign	Group Name	Administration Week-day													
		24-1 1	24-1 2	24-2 1	24-2 2	24-3 1	24-3 2	24-4 1	24-4 2	24-5 1	24-5 2	24-6 1	24-6 2	24-7 1	24-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	23	23	23	23	23	23	23	23	23	23	23	23	23	23
	50 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	100 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	200 mg/kg	25	25	25	25	25	25	25	25	25	25	25	25	25	25

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 52

Clinical sign	Group Name	Administration Week-day													
		25-1 1	25-1 2	25-2 1	25-2 2	25-3 1	25-3 2	25-4 1	25-4 2	25-5 1	25-5 2	25-6 1	25-6 2	25-7 1	25-7 2
ANEMIA	Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	1	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	23	23	23	23	23	23	23	23	23	23	23	23	23	23
	50 mg/kg	23	23	23	23	23	23	23	23	23	23	23	23	23	23
	100 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	200 mg/kg	25	25	25	25	25	25	25	25	25	24	24	24	24	24

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 53

Clinical sign	Group Name	Administration Week-day													
		26-1 1	26-1 2	26-2 1	26-2 2	26-3 1	26-3 2	26-4 1	26-4 2	26-5 1	26-5 2	26-6 1	26-6 2	26-7 1	26-7 2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	50 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	200 mg/kg	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	23	23	23	23	23	23	23	23	23	23	23	23	23	23
	50 mg/kg	23	23	23	23	23	23	23	23	23	23	23	23	23	23
	100 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	200 mg/kg	24	24	24	24	24	24	24	24	24	24	24	24	24	24

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 54

Clinical sign	Group Name	Administration Week-day	
		27-1 1	27-1 2
ANEMIA	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	0	0
	200 mg/kg	0	0
SWELLING	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	0	0
	200 mg/kg	0	0
HEMORRHAGE	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	0	0
	200 mg/kg	0	0
DEEP BREATHING	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	0	0
	200 mg/kg	0	0
OLIGO-STOOL	Control	0	0
	50 mg/kg	0	0
	100 mg/kg	0	0
	200 mg/kg	0	0
NON REMARKABLE	Control	23	9
	50 mg/kg	23	10
	100 mg/kg	24	10
	200 mg/kg	24	11

(HAN190)

BAIS 5



TABLE A 5

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL

NUMBERS : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900

## MEAN BODY WEIGHTS AND SURVIVAL

ANIMAL : Jic: CB6F1-Tg rasH2@Jcl

UNIT : g

SEX : MALE

Week-Day on Study	Control		50 mg/kg			100 mg/kg			200 mg/kg		
	Av. Wt. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.
0-0	24.7 (25)	25/25	24.7 (25)	100	25/25	24.6 (25)	100	25/25	24.7 (25)	100	25/25
1-1	24.8 (25)	25/25	24.6 (25)	99	25/25	24.5 (25)	99	25/25	24.5 (25)	99	25/25
2-1	25.2 (25)	25/25	25.1 (25)	100	25/25	25.2 (25)	100	25/25	25.7 (25)	102	25/25
3-1	25.3 (25)	25/25	25.0 (25)	99	25/25	25.0 (25)	99	25/25	25.5 (25)	101	25/25
4-1	25.7 (25)	25/25	25.5 (25)	99	25/25	25.6 (25)	100	25/25	26.1 (25)	102	25/25
5-1	25.9 (25)	25/25	25.7 (25)	99	25/25	25.7 (25)	99	25/25	25.9 (25)	100	25/25
6-1	26.4 (25)	25/25	25.9 (25)	98	25/25	26.2 (25)	99	25/25	26.4 (25)	100	25/25
7-1	26.8 (25)	25/25	26.3 (25)	98	25/25	26.7 (25)	100	25/25	26.9 (25)	100	25/25
8-1	26.9 (25)	25/25	26.3 (25)	98	25/25	26.5 (25)	99	25/25	26.6 (25)	99	25/25
9-1	27.4 (25)	25/25	26.9 (25)	98	25/25	27.4 (25)	100	25/25	27.7 (25)	101	25/25
10-1	27.8 (25)	25/25	27.2 (25)	98	25/25	27.6 (25)	99	25/25	27.7 (25)	100	25/25
11-1	27.5 (25)	25/25	26.9 (25)	98	25/25	27.3 (25)	99	25/25	27.0 (25)	98	25/25
12-1	27.7 (25)	25/25	27.1 (25)	98	25/25	27.5 (25)	99	25/25	27.4 (25)	99	25/25
13-1	28.0 (25)	25/25	27.3 (25)	98	25/25	27.7 (25)	99	25/25	27.6 (25)	99	25/25
14-1	28.3 (25)	25/25	27.7 (25)	98	25/25	28.2 (25)	100	25/25	28.3 (25)	100	25/25
15-1	28.4 (25)	25/25	27.5 (25)	97	25/25	27.8 (25)	98	25/25	27.8 (24)	98	24/25
16-1	28.5 (25)	25/25	27.6 (25)	97	25/25	28.0 (25)	98	25/25	28.2 (24)	99	24/25
17-1	28.7 (25)	25/25	28.0 (25)	98	25/25	28.4 (25)	99	25/25	28.5 (24)	99	24/25
18-1	28.8 (25)	25/25	27.7 (24)	96	24/25	28.3 (25)	98	25/25	28.2 (24)	98	24/25
19-1	28.6 (25)	25/25	27.5 (24)	96	24/25	28.2 (25)	99	25/25	28.2 (24)	99	24/25
20-1	28.7 (25)	25/25	27.8 (24)	97	24/25	28.3 (25)	99	25/25	28.4 (24)	99	24/25
21-1	28.5 (25)	25/25	27.7 (24)	97	24/25	28.1 (25)	99	25/25	28.2 (24)	99	24/25
22-1	28.7 (25)	25/25	27.9 (24)	97	24/25	28.3 (25)	99	25/25	28.3 (24)	99	24/25
23-1	28.8 (25)	25/25	28.1 (24)	98	24/25	28.5 (25)	99	25/25	28.3 (24)	98	24/25
24-1	29.1 (25)	25/25	28.3 (24)	97	24/25	29.2 (25)	100	25/25	29.1 (23)	100	23/25
25-1	29.0 (25)	25/25	28.3 (24)	98	24/25	29.3 (25)	101	25/25	29.1 (23)	100	23/25
26-1	29.2 (25)	25/25	28.6 (24)	98	24/25	29.3 (25)	100	25/25	29.2 (23)	100	23/25
26-7	29.3 (25)	25/25	28.6 (24)	98	24/25	29.5 (25)	101	25/25	29.5 (23)	101	23/25

&lt; &gt;: No. of effective animals, ( ): No. of measured animals Av. Wt. : g

TABLE A 6

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL

NUMBERS : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901

## MEAN BODY WEIGHTS AND SURVIVAL

ANIMAL : Jic: CB6F1-Tg rasH2@Jcl

UNIT : g

SEX : FEMALE

Week-Day on Study	Control		50 mg/kg			100 mg/kg			200 mg/kg		
	Av. Wt. <25>	No. of Surviv. <25>	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.
0-0	20.3 (25)	25/25	20.3 (25)	100	25/25	20.3 (25)	100	25/25	20.3 (25)	100	25/25
1-1	19.5 (25)	25/25	19.6 (25)	101	25/25	19.5 (25)	100	25/25	19.5 (25)	100	25/25
2-1	20.3 (25)	25/25	20.1 (25)	99	25/25	20.5 (25)	101	25/25	20.6 (25)	101	25/25
3-1	20.5 (25)	25/25	20.5 (25)	100	25/25	21.1 (25)	103	25/25	21.2 (25)	103	25/25
4-1	20.2 (25)	25/25	20.3 (25)	100	25/25	20.9 (25)	103	25/25	21.4 (25)	106	25/25
5-1	20.1 (25)	25/25	20.5 (25)	102	25/25	20.8 (25)	103	25/25	21.3 (25)	106	25/25
6-1	20.2 (25)	25/25	20.5 (25)	101	25/25	20.7 (25)	102	25/25	21.0 (25)	104	25/25
7-1	20.6 (25)	25/25	20.8 (25)	101	25/25	20.8 (25)	101	25/25	21.1 (25)	102	25/25
8-1	21.2 (25)	25/25	20.7 (25)	98	25/25	21.1 (25)	100	25/25	21.7 (25)	102	25/25
9-1	21.4 (25)	25/25	21.2 (25)	99	25/25	21.6 (25)	101	25/25	21.9 (25)	102	25/25
10-1	21.8 (25)	25/25	21.6 (25)	99	25/25	21.7 (25)	100	25/25	21.9 (25)	100	25/25
11-1	21.9 (25)	25/25	21.4 (25)	98	25/25	21.4 (25)	98	25/25	21.2 (25)	97	25/25
12-1	22.0 (25)	25/25	21.6 (25)	98	25/25	22.0 (25)	100	25/25	21.7 (25)	99	25/25
13-1	22.1 (25)	25/25	21.9 (25)	99	25/25	21.7 (25)	98	25/25	21.6 (25)	98	25/25
14-1	22.2 (25)	25/25	21.8 (25)	98	25/25	22.0 (25)	99	25/25	21.8 (25)	98	25/25
15-1	21.9 (25)	25/25	21.5 (25)	98	25/25	22.1 (25)	101	25/25	22.3 (25)	102	25/25
16-1	22.2 (25)	25/25	21.9 (25)	99	25/25	21.9 (25)	99	25/25	21.8 (25)	98	25/25
17-1	22.0 (25)	25/25	21.5 (25)	98	25/25	21.7 (25)	99	25/25	21.7 (25)	99	25/25
18-1	22.3 (25)	25/25	22.0 (25)	99	25/25	22.5 (25)	101	25/25	22.4 (25)	100	25/25
19-1	22.3 (25)	25/25	21.9 (25)	98	25/25	22.0 (25)	99	25/25	21.8 (25)	98	25/25
20-1	22.2 (25)	25/25	21.7 (25)	98	25/25	21.9 (25)	99	25/25	22.1 (25)	100	25/25
21-1	22.8 (24)	24/25	22.0 (25)	96	25/25	21.9 (25)	96	25/25	21.8 (25)	96	25/25
22-1	22.8 (24)	24/25	22.1 (24)	97	24/25	22.4 (25)	98	25/25	22.2 (25)	97	25/25
23-1	22.3 (24)	24/25	22.1 (24)	99	24/25	22.2 (25)	100	25/25	21.7 (25)	97	25/25
24-1	22.6 (24)	24/25	22.4 (24)	99	24/25	22.4 (25)	99	25/25	22.0 (25)	97	25/25
25-1	22.9 (24)	24/25	22.1 (24)	97	24/25	22.3 (25)	97	25/25	21.9 (25)	96	25/25
26-1	22.7 (23)	23/25	22.6 (24)	100	24/25	22.7 (25)	100	25/25	22.3 (24)	98	24/25
26-7	23.1 (23)	23/25	22.4 (24)	97	24/25	22.8 (25)	99	25/25	22.4 (24)	97	24/25

< >: No. of effective animals, ( ): No. of measured animals Av. Wt. : g

TABLE A 7

BODY WEIGHT CHANGES : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	0-0	1-1	2-1	3-1	4-1	5-1	6-1
Control	24.7± 1.0	24.8± 1.0	25.2± 1.2	25.3± 1.2	25.7± 1.2	25.9± 1.5	26.4± 1.4
50 mg/kg	24.7± 1.0	24.6± 0.9	25.1± 1.3	25.0± 1.2	25.5± 1.1	25.7± 1.2	25.9± 1.0
100 mg/kg	24.6± 1.1	24.5± 1.0	25.2± 1.0	25.0± 0.9	25.6± 1.2	25.7± 1.0	26.2± 1.2
200 mg/kg	24.7± 1.0	24.5± 0.9	25.7± 1.1	25.5± 1.0	26.1± 1.1	25.9± 1.1	26.4± 1.1

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jc1  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	7-1	8-1	9-1	10-1	11-1	12-1	13-1
Control	26.8± 1.6	26.9± 1.6	27.4± 1.7	27.8± 1.7	27.5± 1.8	27.7± 1.8	28.0± 1.8
50 mg/kg	26.3± 1.1	26.3± 1.2	26.9± 1.3	27.2± 1.4	26.9± 1.3	27.1± 1.3	27.3± 1.3
100 mg/kg	26.7± 1.4	26.5± 1.3	27.4± 1.4	27.6± 1.4	27.3± 1.5	27.5± 1.3	27.7± 1.5
200 mg/kg	26.9± 1.2	26.6± 1.2	27.7± 1.3	27.7± 1.4	27.0± 1.4	27.4± 1.4	27.6± 1.6

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20JcI  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	14-1	15-1	16-1	17-1	18-1	19-1	20-1
Control	28.3± 1.5	28.4± 1.8	28.5± 1.9	28.7± 1.9	28.8± 1.8	28.6± 2.0	28.7± 2.1
50 mg/kg	27.7± 1.1	27.5± 1.3	27.6± 1.4	28.0± 1.3	27.7± 1.3	27.5± 1.4	27.8± 1.4
100 mg/kg	28.2± 1.4	27.8± 1.6	28.0± 1.7	28.4± 1.6	28.3± 1.5	28.2± 1.5	28.3± 1.5
200 mg/kg	28.3± 1.7	27.8± 1.7	28.2± 1.7	28.5± 1.6	28.2± 1.5	28.2± 1.4	28.4± 1.4

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	21-1	22-1	23-1	24-1	25-1	26-1	26-7
Control	28.5± 1.9	28.7± 2.0	28.8± 1.9	29.1± 2.1	29.0± 2.0	29.2± 1.9	29.3± 2.1
50 mg/kg	27.7± 1.3	27.9± 1.4	28.1± 1.5	28.3± 1.5	28.3± 1.4	28.6± 1.5	28.6± 1.4
100 mg/kg	28.1± 1.4	28.3± 1.5	28.5± 1.4	29.2± 1.6	29.3± 1.5	29.3± 1.5	29.5± 1.7
200 mg/kg	28.2± 1.4	28.3± 1.5	28.3± 1.5	29.1± 1.6	29.1± 1.7	29.2± 1.7	29.5± 1.8

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE A 8

BODY WEIGHT CHANGES : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	0-0	1-1	2-1	3-1	4-1	5-1	6-1
Control	20.3± 1.2	19.5± 1.2	20.3± 1.5	20.5± 1.4	20.2± 1.2	20.1± 1.2	20.2± 1.1
50 mg/kg	20.3± 1.2	19.6± 1.1	20.1± 1.2	20.5± 1.5	20.3± 1.4	20.5± 1.5	20.5± 1.3
100 mg/kg	20.3± 1.2	19.5± 1.1	20.5± 1.5	21.1± 1.6	20.9± 1.4	20.8± 1.4	20.7± 1.3
200 mg/kg	20.3± 1.2	19.5± 1.0	20.6± 1.2	21.2± 1.2	21.4± 1.3**	21.3± 1.3**	21.0± 1.2

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	7-1	8-1	9-1	10-1	11-1	12-1	13-1
Control	20.6± 1.2	21.2± 1.1	21.4± 1.3	21.8± 1.3	21.9± 1.5	22.0± 1.4	22.1± 1.3
50 mg/kg	20.8± 1.4	20.7± 1.3	21.2± 1.2	21.6± 1.3	21.4± 1.4	21.6± 1.2	21.9± 1.5
100 mg/kg	20.8± 1.2	21.1± 1.2	21.6± 1.2	21.7± 1.0	21.4± 1.2	22.0± 1.3	21.7± 1.0
200 mg/kg	21.1± 1.3	21.7± 1.2	21.9± 1.1	21.9± 0.8	21.2± 1.0	21.7± 1.0	21.6± 0.8

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	14-1	15-1	16-1	17-1	18-1	19-1	20-1
Control	22.2± 1.6	21.9± 1.2	22.2± 1.5	22.0± 1.3	22.3± 1.3	22.3± 1.6	22.2± 1.5
50 mg/kg	21.8± 1.3	21.5± 1.2	21.9± 1.5	21.5± 1.5	22.0± 1.2	21.9± 1.5	21.7± 1.1
100 mg/kg	22.0± 1.1	22.1± 1.3	21.9± 1.1	21.7± 1.0	22.5± 1.2	22.0± 1.1	21.9± 1.0
200 mg/kg	21.8± 1.1	22.3± 1.1	21.8± 1.2	21.7± 1.1	22.4± 0.8	21.8± 1.0	22.1± 1.0

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

PAGE : 4

Group Name	Administration week-day						
	21-1	22-1	23-1	24-1	25-1	26-1	26-7
Control	22.8± 1.5	22.8± 1.3	22.3± 1.2	22.6± 1.3	22.9± 1.3	22.7± 1.3	23.1± 1.5
50 mg/kg	22.0± 1.2	22.1± 1.4	22.1± 1.5	22.4± 1.5	22.1± 1.2	22.6± 1.6	22.4± 1.0
100 mg/kg	21.9± 1.2*	22.4± 1.2	22.2± 1.2	22.4± 1.2	22.3± 1.6	22.7± 1.1	22.8± 1.3
200 mg/kg	21.8± 0.9*	22.2± 1.1	21.7± 0.9	22.0± 1.0	21.9± 1.0	22.3± 1.1	22.4± 1.3

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

(HAN260)

BAIS 5

TABLE A 9

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL

NUMBERS : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900

## MEAN FOOD CONSUMPTION AND SURVIVAL

ANIMAL : Jic: CB6F1-Tg rasH2@Jcl

UNIT : g

SEX : MALE

Week-Day on Study	Control		50 mg/kg			100 mg/kg			200 mg/kg		
	Av. FC. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.
2-1	3.9 (25)	25/25	3.9 (25)	100	25/25	4.0 (25)	103	25/25	4.2 (25)	108	25/25
3-1	3.3 (25)	25/25	3.5 (25)	106	25/25	3.5 (25)	106	25/25	3.6 (25)	109	25/25
4-1	3.3 (25)	25/25	3.3 (25)	100	25/25	3.3 (25)	100	25/25	3.5 (25)	106	25/25
5-1	3.4 (25)	25/25	3.4 (25)	100	25/25	3.5 (25)	103	25/25	3.5 (25)	103	25/25
6-1	3.3 (25)	25/25	3.1 (25)	94	25/25	3.2 (25)	97	25/25	3.4 (25)	103	25/25
7-1	3.3 (25)	25/25	3.3 (25)	100	25/25	3.3 (25)	100	25/25	3.5 (25)	106	25/25
8-1	3.3 (25)	25/25	3.2 (25)	97	25/25	3.3 (25)	100	25/25	3.4 (25)	103	25/25
9-1	3.4 (25)	25/25	3.3 (25)	97	25/25	3.5 (25)	103	25/25	3.6 (25)	106	25/25
10-1	3.2 (25)	25/25	3.2 (25)	100	25/25	3.3 (25)	103	25/25	3.4 (25)	106	25/25
11-1	3.1 (25)	25/25	3.1 (25)	100	25/25	3.3 (25)	106	25/25	3.3 (25)	106	25/25
12-1	3.2 (25)	25/25	3.1 (25)	97	25/25	3.3 (25)	103	25/25	3.4 (25)	106	25/25
13-1	3.3 (25)	25/25	3.2 (25)	97	25/25	3.3 (25)	100	25/25	3.5 (25)	106	25/25
14-1	3.2 (25)	25/25	3.1 (25)	97	25/25	3.3 (25)	103	25/25	3.4 (25)	106	25/25
15-1	3.3 (25)	25/25	3.1 (25)	94	25/25	3.2 (25)	97	25/25	3.3 (24)	100	24/25
16-1	3.2 (25)	25/25	3.0 (25)	94	25/25	3.3 (25)	103	25/25	3.4 (24)	106	24/25
17-1	3.3 (25)	25/25	3.1 (25)	94	25/25	3.3 (25)	100	25/25	3.4 (24)	103	24/25
18-1	3.3 (25)	25/25	3.0 (24)	91	24/25	3.2 (25)	97	25/25	3.3 (24)	100	24/25
19-1	3.1 (25)	25/25	2.9 (24)	94	24/25	3.2 (25)	103	25/25	3.3 (24)	106	24/25
20-1	3.1 (25)	25/25	3.0 (24)	97	24/25	3.2 (25)	103	25/25	3.3 (24)	106	24/25
21-1	3.1 (25)	25/25	3.0 (24)	97	24/25	3.2 (25)	103	25/25	3.3 (24)	106	24/25
22-1	3.2 (25)	25/25	3.0 (24)	94	24/25	3.3 (25)	103	25/25	3.3 (24)	103	24/25
23-1	3.1 (25)	25/25	3.0 (24)	97	24/25	3.2 (25)	103	25/25	3.3 (24)	106	24/25
24-1	3.2 (25)	25/25	3.0 (24)	94	24/25	3.3 (25)	103	25/25	3.4 (23)	106	23/25
25-1	3.1 (25)	25/25	2.9 (24)	94	24/25	3.1 (25)	100	25/25	3.2 (23)	103	23/25
26-1	3.3 (25)	25/25	3.1 (24)	94	24/25	3.3 (25)	100	25/25	3.4 (23)	103	23/25
26-7	3.2 (25)	25/25	3.0 (24)	94	24/25	3.2 (25)	100	25/25	3.4 (23)	106	23/25

&lt; &gt;: No. of effective animals, ( ): No. of measured animals Av. FC. : g



TABLE A 10

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL

NUMBERS : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901

## MEAN FOOD CONSUMPTION AND SURVIVAL

ANIMAL : Jic: CB6F1-Tg rasH2@Jcl

UNIT : g

SEX : FEMALE

Week-Day on Study	Control		50 mg/kg			100 mg/kg			200 mg/kg		
	Av. FC. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.
2-1	3.3 (25)	25/25	3.3 (25)	100	25/25	3.4 (25)	103	25/25	3.4 (25)	103	25/25
3-1	3.0 (25)	25/25	3.2 (25)	107	25/25	3.2 (25)	107	25/25	3.3 (25)	110	25/25
4-1	2.7 (25)	25/25	2.9 (25)	107	25/25	2.8 (25)	104	25/25	3.0 (25)	111	25/25
5-1	2.8 (25)	25/25	2.9 (25)	104	25/25	2.8 (25)	100	25/25	3.0 (25)	107	25/25
6-1	2.9 (25)	25/25	2.9 (25)	100	25/25	2.9 (25)	100	25/25	2.9 (25)	100	25/25
7-1	3.0 (25)	25/25	2.9 (25)	97	25/25	2.9 (25)	97	25/25	3.1 (25)	103	25/25
8-1	3.0 (25)	25/25	2.9 (25)	97	25/25	2.9 (25)	97	25/25	3.0 (25)	100	25/25
9-1	3.0 (25)	25/25	3.0 (25)	100	25/25	2.9 (25)	97	25/25	3.0 (25)	100	25/25
10-1	3.0 (25)	25/25	3.0 (25)	100	25/25	2.9 (25)	97	25/25	2.9 (25)	97	25/25
11-1	3.0 (25)	25/25	3.0 (25)	100	25/25	2.9 (25)	97	25/25	2.9 (25)	97	25/25
12-1	3.0 (25)	25/25	3.0 (25)	100	25/25	2.9 (25)	97	25/25	3.0 (25)	100	25/25
13-1	2.9 (25)	25/25	3.0 (25)	103	25/25	2.8 (25)	97	25/25	2.9 (25)	100	25/25
14-1	3.0 (25)	25/25	2.9 (25)	97	25/25	2.8 (25)	93	25/25	2.9 (25)	97	25/25
15-1	2.9 (25)	25/25	2.8 (25)	97	25/25	2.9 (25)	100	25/25	2.9 (25)	100	25/25
16-1	2.9 (25)	25/25	2.9 (25)	100	25/25	2.8 (25)	97	25/25	2.9 (25)	100	25/25
17-1	2.9 (25)	25/25	2.8 (25)	97	25/25	2.9 (25)	100	25/25	2.9 (25)	100	25/25
18-1	2.9 (25)	25/25	2.9 (25)	100	25/25	2.9 (25)	100	25/25	2.8 (25)	97	25/25
19-1	2.8 (25)	25/25	2.8 (25)	100	25/25	2.8 (25)	100	25/25	2.8 (25)	100	25/25
20-1	2.9 (25)	25/25	2.8 (25)	97	25/25	2.9 (25)	100	25/25	2.8 (25)	97	25/25
21-1	2.8 (24)	24/25	2.9 (25)	104	25/25	2.7 (25)	96	25/25	2.8 (25)	100	25/25
22-1	2.8 (24)	24/25	2.9 (24)	104	24/25	3.0 (25)	107	25/25	2.9 (25)	104	25/25
23-1	2.8 (24)	24/25	2.9 (24)	104	24/25	2.8 (25)	100	25/25	2.8 (25)	100	25/25
24-1	2.8 (24)	24/25	3.0 (24)	107	24/25	2.9 (25)	104	25/25	2.9 (25)	104	25/25
25-1	3.0 (24)	24/25	2.8 (24)	93	24/25	2.8 (25)	93	25/25	2.8 (25)	93	25/25
26-1	2.8 (23)	23/25	3.0 (24)	107	24/25	2.9 (25)	104	25/25	2.8 (24)	100	24/25
26-7	2.8 (23)	23/25	2.9 (24)	104	24/25	2.8 (25)	100	25/25	2.7 (24)	96	24/25

&lt; &gt;: No. of effective animals, ( ): No. of measured animals Av. FC. : g

TABLE A 11

FOOD CONSUMPTION CHANGES : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	2-1 (7)	3-1 (7)	4-1 (7)	5-1 (7)	6-1 (7)	7-1 (7)	8-1 (7)
Control	3.9± 0.4	3.3± 0.3	3.3± 0.3	3.4± 0.3	3.3± 0.3	3.3± 0.3	3.3± 0.3
50 mg/kg	3.9± 0.4	3.5± 0.3	3.3± 0.2	3.4± 0.2	3.1± 0.2	3.3± 0.3	3.2± 0.2
100 mg/kg	4.0± 0.4	3.5± 0.3	3.3± 0.4	3.5± 0.2	3.2± 0.3	3.3± 0.3	3.3± 0.3
200 mg/kg	4.2± 0.4	3.6± 0.3*	3.5± 0.2*	3.5± 0.3	3.4± 0.3	3.5± 0.3	3.4± 0.3

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	9-1 (7)	10-1 (7)	11-1 (7)	12-1 (7)	13-1 (7)	14-1 (7)	15-1 (7)
Control	3.4± 0.3	3.2± 0.3	3.1± 0.3	3.2± 0.3	3.3± 0.3	3.2± 0.3	3.3± 0.3
50 mg/kg	3.3± 0.3	3.2± 0.3	3.1± 0.2	3.1± 0.2	3.2± 0.2	3.1± 0.2	3.1± 0.2*
100 mg/kg	3.5± 0.3	3.3± 0.3	3.3± 0.3	3.3± 0.3	3.3± 0.3	3.3± 0.3	3.2± 0.3
200 mg/kg	3.6± 0.4**	3.4± 0.3	3.3± 0.3	3.4± 0.3	3.5± 0.4	3.4± 0.3	3.3± 0.4

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	16-1 (7)	17-1 (7)	18-1 (7)	19-1 (7)	20-1 (7)	21-1 (7)	22-1 (7)
Control	3.2± 0.3	3.3± 0.3	3.3± 0.3	3.1± 0.3	3.1± 0.4	3.1± 0.3	3.2± 0.4
50 mg/kg	3.0± 0.2	3.1± 0.2	3.0± 0.2**	2.9± 0.2	3.0± 0.2	3.0± 0.2	3.0± 0.2
100 mg/kg	3.3± 0.3	3.3± 0.3	3.2± 0.3	3.2± 0.2	3.2± 0.3	3.2± 0.3	3.3± 0.3
200 mg/kg	3.4± 0.3	3.4± 0.3	3.3± 0.3	3.3± 0.4	3.3± 0.3	3.3± 0.3	3.3± 0.4

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
UNIT : g  
REPORT TYPE : A1 26  
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
ALL ANIMALS

Group Name	Administration week-day (effective)				
	23-1 (7)	24-1 (7)	25-1 (7)	26-1 (7)	26-7 (6)
Control	3.1± 0.3	3.2± 0.4	3.1± 0.3	3.3± 0.3	3.2± 0.3
50 mg/kg	3.0± 0.2	3.0± 0.2	2.9± 0.2	3.1± 0.3	3.0± 0.2
100 mg/kg	3.2± 0.3	3.3± 0.3	3.1± 0.3	3.3± 0.3	3.2± 0.3
200 mg/kg	3.3± 0.3	3.4± 0.3	3.2± 0.4	3.4± 0.3	3.4± 0.4

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE A 12

FOOD CONSUMPTION CHANGES : FEMALE

(Control, 50, 100 and 200 mg/kg groups)



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	2-1 (7)	3-1 (7)	4-1 (7)	5-1 (7)	6-1 (7)	7-1 (7)	8-1 (7)
Control	3.3± 0.4	3.0± 0.2	2.7± 0.2	2.8± 0.3	2.9± 0.3	3.0± 0.2	3.0± 0.2
50 mg/kg	3.3± 0.3	3.2± 0.3*	2.9± 0.3*	2.9± 0.3	2.9± 0.3	2.9± 0.3	2.9± 0.2
100 mg/kg	3.4± 0.4	3.2± 0.3**	2.8± 0.2	2.8± 0.2	2.9± 0.3	2.9± 0.2	2.9± 0.3
200 mg/kg	3.4± 0.3	3.3± 0.3**	3.0± 0.3**	3.0± 0.3**	2.9± 0.3	3.1± 0.3	3.0± 0.2

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	9-1 (7)	10-1 (7)	11-1 (7)	12-1 (7)	13-1 (7)	14-1 (7)	15-1 (7)
Control	3.0± 0.3	3.0± 0.3	3.0± 0.4	3.0± 0.3	2.9± 0.3	3.0± 0.4	2.9± 0.2
50 mg/kg	3.0± 0.2	3.0± 0.2	3.0± 0.3	3.0± 0.3	3.0± 0.3	2.9± 0.3	2.8± 0.2
100 mg/kg	2.9± 0.2	2.9± 0.2	2.9± 0.3	2.9± 0.3	2.8± 0.2	2.8± 0.2	2.9± 0.2
200 mg/kg	3.0± 0.3	2.9± 0.3	2.9± 0.4	3.0± 0.4	2.9± 0.3	2.9± 0.4	2.9± 0.4

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	16-1 (7)	17-1 (7)	18-1 (7)	19-1 (7)	20-1 (7)	21-1 (7)	22-1 (7)
Control	2.9± 0.3	2.9± 0.3	2.9± 0.2	2.8± 0.3	2.9± 0.3	2.8± 0.3	2.8± 0.3
50 mg/kg	2.9± 0.3	2.8± 0.3	2.9± 0.2	2.8± 0.3	2.8± 0.3	2.9± 0.2	2.9± 0.2
100 mg/kg	2.8± 0.2	2.9± 0.3	2.9± 0.4	2.8± 0.2	2.9± 0.3	2.7± 0.2	3.0± 0.3
200 mg/kg	2.9± 0.3	2.9± 0.4	2.8± 0.3	2.8± 0.3	2.8± 0.3	2.8± 0.3	2.9± 0.3

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)				
	23-1 (7)	24-1 (7)	25-1 (7)	26-1 (7)	26-7 (6)
Control	2.8± 0.3	2.8± 0.2	3.0± 0.3	2.8± 0.2	2.8± 0.3
50 mg/kg	2.9± 0.3	3.0± 0.4	2.8± 0.2	3.0± 0.4	2.9± 0.2
100 mg/kg	2.8± 0.4	2.9± 0.2	2.8± 0.3	2.9± 0.2	2.8± 0.3
200 mg/kg	2.8± 0.3	2.9± 0.3	2.8± 0.3	2.8± 0.3	2.7± 0.3

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

TABLE A 13

URINALYSIS : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900

ANIMAL : Jic:CB6F1-Tg rasH2@Jcl

MEASURE TIME : 1

SEX : MALE

REPORT TYPE : A1

URINALYSIS

PAGE : 1

Group Name	NO. of Animals	pH							CHI	Protein					CHI	Glucose					CHI	Ketone body					CHI	Occult blood					CHI
		5.0	6.0	6.5	7.0	7.5	8.0	8.5		-	±	+	2+	3+		4+	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-	±	
Control	20	0	0	0	0	0	1	19	0	2	14	4	0	0	20	0	0	0	0	0	0	5	10	5	0	0	20	0	0	0	0	0	
50 mg/kg	19	0	0	0	0	1	1	17	0	4	14	1	0	0	19	0	0	0	0	0	3	4	10	2	0	0	19	0	0	0	0	0	
100 mg/kg	20	0	0	0	0	2	3	15	0	9	10	1	0	0	20	0	0	0	0	0	10	6	4	0	0	0	20	0	0	0	0	0	
200 mg/kg	19	0	0	0	0	0	0	19	1	15	3	0	0	0	19	0	0	0	0	0	17	1	1	0	0	0	19	0	0	0	0	0	

Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01

Test of CHI SQUARE

(HCL101)

BAIS5

STUDY NO. : 0900

URINALYSIS

ANIMAL : Jic:CB6F1-Tg rasH2@Jcl

MEASURE TIME : 1

SEX : MALE

REPORT TYPE : A1

PAGE : 2

---

Group Name	NO. of Animals	Urobilinogen ± + 2+ 3+ 4+	CHI
Control	20	20 0 0 0 0	
50 mg/kg	19	19 0 0 0 0	
100 mg/kg	20	20 0 0 0 0	
200 mg/kg	19	19 0 0 0 0	

---

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of CHI SQUARE

(HCL101)

BAIS 5

TABLE A 14

URINALYSIS : FEMALE

(Control, 50, 100 and 200 mg/kg groups)



STUDY NO. : 0901

URINALYSIS

ANIMAL : Jic:CB6F1-Tg rash20JcI

MEASURE TIME : 1

SEX : FEMALE

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	pH							CHI	Protein					CHI	Glucose					CHI	Ketone body					CHI	Occult blood					CHI		
		5.0	6.0	6.5	7.0	7.5	8.0	8.5		-	±	+	2+	3+		4+	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-	±		+	2+
Control	13	0	0	0	1	2	4	6		0	5	6	0	2	0		13	0	0	0	0	0		0	6	5	2	0	0		13	0	0	0	0
50 mg/kg	19	0	0	3	4	3	7	2		0	10	8	1	0	0		19	0	0	0	0	0		0	8	8	3	0	0		19	0	0	0	0
100 mg/kg	25	0	0	0	0	2	6	17		0	23	2	0	0	0	**	25	0	0	0	0	0		1	22	2	0	0	0	*	25	0	0	0	0
200 mg/kg	23	0	0	0	1	0	4	18		3	18	2	0	0	0	**	23	0	0	0	0	0		7	15	1	0	0	0	**	23	0	0	0	0

Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01

Test of CHI SQUARE

(HCL101)

BAIS5

STUDY NO. : 0901

URINALYSIS

ANIMAL : Jic:CB6F1-Tg rash20Jcl

MEASURE. TIME : 1

SEX : FEMALE

REPORT TYPE : A1

PAGE : 2

---

Group Name	NO. of Animals	Urobilinogen ± + 2+ 3+ 4+	CHI
Control	13	13 0 0 0 0	
50 mg/kg	19	19 0 0 0 0	
100 mg/kg	25	25 0 0 0 0	
200 mg/kg	23	23 0 0 0 0	

---

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of CHI SQUARE

(HCL101)

BAIS5

TABLE A 15

HEMATOLOGY : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 MEASURE. TIME : 1  
 SEX : MALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>9</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g/dl		PLATELET 10 <sup>9</sup> /μl	
Control	25	11.54±	0.57	16.6±	0.6	48.5±	1.7	42.0±	1.0	14.4±	0.3	34.3±	0.4	1534±	113
50 mg/kg	23	11.74±	0.35	16.8±	0.4	49.1±	1.5	41.8±	0.6	14.4±	0.2	34.4±	0.4	1562±	101
100 mg/kg	25	11.65±	0.36	16.7±	0.4	48.9±	1.2	42.0±	0.6	14.3±	0.3	34.1±	0.3	1560±	101
200 mg/kg	23	11.36±	0.52	16.5±	0.6	48.4±	1.3	42.6±	1.3*	14.5±	0.4	34.0±	0.6	1556±	98

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett

(HCL070)

BAIS 5

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash20Jcl  
MEASURE TIME : 1  
SEX : MALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

Group Name	NO. of Animals	RETICULOCYTE %	
Control	25	3.5±	2.1
50 mg/kg	23	3.0±	0.2
100 mg/kg	25	3.0±	0.2
200 mg/kg	23	3.5±	1.0**

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL070)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 MEASURE TIME : 1  
 SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		10 <sup>9</sup> /μl		NEUTRO		LYMPHO							
Control	25	1.68±	0.92	30.3±	6.4	63.8±	6.7	3.4±	2.0	2.2±	2.4	0.3±	0.7
50 mg/kg	23	1.79±	0.88	34.6±	9.1	60.5±	7.8	3.0±	1.4	1.6±	1.6	0.2±	0.3
100 mg/kg	25	1.64±	0.86	30.8±	7.7	64.4±	7.9	2.7±	1.1	1.8±	1.9	0.3±	0.3
200 mg/kg	23	1.68±	0.89	28.4±	6.4	66.3±	6.2	3.3±	1.0	1.6±	1.0	0.5±	0.4*

Significant difference ; \* : P ≤ 0.05      \*\* : P ≤ 0.01      Test of Dunnett

TABLE A 16

HEMATOLOGY : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901

ANIMAL : Jic:CB6F1-Tg rash2@Jcl

MEASURE TIME : 1

SEX : FEMALE

REPORT TYPE : A1

HEMATOLOGY (SUMMARY)

ALL ANIMALS ( 27W)

PAGE : 1

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g/dl		PLATELET 10 <sup>9</sup> /μl	
Control	23	11.35±	0.33	16.6±	0.3	48.0±	1.1	42.3±	0.6	14.6±	0.3	34.6±	0.4	1382±	128
50 mg/kg	24	11.32±	0.28	16.5±	0.4	48.1±	1.3	42.5±	0.6	14.6±	0.2	34.4±	0.5	1399±	119
100 mg/kg	25	11.05±	0.71	16.1±	1.0*	46.9±	2.4	42.5±	1.4	14.6±	0.4	34.2±	0.7	1394±	189
200 mg/kg	24	10.93±	0.67**	15.5±	1.0**	45.7±	2.7**	41.8±	0.8	14.2±	0.3**	33.9±	0.5**	1450±	97

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett

(HCL070)

BAIS5



STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
MEASURE TIME : 1  
SEX : FEMALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

Group Name	NO. of Animals	RETICULOCYTE %	
Control	23	3.5±	0.5
50 mg/kg	24	3.4±	0.5
100 mg/kg	25	4.6±	4.9
200 mg/kg	24	4.0±	1.4

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL070)

BAIS5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		10 <sup>9</sup> /μl		NEUTRO		LYMPHO							
Control	23	2.27±	1.32	30.1±	8.3	63.8±	7.0	4.1±	1.3	1.5±	1.2	0.5±	0.4
50 mg/kg	24	2.49±	2.03	31.2±	10.6	62.6±	10.6	4.1±	0.9	1.6±	1.1	0.6±	0.3
100 mg/kg	25	2.70±	2.36	30.8±	11.5	61.1±	10.0	5.2±	1.7*	2.1±	2.4	0.8±	0.6
200 mg/kg	24	2.75±	1.32	34.7±	11.2	57.7±	10.9	4.0±	1.4	3.1±	3.6	0.5±	0.3

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett

TABLE A 17

BIOCHEMISTRY : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20JcI  
 MEASURE TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	25	5.1±	0.2	2.8±	0.1	1.2±	0.1	0.06±	0.01	200±	19	94±	10	44±	15
50 mg/kg	23	5.2±	0.2	2.9±	0.1	1.2±	0.1	0.06±	0.01	204±	23	104±	10**	61±	15**
100 mg/kg	25	5.2±	0.2	2.8±	0.1	1.2±	0.1*	0.05±	0.01	225±	16**	116±	9**	57±	21*
200 mg/kg	23	5.3±	0.3	2.7±	0.1**	1.0±	0.1**	0.05±	0.01**	221±	24**	140±	17**	58±	20*

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

(HCL074)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 MEASURE TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	25	188±	19	53±	14	16±	5	210±	48	227±	26	0.4±	0.4	60±	17
50 mg/kg	23	210±	18**	52±	9	17±	4	183±	29	501±	61**	0.5±	0.6	53±	12
100 mg/kg	25	228±	18**	49±	9	17±	4	184±	24	540±	51**	0.3±	0.5	57±	17
200 mg/kg	23	263±	32**	51±	13	16±	3	191±	37	550±	61**	0.5±	0.4	65±	23

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL074)

BAIS 5

STUDY NO. : 0900

ANIMAL : Jic:CB6F1-Tg rash20Jcl

MEASURE. TIME : 1

SEX : MALE

REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)

ALL ANIMALS ( 27W)

PAGE : 3

Group Name	NO. of Animals	UREA NITROGEN		SODIUM		POTASSIUM		CHLORIDE		CALCIUM		INORGANIC PHOSPHORUS	
		mg/dl		mEq/l		mEq/l		mEq/l		mg/dl		mg/dl	
Control	25	20.6±	3.2	153±	2	3.6±	0.2	118±	2	8.5±	0.3	5.1±	0.8
50 mg/kg	23	20.3±	4.9	153±	1	3.6±	0.3	119±	2	8.5±	0.2	4.8±	0.8
100 mg/kg	25	19.8±	3.8	153±	2	3.7±	0.3	118±	2	8.5±	0.3	4.9±	0.8
200 mg/kg	23	25.8±	4.7**	153±	2	3.5±	0.2	119±	2	8.8±	0.3**	5.2±	0.9

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

(HCL074)

BAIS 5

TABLE A 18

BIOCHEMISTRY : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901

ANIMAL : Jic:CB6F1-Tg rash2@Jcl

MEASURE TIME : 1

SEX : FEMALE

REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)

ALL ANIMALS ( 27W)

PAGE : 1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	23	5.2±	0.2	3.1±	0.1	1.4±	0.1	0.05±	0.01	180±	18	67±	7	34±	12
50 mg/kg	24	5.2±	0.2	3.0±	0.1	1.4±	0.1	0.05±	0.01	173±	19	71±	7	36±	12
100 mg/kg	25	5.3±	0.2	3.0±	0.1	1.3±	0.1**	0.04±	0.01	182±	18	79±	12**	43±	21
200 mg/kg	24	5.7±	0.2**	3.2±	0.1**	1.3±	0.1**	0.04±	0.01**	179±	22	113±	10**	56±	14**

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

(HCL074)

BAIS5



STUDY NO. : 0901

ANIMAL : Jic:CB6F1-Tg rash2@Jcl

MEASURE TIME : 1

SEX : FEMALE

REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)  
ALL ANIMALS ( 27W)

PAGE : 2

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	23	137±	13	51±	7	16±	2	159±	30	310±	40	0.5±	0.6	47±	16
50 mg/kg	24	146±	16	55±	10	16±	3	148±	25	355±	52*	0.5±	0.5	54±	10*
100 mg/kg	25	159±	25**	52±	13	15±	3	164±	34	360±	64**	0.7±	1.2	59±	20**
200 mg/kg	24	225±	17**	54±	10	18±	4	171±	33	480±	81**	2.8±	1.4**	61±	19**

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

(HCL074)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 MEASURE. TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 3

Group Name	NO. of Animals	UREA NITROGEN		SODIUM		POTASSIUM		CHLORIDE		CALCIUM		INORGANIC PHOSPHORUS	
		mg/dl		mEq/l		mEq/l		mEq/l		mg/dl		mg/dl	
Control	23	16.7±	3.9	152±	2	3.3±	0.2	118±	2	8.8±	0.3	4.6±	0.8
50 mg/kg	24	15.3±	3.0	152±	2	3.4±	0.3	119±	2	8.8±	0.2	4.9±	0.7
100 mg/kg	25	18.1±	2.7	151±	2	3.2±	0.2	118±	3	8.9±	0.3	5.2±	0.9
200 mg/kg	24	30.3±	4.9**	150±	2*	3.3±	0.2	116±	2**	9.6±	0.2**	6.8±	1.1**

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

(HCL074)

BAIS 5

TABLE A 19

GROSS FINDINGS : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1  
 SEX : MALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control 25 (%)	50 mg/kg 25 (%)	100 mg/kg 25 (%)	200 mg/kg 25 (%)
lung	white zone		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	nodule		1 ( 4)	2 ( 8)	0 ( 0)	0 ( 0)
lymph node	enlarged		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)
thymus	enlarged		0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)
	atrophic		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)
spleen	black zone		2 ( 8)	3 ( 12)	1 ( 4)	1 ( 4)
	nodule		1 ( 4)	1 ( 4)	0 ( 0)	2 ( 8)
stomach	forestomach:nodule		0 ( 0)	0 ( 0)	0 ( 0)	3 ( 12)
small intes	nodule		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)
liver	white zone		0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)
kidney	pale		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)
	white zone		0 ( 0)	0 ( 0)	1 ( 4)	2 ( 8)
	granular		0 ( 0)	0 ( 0)	0 ( 0)	3 ( 12)
muscle	red zone		0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)
abdominal c	ascites		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)
thoracic ca	pleural fluid		0 ( 0)	1 ( 4)	0 ( 0)	1 ( 4)

TABLE A 20

GROSS FINDINGS : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control 25 (%)	50 mg/kg 25 (%)	100 mg/kg 25 (%)	200 mg/kg 25 (%)
skin/app	nodule		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
lung	white zone		2 ( 8)	0 ( 0)	1 ( 4)	0 ( 0)
	nodule		0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)
lymph node	red		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
thymus	atrophic		0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)
spleen	enlarged		2 ( 8)	1 ( 4)	0 ( 0)	0 ( 0)
	black zone		3 ( 12)	1 ( 4)	1 ( 4)	1 ( 4)
	nodule		0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)
stomach	forestomach:nodule		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)
kidney	pale		0 ( 0)	0 ( 0)	0 ( 0)	16 ( 64)
	granular		0 ( 0)	0 ( 0)	0 ( 0)	10 ( 40)
ovary	enlarged		1 ( 4)	0 ( 0)	0 ( 0)	1 ( 4)
uterus	red zone		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)
	nodule		0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)
muscle	red zone		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)
peritoneum	nodule		0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)
thoracic ca	pleural fluid		0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)
other	hindlimb:swollen		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	nose:nodule		0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)

TABLE A 21

ORGAN WEIGHT, ABSOLUTE : MALE  
(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20JcI  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight	THYMUS		ADRENALS		TESTES		HEART		LUNGS	
Control	25	26.3± 2.1	0.059±	0.023	0.016±	0.004	0.262±	0.029	0.156±	0.015	0.157±	0.019
50 mg/kg	24	25.5± 1.6	0.049±	0.010	0.016±	0.003	0.248±	0.031	0.151±	0.017	0.154±	0.016
100 mg/kg	25	26.2± 1.7	0.060±	0.043	0.016±	0.003	0.264±	0.019	0.152±	0.012	0.159±	0.011
200 mg/kg	23	25.9± 1.9	0.044±	0.008**	0.014±	0.003	0.263±	0.026	0.151±	0.016	0.154±	0.017

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	KIDNEYS		SPLEEN		LIVER		BRAIN	
Control	25	0.519±	0.050	0.061±	0.017	1.069±	0.091	0.477±	0.015
50 mg/kg	24	0.496±	0.042	0.058±	0.012	1.124±	0.073	0.476±	0.015
100 mg/kg	25	0.490±	0.035	0.057±	0.008	1.218±	0.087**	0.476±	0.013
200 mg/kg	23	0.505±	0.050	0.069±	0.013**	1.306±	0.119**	0.477±	0.015

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE A 22

ORGAN WEIGHT, ABSOLUTE : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT: ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

PAGE : 1

Group Name	NO. of Animals	Body Weight	THYMUS	ADRENALS	OVARIES	HEART	LUNGS
Control	23	20.4 ± 1.4	0.044 ± 0.019	0.015 ± 0.002	0.031 ± 0.008	0.117 ± 0.010	0.146 ± 0.014
50 mg/kg	24	19.8 ± 1.1	0.032 ± 0.011*	0.014 ± 0.002	0.028 ± 0.005	0.113 ± 0.007	0.142 ± 0.009
100 mg/kg	25	20.1 ± 1.1	0.035 ± 0.011	0.015 ± 0.002	0.029 ± 0.004	0.116 ± 0.010	0.147 ± 0.014
200 mg/kg	24	19.3 ± 1.0**	0.033 ± 0.014*	0.014 ± 0.001	0.028 ± 0.005	0.108 ± 0.008**	0.143 ± 0.014

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL040)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	KIDNEYS		SPLEEN		LIVER		BRAIN	
Control	23	0.343±	0.026	0.068±	0.012	0.885±	0.085	0.481±	0.013
50 mg/kg	24	0.338±	0.017	0.062±	0.012	0.860±	0.057	0.479±	0.014
100 mg/kg	25	0.357±	0.034	0.086±	0.053	0.904±	0.094	0.482±	0.014
200 mg/kg	24	0.358±	0.030	0.079±	0.015**	0.932±	0.073	0.475±	0.014

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE A 23

ORGAN WEIGHT, RELATIVE : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
REPORT TYPE : A1  
SEX : MALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27#)

PAGE : 1

Group Name	NO. of Animals	Body Weight (g)	THYMUS	ADRENALS	TESTES	HEART	LUNGS
Control	25	26.3 ± 2.1	0.224 ± 0.080	0.060 ± 0.015	0.996 ± 0.101	0.592 ± 0.035	0.596 ± 0.068
50 mg/kg	24	25.5 ± 1.6	0.192 ± 0.036	0.062 ± 0.012	0.969 ± 0.100	0.592 ± 0.055	0.605 ± 0.065
100 mg/kg	25	26.2 ± 1.7	0.225 ± 0.143	0.061 ± 0.011	1.009 ± 0.073	0.583 ± 0.035	0.608 ± 0.048
200 mg/kg	23	25.9 ± 1.9	0.172 ± 0.032*	0.055 ± 0.010	1.019 ± 0.113	0.585 ± 0.038	0.597 ± 0.053

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL042)

BAIS 5

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash20Jcl  
REPORT TYPE : A1  
SEX : MALE  
UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 2

Group Name	NO. of Animals	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	25	1.973 ± 0.121	0.231 ± 0.058	4.059 ± 0.165	1.819 ± 0.128
50 mg/kg	24	1.941 ± 0.134	0.227 ± 0.041	4.403 ± 0.198**	1.868 ± 0.088
100 mg/kg	25	1.875 ± 0.108*	0.218 ± 0.029	4.655 ± 0.220**	1.826 ± 0.107
200 mg/kg	23	1.951 ± 0.110	0.267 ± 0.055**	5.045 ± 0.197**	1.852 ± 0.111

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL042)

BAIS 5

TABLE A 24

ORGAN WEIGHT, RELATIVE : FEMALE

(Control, 50, 100 and 200 mg/kg groups)



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight (g)	THYMUS	ADRENALS	OVARIES	HEART	LUNGS
Control	23	20.4 ± 1.4	0.216 ± 0.082	0.073 ± 0.010	0.151 ± 0.039	0.575 ± 0.046	0.713 ± 0.049
50 mg/kg	24	19.8 ± 1.1	0.162 ± 0.049	0.071 ± 0.013	0.143 ± 0.025	0.570 ± 0.029	0.716 ± 0.036
100 mg/kg	25	20.1 ± 1.1	0.171 ± 0.049	0.073 ± 0.009	0.142 ± 0.020	0.580 ± 0.049	0.733 ± 0.072
200 mg/kg	24	19.3 ± 1.0**	0.168 ± 0.060	0.070 ± 0.006	0.144 ± 0.028	0.560 ± 0.037	0.739 ± 0.069

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	23	1.681 ± 0.103	0.332 ± 0.061	4.335 ± 0.296	2.364 ± 0.146
50 mg/kg	24	1.706 ± 0.089	0.311 ± 0.052	4.341 ± 0.218	2.422 ± 0.098
100 mg/kg	25	1.777 ± 0.114**	0.425 ± 0.258	4.495 ± 0.294	2.406 ± 0.109
200 mg/kg	24	1.851 ± 0.096**	0.409 ± 0.070**	4.826 ± 0.203**	2.463 ± 0.104*

Significant difference ; \* : P ≤ 0.05    \*\* : P ≤ 0.01

Test of Dunnett

TABLE A 25

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
 ANIMAL : Jic:CBGF1-Tg rasH2@Jcl  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	50 mg/kg 25	100 mg/kg 25	200 mg/kg 25
(Respiratory system)						
nasal cavit	hemangioma		<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)
lung	bronchiolar-alveolar adenoma		<25> 1 ( 4%)	<25> 4 (16%)	<25> 1 ( 4%)	<25> 1 ( 4%)
(Hematopoietic system)						
spleen	hemangioma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)
	hemangiosarcoma		0 ( 0%)	1 ( 4%)	0 ( 0%)	2 ( 8%)
(Digestive system)						
stomach	squamous cell papilloma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 2 ( 8%)
	squamous cell carcinoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	1 ( 4%)
small intes	hemangiosarcoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
(Urinary system)						
urin bladd	hemangioma		<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)
(Body cavities)						
pleura	hemangioma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
ALL ANIMALS (0- 27W)

PAGE : 2

Organ	Findings	Group Name No. of animals on Study	Control 25	50 mg/kg 25	100 mg/kg 25	200 mg/kg 25
(Body cavities)						
pleura	hemangiosarcoma		<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)

< a > a : Number of animals examined at the site  
b ( c ) b : Number of animals with neoplasm c : b / a \* 100

(HPT085)

BAIS6

TABLE A 26

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@JcI  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	50 mg/kg 25	100 mg/kg 25	200 mg/kg 25
(Integumentary system/appandage)						
skin/app	schwannoma:malignant		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)
(Respiratory system)						
nasal cavit	hemangioma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)
lung	bronchiolar-alveolar adenoma		<25> 3 ( 12%)	<25> 3 ( 12%)	<25> 2 ( 8%)	<25> 0 ( 0%)
	bronchiolar-alveolar carcinoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)
(Hematopoietic system)						
spleen	hemangiosarcoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)
(Digestive system)						
salivary gl	hemangioma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)
stomach	squamous cell carcinoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
(Reproductive system)						
uterus	hemangioma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)
(Musculoskeletal system)						
muscle	hemangioma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rasH20Jc1  
REPORT TYPE : A1  
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	50 mg/kg 25	100 mg/kg 25	200 mg/kg 25
(Body cavities)						
peritoneum	hemangiosarcoma		<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)

< a > a : Number of animals examined at the site  
b ( c ) b : Number of animals with neoplasm c : b / a \* 100

(HPT085)

BA1S6



TABLE A 27

NEOPLASTIC LESIONS-INCIDENCE  
AND STATISTICAL ANALYSIS : MALE  
(Control, 50, 100 and 200 mg/kg groups)

STUDY No. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	50 mg/kg	100 mg/kg	200 mg/kg
SITE : lung TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates (a)	1/25 ( 4.0)	4/25 ( 16.0)	1/25 ( 4.0)	1/25 ( 4.0)
Adjusted rates (b)	4.00	16.67	4.00	4.35
Terminal rates (c)	1/25 ( 4.0)	4/24 ( 16.7)	1/25 ( 4.0)	1/23 ( 4.3)
Statistical analysis				
Peto test				
Standard method (d)	P = _____			
Prevalence method (d)	P = 0.6894			
Combined analysis (d)	P = _____			
Cochran-Armitage test (e)	P = 0.5510			
Fisher Exact test (e)		P = 0.1743	P = 0.7551	P = 0.7551
SITE : spleen TUMOR : hemangiosarcoma				
Tumor rate				
Overall rates (a)	0/25 ( 0.0)	1/25 ( 4.0)	0/25 ( 0.0)	2/25 ( 8.0)
Adjusted rates (b)	0.00	4.17	0.00	4.35
Terminal rates (c)	0/25 ( 0.0)	1/24 ( 4.2)	0/25 ( 0.0)	1/23 ( 4.3)
Statistical analysis				
Peto test				
Standard method (d)	P = 0.1033			
Prevalence method (d)	P = 0.2337			
Combined analysis (d)	P = 0.0763			
Cochran-Armitage test (e)	P = 0.1372			
Fisher Exact test (e)		P = 0.5000	P = N. C.	P = 0.2449
SITE : spleen TUMOR : hemangioma, hemangiosarcoma				
Tumor rate				
Overall rates (a)	1/25 ( 4.0)	1/25 ( 4.0)	0/25 ( 0.0)	2/25 ( 8.0)
Adjusted rates (b)	4.00	4.17	0.00	4.35
Terminal rates (c)	1/25 ( 4.0)	1/24 ( 4.2)	0/25 ( 0.0)	1/23 ( 4.3)
Statistical analysis				
Peto test				
Standard method (d)	P = 0.1033			
Prevalence method (d)	P = 0.4989			
Combined analysis (d)	P = 0.2349			
Cochran-Armitage test (e)	P = 0.4902			
Fisher Exact test (e)		P = 0.7551	P = 0.5000	P = 0.5000

STUDY No. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jc1  
 SEX : MALE

NEOPLASTIC LESIONS—INCIDENCE AND STATISTICAL ANALYSIS

PAGE : 2

Group Name	Control	50 mg/kg	100 mg/kg	200 mg/kg
SITE : stomach TUMOR : squamous cell papilloma				
Tumor rate				
Overall rates (a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	2/25 ( 8.0)
Adjusted rates (b)	0.00	0.00	0.00	8.70
Terminal rates (c)	0/25 ( 0.0)	0/24 ( 0.0)	0/25 ( 0.0)	2/23 ( 8.7)
Statistical analysis				
Peto test				
Standard method (d)	P = -----			
Prevalence method (d)	P = 0.0157* ?			
Combined analysis (d)	P = -----			
Cochran-Armitage test (e)	P = 0.0298*			
Fisher Exact test (e)		P = N. C.	P = N. C.	P = 0.2449
SITE : stomach TUMOR : squamous cell papilloma, squamous cell carcinoma				
Tumor rate				
Overall rates (a)	0/25 ( 0.0)	0/25 ( 0.0)	0/25 ( 0.0)	3/25 ( 12.0)
Adjusted rates (b)	0.00	0.00	0.00	8.70
Terminal rates (c)	0/25 ( 0.0)	0/24 ( 0.0)	0/25 ( 0.0)	2/23 ( 8.7)
Statistical analysis				
Peto test				
Standard method (d)	P = 0.1064			
Prevalence method (d)	P = 0.0157* ?			
Combined analysis (d)	P = 0.0036***?			
Cochran-Armitage test (e)	P = 0.0075**			
Fisher Exact test (e)		P = N. C.	P = N. C.	P = 0.1173

(HPT360A)

BAIS6

- (a): Number of tumor-bearing animals/number of animals examined at the site.  
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c): Observed tumor incidence at terminal kill.  
 (d): Beneath the control incidence are the P-values associated with the trend test.  
     Standard method : Death analysis  
     Prevalence method : Incidental tumor test  
     Combined analysis : Death analysis + Incidental tumor test  
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$   
 N. C. : Statistical value cannot be calculated and was not significant.

STUDY No. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@JcI  
 SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	50 mg/kg	100 mg/kg	200 mg/kg
SITE : ALL SITE TUMOR : hemangioma				
Tumor rate				
Overall rates (a)	1/25 ( 4.0)	2/25 ( 8.0)	0/25 ( 0.0)	1/25 ( 4.0)
Adjusted rates (b)	4.00	8.33	0.00	4.35
Terminal rates (c)	1/25 ( 4.0)	2/24 ( 8.3)	0/25 ( 0.0)	1/23 ( 4.3)
Statistical analysis				
Peto test				
Standard method (d)	P = -----			
Prevalence method (d)	P = 0.5947			
Combined analysis (d)	P = -----			
Cochran-Armitage test (e)	P = 0.7301			
Fisher Exact test (e)		P = 0.5000	P = 0.5000	P = 0.7551
SITE : ALL SITE TUMOR : hemangiosarcoma				
Tumor rate				
Overall rates (a)	0/25 ( 0.0)	2/25 ( 8.0)	0/25 ( 0.0)	3/25 ( 12.0)
Adjusted rates (b)	0.00	4.17	0.00	8.70
Terminal rates (c)	0/25 ( 0.0)	1/24 ( 4.2)	0/25 ( 0.0)	2/23 ( 8.7)
Statistical analysis				
Peto test				
Standard method (d)	P = 0.2413			
Prevalence method (d)	P = 0.0731			
Combined analysis (d)	P = 0.0558			
Cochran-Armitage test (e)	P = 0.1034			
Fisher Exact test (e)		P = 0.2449	P = N. C.	P = 0.1173

(HPT360A)

BA156

- (a): Number of tumor-bearing animals/number of animals examined at the site.  
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c): Observed tumor incidence at terminal kill.  
 (d): Beneath the control incidence are the P-values associated with the trend test.  
 Standard method : Death analysis  
 Prevalence method : Incidental tumor test  
 Combined analysis : Death analysis + Incidental tumor test  
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$   
 N. C. : Statistical value cannot be calculated and was not significant.

TABLE A 28

NEOPLASTIC LESIONS-INCIDENCE  
AND STATISTICAL ANALYSIS : FEMALE  
(Control, 50, 100 and 200 mg/kg groups)

STUDY No. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH20Jc1  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

PAGE : 1

Group Name	Control	50 mg/kg	100 mg/kg	200 mg/kg
SITE : lung TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates (a)	3/25 ( 12.0)	3/25 ( 12.0)	2/25 ( 8.0)	0/25 ( 0.0)
Adjusted rates (b)	13.04	12.50	8.00	0.00
Terminal rates (c)	3/23 ( 13.0)	3/24 ( 12.5)	2/25 ( 8.0)	0/24 ( 0.0)
Statistical analysis				
Peto test				
Standard method (d)	P = -----			
Prevalence method (d)	P = 0.9685			
Combined analysis (d)	P = -----			
Cochran-Armitage test (e)	P = 0.0811			
Fisher Exact test (e)		P = 0.6664	P = 0.5000	P = 0.1173
SITE : lung TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates (a)	3/25 ( 12.0)	3/25 ( 12.0)	3/25 ( 12.0)	0/25 ( 0.0)
Adjusted rates (b)	13.04	12.50	12.00	0.00
Terminal rates (c)	3/23 ( 13.0)	3/24 ( 12.5)	3/25 ( 12.0)	0/24 ( 0.0)
Statistical analysis				
Peto test				
Standard method (d)	P = -----			
Prevalence method (d)	P = 0.9541			
Combined analysis (d)	P = -----			
Cochran-Armitage test (e)	P = 0.1108			
Fisher Exact test (e)		P = 0.6664	P = 0.6664	P = 0.1173

(HPT360A)

BAIS6

- (a) : Number of tumor-bearing animals/number of animals examined at the site.  
 (b) : Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c) : Observed tumor incidence at terminal kill.  
 (d) : Beneath the control incidence are the P-values associated with the trend test.  
       Standard method : Death analysis  
       Prevalence method : Incidental tumor test  
       Combined analysis : Death analysis + Incidental tumor test  
 (e) : The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$   
 N.C. : Statistical value cannot be calculated and was not significant.

STUDY No. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

PAGE : 1

Group Name	Control	50 mg/kg	100 mg/kg	200 mg/kg
SITE : ALL SITE				
TUMOR : hemangioma				
Tumor rate				
Overall rates (a)	1/25 ( 4.0)	0/25 ( 0.0)	2/25 ( 8.0)	1/25 ( 4.0)
Adjusted rates (b)	4.35	0.00	8.00	0.00
Terminal rates (c)	1/23 ( 4.3)	0/24 ( 0.0)	2/25 ( 8.0)	0/24 ( 0.0)
Statistical analysis				
Peto test				
Standard method (d)	P = 0.1130			
Prevalence method (d)	P = 0.6101			
Combined analysis (d)	P = 0.3490			
Cochran-Armitage test (e)	P = 0.6481			
Fisher Exact test (e)		P = 0.5000	P = 0.5000	P = 0.7551

(HPT370A)

BA1S6

- (a) : Number of tumor-bearing animals/number of animals examined at the site.  
 (b) : Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c) : Observed tumor incidence at terminal kill.  
 (d) : Beneath the control incidence are the P-values associated with the trend test.  
     Standard method : Death analysis  
     Prevalence method : Incidental tumor test  
     Combined analysis : Death analysis + Incidental tumor test  
 (e) : The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$   
 N.C. : Statistical value cannot be calculated and was not significant.

TABLE A 29

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF  
TUMORS - TIME RELATED: MALE  
(Control, 50, 100 and 200 mg/kg groups)



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	50 mg/kg	100 mg/kg	200 mg/kg
0 - 26	NO. OF EXAMINED ANIMALS		0	1	0	2
	NO. OF ANIMALS WITH TUMORS		0	1	0	2
	NO. OF ANIMALS WITH SINGLE TUMORS		0	1	0	2
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	0
	NO. OF MALIGNANT TUMORS		0	1	0	2
	NO. OF TOTAL TUMORS		0	1	0	2
27 - 27	NO. OF EXAMINED ANIMALS		25	24	25	23
	NO. OF ANIMALS WITH TUMORS		2	6	1	5
	NO. OF ANIMALS WITH SINGLE TUMORS		2	5	1	4
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	1	0	1
	NO. OF BENIGN TUMORS		2	6	1	4
	NO. OF MALIGNANT TUMORS		0	1	0	2
	NO. OF TOTAL TUMORS		2	7	1	6
0 - 27	NO. OF EXAMINED ANIMALS		25	25	25	25
	NO. OF ANIMALS WITH TUMORS		2	7	1	7
	NO. OF ANIMALS WITH SINGLE TUMORS		2	6	1	6
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	1	0	1
	NO. OF BENIGN TUMORS		2	6	1	4
	NO. OF MALIGNANT TUMORS		0	2	0	4
	NO. OF TOTAL TUMORS		2	8	1	8

TABLE A 30

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF  
TUMORS - TIME RELATED: FEMALE  
(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1  
 SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	50 mg/kg	100 mg/kg	200 mg/kg
0 - 26	NO. OF EXAMINED ANIMALS		2	1	0	1
	NO. OF ANIMALS WITH TUMORS		1	1	0	1
	NO. OF ANIMALS WITH SINGLE TUMORS		1	1	0	1
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		0	0	0	1
	NO. OF MALIGNANT TUMORS		1	1	0	0
	NO. OF TOTAL TUMORS		1	1	0	1
27 - 27	NO. OF EXAMINED ANIMALS		23	24	25	24
	NO. OF ANIMALS WITH TUMORS		4	3	6	1
	NO. OF ANIMALS WITH SINGLE TUMORS		4	3	6	1
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		4	3	4	0
	NO. OF MALIGNANT TUMORS		0	0	2	1
	NO. OF TOTAL TUMORS		4	3	6	1
0 - 27	NO. OF EXAMINED ANIMALS		25	25	25	25
	NO. OF ANIMALS WITH TUMORS		5	4	6	2
	NO. OF ANIMALS WITH SINGLE TUMORS		5	4	6	2
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0
	NO. OF BENIGN TUMORS		4	3	4	1
	NO. OF MALIGNANT TUMORS		1	1	2	1
	NO. OF TOTAL TUMORS		5	4	6	2

TABLE A 31

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR: MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jci  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
ALL ANIMALS (0- 27W)

PAGE : 1

Organ	Findings	Group Name No. of Animals on Study	Control 25	50 mg/kg 25	100 mg/kg 25	200 mg/kg 25
(Hematopoietic system)						
Lymph node	metastasis:stomach tumor		<25> 0	<25> 0	<25> 0	<25> 1

< a > a : Number of animals examined at the site  
b b : Number of animals with lesion

(JPT150)

BA1S6

TABLE A 32

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR: FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rasH20Jc1  
REPORT TYPE : A1  
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
ALL ANIMALS (0- 27W)

PAGE : 1

Organ	Findings	Group Name No. of Animals on Study	Control 25	50 mg/kg 25	100 mg/kg 25	200 mg/kg 25
(Respiratory system)						
lung	metastasis:skin/appendage tumor		<25> 1	<25> 0	<25> 0	<25> 0

< a > a : Number of animals examined at the site  
b : Number of animals with lesion

(JPT150)

BA1S6

TABLE A 33

HISTOPATHOLOGICAL FINDINGS:

NON-NEOPLASTIC LESIONS: MALE

(Control, 50, 100 and 200 mg/kg groups)



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

PAGE : 1

Organ	Findings	Control No. of Animals on Study Grade				50 mg/kg 25				100 mg/kg 25				200 mg/kg 25				
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
(Respiratory system)																		
nasal cavit	angiectasis	<25>				<25>				<25>				<25>				
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	epidermal cyst	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	eosinophilic change:olfactory epithelium	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
	eosinophilic change:respiratory epithelium	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
	respiratory metaplasia:gland	20 ( 80)	0 ( 0)	0 ( 0)	0 ( 0)	19 ( 76)	0 ( 0)	0 ( 0)	0 ( 0)	19 ( 76)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	22 ( 88)	0 ( 0)	0 ( 0)	0 ( 0)
	atrophy:olfactory epithelium	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
nasopharynx	eosinophilic change	<25>				<25>				<25>				<25>				
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
lung	bronchiolar-alveolar cell hyperplasia	<25>				<25>				<25>				<25>				
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study Grade				50 mg/kg 25				100 mg/kg 25				200 mg/kg 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
(Hematopoietic system)																	
thymus	atrophy	<25>				<25>				<25>				<25>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	lymphoid hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
spleen	deposit of melanin	<25>				<25>				<25>				<25>			
		2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	extramedullary hematopoiesis	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)
(Digestive system)																	
stomach	squamous cell hyperplasia:forestomach	<25>				<25>				<25>				<25>			
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
liver	necrosis:focal	<25>				<25>				<25>				<25>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study Grade				50 mg/kg 25				100 mg/kg 25				200 mg/kg 25				
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
(Digestive system)																		
liver	hepatocellular hypertrophy:central	<25>				<25>				<25>				<25>				
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	9 ( 36)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0) **
	focus of cellular alteration	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	1 ( 4)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
(Urinary system)																		
kidney	chronic nephritis	<25>				<25>				<25>				<25>				
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	7 ( 28)	15 ( 60)	0 ( 0)	0 ( 0)	0 ( 0) **
(Endocrine system)																		
pituitary	hemorrhage	<25>				<25>				<25>				<25>				
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	Rathke pouch	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 { c } c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Control 25				50 mg/kg 25				100 mg/kg 25				200 mg/kg 25			
		Grade	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+			
			(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)			
[Endocrine system]																					
pituitary	cystic degeneration:anterior lobe		<25>				<25>				<25>				<25>						
			3	0	0	0	1	0	0	0	3	0	0	0	1	0	0	0			
			( 12)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 12)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)			
thyroid	cyst		<25>				<25>				<25>				<25>						
			1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0			
			( 4)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)			
parathyroid	cyst		<25>				<25>				<25>				<25>						
			0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0			
			( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)				
adrenal	spindle-cell hyperplasia		<25>				<25>				<25>				<25>						
			14	0	0	0	12	0	0	0	11	0	0	0	15	0	0	0			
			( 56)	( 0)	( 0)	( 0)	( 48)	( 0)	( 0)	( 0)	( 44)	( 0)	( 0)	( 0)	( 60)	( 0)	( 0)	( 0)			
[Body cavities]																					
pleura	inflammatory infiltration		<25>				<25>				<25>				<25>						
			0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0			
			( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)				

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

TABLE A 34

HISTOPATHOLOGICAL FINDINGS:  
NON-NEOPLASTIC LESIONS: FEMALE  
(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study Grade				50 mg/kg 25				100 mg/kg 25				200 mg/kg 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
(Integumentary system/appandage)																	
subcutis	inflammation	<25>				<25>				<25>				<25>			
		0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
(Respiratory system)																	
nasal cavit	eosinophilic change:olfactory epithelium	<25>				<25>				<25>				<25>			
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	eosinophilic change:respiratory epithelium	5 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
	respiratory metaplasia:gland	23 ( 92)	0 ( 0)	0 ( 0)	0 ( 0)	22 ( 88)	0 ( 0)	0 ( 0)	0 ( 0)	22 ( 88)	1 ( 4)	0 ( 0)	0 ( 0)	23 ( 92)	0 ( 0)	0 ( 0)	0 ( 0)
nasopharynx	eosinophilic change	<25>				<25>				<25>				<25>			
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
(Hematopoietic system)																	
thymus	atrophy	<25>				<25>				<25>				<25>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study Grade				50 mg/kg 25				100 mg/kg 25				200 mg/kg 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
(Hematopoietic system)																	
spleen	deposit of melanin	<25> 3 0 0 0 ( 12) ( 0) ( 0) ( 0)				<25> 1 0 0 0 ( 4) ( 0) ( 0) ( 0)				<25> 1 0 0 0 ( 4) ( 0) ( 0) ( 0)				<25> 1 0 0 0 ( 4) ( 0) ( 0) ( 0)			
	extramedullary hematopoiesis	0 2 0 0 ( 0) ( 8) ( 0) ( 0)				0 1 0 0 ( 0) ( 4) ( 0) ( 0)				1 0 0 0 ( 4) ( 0) ( 0) ( 0)				2 0 0 0 ( 8) ( 0) ( 0) ( 0)			
(Circulatory system)																	
heart	inflammatory infiltration	<25> 0 1 0 0 ( 0) ( 4) ( 0) ( 0)				<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)				<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)				<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)			
	(Digestive system)																
stomach	erosion:glandular stomach	<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)				<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)				<25> 1 0 0 0 ( 4) ( 0) ( 0) ( 0)				<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)			
	squamous cell hyperplasia:forestomach	0 0 0 0 ( 0) ( 0) ( 0) ( 0)				0 0 0 0 ( 0) ( 0) ( 0) ( 0)				1 0 0 0 ( 4) ( 0) ( 0) ( 0)				0 0 0 0 ( 0) ( 0) ( 0) ( 0)			

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study Grade				50 mg/kg 25				100 mg/kg 25				200 mg/kg 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
<b>(Digestive system)</b>																	
liver	granulation	<25>				<25>				<25>				<25>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	3 (12)	1 ( 4)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	focus of cellular alteration	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
gall bladd	ectopic tissue	<25>				<25>				<25>				<25>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	eosinophilic change	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
<b>(Urinary system)</b>																	
kidney	chronic nephritis	<25>				<25>				<25>				<25>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	7 (28)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	14 (56)	11 (44)	0 ( 0)
<b>(Endocrine system)</b>																	
pituitary	cystic degeneration:anterior lobe	<24>				<25>				<25>				<25>			
		3 (13)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	3 (12)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

PAGE : 4

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				50 mg/kg 25				100 mg/kg 25				200 mg/kg 25			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
<b>(Endocrine system)</b>																		
thyroid	cyst		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
parathyroid	cyst		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
adrenal	spindle-cell hyperplasia		<25>				<25>				<25>				<25>			
			15 ( 60)	10 ( 40)	0 ( 0)	0 ( 0)	19 ( 76)	6 ( 24)	0 ( 0)	0 ( 0)	21 ( 84)	4 ( 16)	0 ( 0)	0 ( 0)	16 ( 64)	8 ( 32)	0 ( 0)	0 ( 0)
<b>(Reproductive system)</b>																		
ovary	thrombus		<25>				<25>				<25>				<25>			
			0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)
ovary	granuloma		<25>				<25>				<25>				<25>			
			0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
uterus	atrophy		<25>				<25>				<25>				<25>			
			1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study 25				50 mg/kg 25				100 mg/kg 25				200 mg/kg 25					
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	
<b>(Reproductive system)</b>																			
uterus	cystic endometrial hyperplasia		<25>				<25>				<25>				<25>				
		10 ( 40)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	14 ( 56)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	13 ( 52)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 20)	0 ( 0)	0 ( 0)
	vascular anomaly	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
vagina	inflammatory polyp		<25>				<25>				<25>				<25>				
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	vascular anomaly	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
<b>(Nervous system)</b>																			
brain	epidermal cyst		<25>				<25>				<25>				<25>				
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

TABLE A 35

CAUSE OF DEATH: MALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
SEX : MALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

PAGE : 1

Group Name	Control	50 mg/kg	100 mg/kg	200 mg/kg
Number of Dead and Moribund Animal	0	1	0	2
tumor d:leukemia	0	0	0	0
tumor d:spleen	0	0	0	1
tumor d:stomach	0	0	0	1
tumor d:pleura	0	1	0	0

(B10120)

BA156

TABLE A 36

CAUSE OF DEATH: FEMALE

(Control, 50, 100 and 200 mg/kg groups)

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
SEX : FEMALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

PAGE : 1

Group Name	Control	50 mg/kg	100 mg/kg	200 mg/kg
Number of Dead and Moribund Animal	2	1	0	1
no microscop confirm	1	0	0	0
tumor d:leukemia	0	0	0	0
tumor d:skin/app	1	0	0	0
tumor d:stomach	0	0	0	0
tumor d:muscle	0	0	0	1
tumor d:peritoneum	0	1	0	0

(B10120)

BA1S6

TABLE B 1

SURVIVAL ANIMAL NUMBERS : MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2θJc1  
 REPORT TYPE : A1 26  
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	15	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BA155



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 26  
 SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)												
		14	15	16	17	18	19	20	21	22	23	24	25	26
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	15	15/15 100.0	14/15 93.3	14/15 93.3	14/15 93.3	13/15 86.7	12/15 80.0	10/15 66.7	10/15 66.7	10/15 66.7	8/15 53.3	8/15 53.3	8/15 53.3	8/15 53.3

Number of survival/ Number of effective animals  
Survival rate(%)

(HAN360)

BAIS5

TABLE B 2

SURVIVAL ANIMAL NUMBERS : FEMALE

(Control and Positive control group)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 26  
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
Posi. Control	15	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0	15/15 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1 26  
 SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks)												
		14	15	16	17	18	19	20	21	22	23	24	25	26
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	23/25 92.0	23/25 92.0
Posi. Control	15	15/15 100.0	15/15 100.0	15/15 100.0	14/15 93.3	10/15 66.7	8/15 53.3	8/15 53.3	7/15 46.7	6/15 40.0	5/15 33.3	5/15 33.3	5/15 33.3	4/15 26.7
		Number of survival/ Number of effective animals Survival rate(%)												

(HAN360)

BA1S5

TABLE B 3

CLINICAL OBSERVATION : MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-1 1	1-1 2	1-2 1	1-2 2	1-3 1	1-3 2	1-4 1	1-4 2	1-5 1	1-5 2	1-6 1	1-6 2	1-7 1	1-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day													
		2-1 1	2-1 2	2-2 1	2-2 2	2-3 1	2-3 2	2-4 1	2-4 2	2-5 1	2-5 2	2-6 1	2-6 2	2-7 1	2-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		3-1 1	3-1 2	3-2 1	3-2 2	3-3 1	3-3 2	3-4 1	3-4 2	3-5 1	3-5 2	3-6 1	3-6 2	3-7 1	3-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day													
		4-1 1	4-1 2	4-2 1	4-2 2	4-3 1	4-3 2	4-4 1	4-4 2	4-5 1	4-5 2	4-6 1	4-6 2	4-7 1	4-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day													
		5-1 1	5-1 2	5-2 1	5-2 2	5-3 1	5-3 2	5-4 1	5-4 2	5-5 1	5-5 2	5-6 1	5-6 2	5-7 1	5-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day													
		6-1 1	6-1 2	6-2 1	6-2 2	6-3 1	6-3 2	6-4 1	6-4 2	6-5 1	6-5 2	6-6 1	6-6 2	6-7 1	6-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 7

Clinical sign	Group Name	Administration Week-day													
		7-1 1	7-1 2	7-2 1	7-2 2	7-3 1	7-3 2	7-4 1	7-4 2	7-5 1	7-5 2	7-6 1	7-6 2	7-7 1	7-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 8

Clinical sign	Group Name	Administration Week-day													
		8-1 1	8-1 2	8-2 1	8-2 2	8-3 1	8-3 2	8-4 1	8-4 2	8-5 1	8-5 2	8-6 1	8-6 2	8-7 1	8-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 9

Clinical sign	Group Name	Administration Week-day													
		9-1 1	9-1 2	9-2 1	9-2 2	9-3 1	9-3 2	9-4 1	9-4 2	9-5 1	9-5 2	9-6 1	9-6 2	9-7 1	9-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 10

Clinical sign	Group Name	Administration Week-day													
		10-1 1	10-1 2	10-2 1	10-2 2	10-3 1	10-3 2	10-4 1	10-4 2	10-5 1	10-5 2	10-6 1	10-6 2	10-7 1	10-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE: A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 11

Clinical sign	Group Name	Administration Week-day													
		11-1 1	11-1 2	11-2 1	11-2 2	11-3 1	11-3 2	11-4 1	11-4 2	11-5 1	11-5 2	11-6 1	11-6 2	11-7 1	11-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 12

Clinical sign	Group Name	Administration Week-day													
		12-1 1	12-1 2	12-2 1	12-2 2	12-3 1	12-3 2	12-4 1	12-4 2	12-5 1	12-5 2	12-6 1	12-6 2	12-7 1	12-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 13

Clinical sign	Group Name	Administration Week-day													
		13-1 1	13-1 2	13-2 1	13-2 2	13-3 1	13-3 2	13-4 1	13-4 2	13-5 1	13-5 2	13-6 1	13-6 2	13-7 1	13-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 14

Clinical sign	Group Name	Administration Week-day													
		14-1 1	14-1 2	14-2 1	14-2 2	14-3 1	14-3 2	14-4 1	14-4 2	14-5 1	14-5 2	14-6 1	14-6 2	14-7 1	14-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 15

Clinical sign	Group Name	Administration Week-day													
		15-1 1	15-1 2	15-2 1	15-2 2	15-3 1	15-3 2	15-4 1	15-4 2	15-5 1	15-5 2	15-6 1	15-6 2	15-7 1	15-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	1	1	1	1	1	1	1	1	1
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	1	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	1	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 16

Clinical sign	Group Name	Administration Week-day													
		16-1 1	16-1 2	16-2 1	16-2 2	16-3 1	16-3 2	16-4 1	16-4 2	16-5 1	16-5 2	16-6 1	16-6 2	16-7 1	16-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILDERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 17

Clinical sign	Group Name	Administration Week-day																																																																																																																																																																																																																																																																																																																																																																																																																																																																																													
		17-1 1	17-1 2	17-2 1	17-2 2	17-3 1	17-3 2	17-4 1	17-4 2	17-5 1	17-5 2	17-6 1	17-6 2	17-7 1	17-7 2																																																																																																																																																																																																																																																																																																																																																																																																																																																																																
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1	A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1	A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1	A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1	A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																																
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																																																																
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																																																																																																
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																																																																																																																																
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0		Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																																																																																																																																																
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0																																																																																																																																																																																																																																																																																																																																																																																																																																																																																

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 18

Clinical sign	Group Name	Administration Week-day													
		18-1 1	18-1 2	18-2 1	18-2 2	18-3 1	18-3 2	18-4 1	18-4 2	18-5 1	18-5 2	18-6 1	18-6 2	18-7 1	18-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	1	1	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 19

Clinical sign	Group Name	Administration Week-day													
		19-1 1	19-1 2	19-2 1	19-2 2	19-3 1	19-3 2	19-4 1	19-4 2	19-5 1	19-5 2	19-6 1	19-6 2	19-7 1	19-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	2	2	2	2	2	2	2	2
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 20

Clinical sign	Group Name	Administration Week-day													
		20-1 1	20-1 2	20-2 1	20-2 2	20-3 1	20-3 2	20-4 1	20-4 2	20-5 1	20-5 2	20-6 1	20-6 2	20-7 1	20-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	3	3	3	3	3	3	3	3	3	3	4	4
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	0	0	0	0	1	1	1	1	1	1	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 21

Clinical sign	Group Name	Administration Week-day													
		21-1 1	21-1 2	21-2 1	21-2 2	21-3 1	21-3 2	21-4 1	21-4 2	21-5 1	21-5 2	21-6 1	21-6 2	21-7 1	21-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	1	1	1	1	1	1	1
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 22

Clinical sign	Group Name	Administration		Week-day		22-2		22-3		22-4		22-5		22-6		22-7	
		22-1 1	22-1 2	22-2 1	22-2 2	22-3 1	22-3 2	22-4 1	22-4 2	22-5 1	22-5 2	22-6 1	22-6 2	22-7 1	22-7 2		
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 23

Clinical sign	Group Name	Administration Week-day													
		23-1 1	23-1 2	23-2 1	23-2 2	23-3 1	23-3 2	23-4 1	23-4 2	23-5 1	23-5 2	23-6 1	23-6 2	23-7 1	23-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	4	4	4	4	4	4	4	4	4	4	5	5	5	5
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	2	2
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	1	1	1	1	1	1	1	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	1	1	1	1	1	1	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	1	1	1	1	1	1	1	1	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	1	1	1	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	1	1	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 24

Clinical sign	Group Name	Administration Week-day													
		24-1 1	24-1 2	24-2 1	24-2 2	24-3 1	24-3 2	24-4 1	24-4 2	24-5 1	24-5 2	24-6 1	24-6 2	24-7 1	24-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	5	5	5	5	5	5	5	5	5	5	5	5	5	5
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	2	2	2	2	2	2	2	2	2	2	2	2
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	1	1	1	1	1	1	1	1	1	1	1	1
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-T& rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 25

Clinical sign	Group Name	Administration Week-day													
		25-1 1	25-1 2	25-2 1	25-2 2	25-3 1	25-3 2	25-4 1	25-4 2	25-5 1	25-5 2	25-6 1	25-6 2	25-7 1	25-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	5	5	5	5	5	5	5	5	5	5	5	5	5	5
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	3	3	3	3	3	3
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	1	1	0	0	0	0
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 26

Clinical sign	Group Name	Administration Week-day													
		26-1 1	26-1 2	26-2 1	26-2 2	26-3 1	26-3 2	26-4 1	26-4 2	26-5 1	26-5 2	26-6 1	26-6 2	26-7 1	26-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	5	5	5	5	5	5	5	5	5	5	5	5	5	5
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	5	5
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	2	2
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. SCROTUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	3	3
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
TACHYPNEA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BLOODY STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 27

Clinical sign	Group Name	Administration		Week-day
		27-1 1	27-1 2	
DEATH	Control	0	0	
	Posi. Control	5	5	
MORIBUND SACRIFICE	Control	0	0	
	Posi. Control	2	2	
A LOT OF SPILLED FOOD	Control	0	0	
	Posi. Control	0	0	
PILOERECTION	Control	0	0	
	Posi. Control	0	0	
PROLAPSE OF ANUS	Control	0	0	
	Posi. Control	0	0	
EXTERNAL MASS	Control	0	0	
	Posi. Control	5	5	
INTERNAL MASS	Control	0	0	
	Posi. Control	0	0	
M. ORAL CAVITY	Control	0	0	
	Posi. Control	2	2	
M. POSTERIOR DORSUM	Control	0	0	
	Posi. Control	1	1	
M. SCROTUM	Control	0	0	
	Posi. Control	3	3	
ANEMIA	Control	0	0	
	Posi. Control	1	1	
HEMORRHAGE	Control	0	0	
	Posi. Control	1	1	
TACHYPNEA	Control	0	0	
	Posi. Control	0	0	
DEEP BREATHING	Control	0	0	
	Posi. Control	0	0	
BLOODY STOOL	Control	0	0	
	Posi. Control	0	0	



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 28

Clinical sign	Group Name	Administration Week-day													
		1-1 1	1-1 2	1-2 1	1-2 2	1-3 1	1-3 2	1-4 1	1-4 2	1-5 1	1-5 2	1-6 1	1-6 2	1-7 1	1-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 29

Clinical sign	Group Name	Administration Week-day													
		2-1 1	2-1 2	2-2 1	2-2 2	2-3 1	2-3 2	2-4 1	2-4 2	2-5 1	2-5 2	2-6 1	2-6 2	2-7 1	2-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 30

Clinical sign	Group Name	Administration Week-day													
		3-1 1	3-1 2	3-2 1	3-2 2	3-3 1	3-3 2	3-4 1	3-4 2	3-5 1	3-5 2	3-6 1	3-6 2	3-7 1	3-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 31

Clinical sign	Group Name	Administration Week-day													
		4-1 1	4-1 2	4-2 1	4-2 2	4-3 1	4-3 2	4-4 1	4-4 2	4-5 1	4-5 2	4-6 1	4-6 2	4-7 1	4-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 32

Clinical sign	Group Name	Administration Week-day													
		5-1 1	5-1 2	5-2 1	5-2 2	5-3 1	5-3 2	5-4 1	5-4 2	5-5 1	5-5 2	5-6 1	5-6 2	5-7 1	5-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HANT90)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 33

Clinical sign	Group Name	Administration Week-day													
		6-1 1	6-1 2	6-2 1	6-2 2	6-3 1	6-3 2	6-4 1	6-4 2	6-5 1	6-5 2	6-6 1	6-6 2	6-7 1	6-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 34

Clinical sign	Group Name	Administration Week-day													
		7-1 1	7-1 2	7-2 1	7-2 2	7-3 1	7-3 2	7-4 1	7-4 2	7-5 1	7-5 2	7-6 1	7-6 2	7-7 1	7-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-T& rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 35

Clinical sign	Group Name	Administration Week-day													
		8-1 1	8-1 2	8-2 1	8-2 2	8-3 1	8-3 2	8-4 1	8-4 2	8-5 1	8-5 2	8-6 1	8-6 2	8-7 1	8-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 36

Clinical sign	Group Name	Administration Week-day													
		9-1 1	9-1 2	9-2 1	9-2 2	9-3 1	9-3 2	9-4 1	9-4 2	9-5 1	9-5 2	9-6 1	9-6 2	9-7 1	9-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HANT90)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg<sup>rasH2@Jc1</sup>  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 37

Clinical sign	Group Name	Administration Week-day													
		10-1 1	10-1 2	10-2 1	10-2 2	10-3 1	10-3 2	10-4 1	10-4 2	10-5 1	10-5 2	10-6 1	10-6 2	10-7 1	10-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 38

Clinical sign	Group Name	Administration Week-day													
		11-1 1	11-1 2	11-2 1	11-2 2	11-3 1	11-3 2	11-4 1	11-4 2	11-5 1	11-5 2	11-6 1	11-6 2	11-7 1	11-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 39

Clinical sign	Group Name	Administration Week-day													
		12-1 1	12-1 2	12-2 1	12-2 2	12-3 1	12-3 2	12-4 1	12-4 2	12-5 1	12-5 2	12-6 1	12-6 2	12-7 1	12-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 40

Clinical sign	Group Name	Administration Week-day													
		13-1 1	13-1 2	13-2 1	13-2 2	13-3 1	13-3 2	13-4 1	13-4 2	13-5 1	13-5 2	13-6 1	13-6 2	13-7 1	13-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HANT90)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-T& rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 41

Clinical sign	Group Name	Administration Week-day													
		14-1 1	14-1 2	14-2 1	14-2 2	14-3 1	14-3 2	14-4 1	14-4 2	14-5 1	14-5 2	14-6 1	14-6 2	14-7 1	14-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HANT90)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 42

Clinical sign	Group Name	Administration Week-day													
		15-1 1	15-1 2	15-2 1	15-2 2	15-3 1	15-3 2	15-4 1	15-4 2	15-5 1	15-5 2	15-6 1	15-6 2	15-7 1	15-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	1	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	14	14	14	14	14	14	14	14	14	14

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 43

Clinical sign	Group Name	Administration Week-day													
		16-1 1	16-1 2	16-2 1	16-2 2	16-3 1	16-3 2	16-4 1	16-4 2	16-5 1	16-5 2	16-6 1	16-6 2	16-7 1	16-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	14	14	14	14	14	14	14	14	14	14	14	14	14	14

(HAN190)

BAIS 5



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 44

Clinical sign	Group Name	Administration Week-day													
		17-1 1	17-1 2	17-2 1	17-2 2	17-3 1	17-3 2	17-4 1	17-4 2	17-5 1	17-5 2	17-6 1	17-6 2	17-7 1	17-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	14	14	14	14	14	14	14	14	14	14	14	14	14	14

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 45

Clinical sign	Group Name	Administration Week-day													
		18-1 1	18-1 2	18-2 1	18-2 2	18-3 1	18-3 2	18-4 1	18-4 2	18-5 1	18-5 2	18-6 1	18-6 2	18-7 1	18-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	1	1	1	1	1	1	1	1	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	14	14	13	13	13	13	12	12	12	12	13	13	13	13

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 46

Clinical sign	Group Name	Administration Week-day													
		19-1 1	19-1 2	19-2 1	19-2 2	19-3 1	19-3 2	19-4 1	19-4 2	19-5 1	19-5 2	19-6 1	19-6 2	19-7 1	19-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	12	12	12	12	12	12	11	11	11	11	11	11	11	10

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 47

Clinical sign	Group Name	Administration Week-day													
		20-1 1	20-1 2	20-2 1	20-2 2	20-3 1	20-3 2	20-4 1	20-4 2	20-5 1	20-5 2	20-6 1	20-6 2	20-7 1	20-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	10	10	10	10	10	10	10	10	10	10	10	10	10	10

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH20JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 48

Clinical sign	Group Name	Administration Week-day													
		21-1 1	21-1 2	21-2 1	21-2 2	21-3 1	21-3 2	21-4 1	21-4 2	21-5 1	21-5 2	21-6 1	21-6 2	21-7 1	21-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	10	10	10	10	10	10	10	9	9	9	9	9	9	9

(HANT90)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 49

Clinical sign	Group Name	Administration Week-day													
		22-1 1	22-1 2	22-2 1	22-2 2	22-3 1	22-3 2	22-4 1	22-4 2	22-5 1	22-5 2	22-6 1	22-6 2	22-7 1	22-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	9	9	9	9	9	9	9	9	8	8	8	8	8	8

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2θJcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 50

Clinical sign	Group Name	Administration Week-day													
		23-1 1	23-1 2	23-2 1	23-2 2	23-3 1	23-3 2	23-4 1	23-4 2	23-5 1	23-5 2	23-6 1	23-6 2	23-7 1	23-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	8	8	8	7	7	7	7	7	7	7	7	7	7	7

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 51

Clinical sign	Group Name	Administration Week-day													
		24-1 1	24-1 2	24-2 1	24-2 2	24-3 1	24-3 2	24-4 1	24-4 2	24-5 1	24-5 2	24-6 1	24-6 2	24-7 1	24-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	7	7	6	6	6	6	6	6	6	6	6	6	6	6

(HAN190)

BAIS 5



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 52

Clinical sign	Group Name	Administration Week-day													
		25-1 1	25-1 2	25-2 1	25-2 2	25-3 1	25-3 2	25-4 1	25-4 2	25-5 1	25-5 2	25-6 1	25-6 2	25-7 1	25-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	6	6	6	6	6	6	6	6	6	5	5	5	5	5

(HAN190)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 53

Clinical sign	Group Name	Administration Week-day													
		26-1 1	26-1 2	26-2 1	26-2 2	26-3 1	26-3 2	26-4 1	26-4 2	26-5 1	26-5 2	26-6 1	26-6 2	26-7 1	26-7 2
SMALL STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	3	3

(HAN190)

BAIS 5

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : MALE

PAGE : 54

Clinical sign	Group Name	Administration Week-day	
		27-1 1	27-1 2
SMALL STOOL	Control	0	0
	Posi. Control	0	0
OLIGO-STOOL	Control	0	0
	Posi. Control	0	0
NON REMARKABLE	Control	25	11
	Posi. Control	3	3

(HAN190)

BAIS 5

TABLE B 4

CLINICAL OBSERVATION : FEMALE

(Control and Positive control group)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-1 1	1-1 2	1-2 1	1-2 2	1-3 1	1-3 2	1-4 1	1-4 2	1-5 1	1-5 2	1-6 1	1-6 2	1-7 1	1-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day			2-2		2-3		2-4		2-5		2-6		2-7	
		2-1 1	2-1 2	2-2 1	2-2 2	2-3 1	2-3 2	2-4 1	2-4 2	2-5 1	2-5 2	2-6 1	2-6 2	2-7 1	2-7 2	
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		3-1 1	3-1 2	3-2 1	3-2 2	3-3 1	3-3 2	3-4 1	3-4 2	3-5 1	3-5 2	3-6 1	3-6 2	3-7 1	3-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day													
		4-1 1	4-1 2	4-2 1	4-2 2	4-3 1	4-3 2	4-4 1	4-4 2	4-5 1	4-5 2	4-6 1	4-6 2	4-7 1	4-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 5

Clinical sign	Group Name	Administration Week-day													
		5-1 1	5-1 2	5-2 1	5-2 2	5-3 1	5-3 2	5-4 1	5-4 2	5-5 1	5-5 2	5-6 1	5-6 2	5-7 1	5-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTON	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 6

Clinical sign	Group Name	Administration Week-day													
		6-1 1	6-1 2	6-2 1	6-2 2	6-3 1	6-3 2	6-4 1	6-4 2	6-5 1	6-5 2	6-6 1	6-6 2	6-7 1	6-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 7

Clinical sign	Group Name	Administration Week-day													
		7-1 1	7-1 2	7-2 1	7-2 2	7-3 1	7-3 2	7-4 1	7-4 2	7-5 1	7-5 2	7-6 1	7-6 2	7-7 1	7-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 8

Clinical sign	Group Name	Administration Week-day													
		8-1 1	8-1 2	8-2 1	8-2 2	8-3 1	8-3 2	8-4 1	8-4 2	8-5 1	8-5 2	8-6 1	8-6 2	8-7 1	8-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 9

Clinical sign	Group Name	Administration Week-day													
		9-1 1	9-1 2	9-2 1	9-2 2	9-3 1	9-3 2	9-4 1	9-4 2	9-5 1	9-5 2	9-6 1	9-6 2	9-7 1	9-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : D901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 10

Clinical sign	Group Name	Administration Week-day													
		10-1 1	10-1 2	10-2 1	10-2 2	10-3 1	10-3 2	10-4 1	10-4 2	10-5 1	10-5 2	10-6 1	10-6 2	10-7 1	10-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 11

Clinical sign	Group Name	Administration Week-day													
		11-1 1	11-1 2	11-2 1	11-2 2	11-3 1	11-3 2	11-4 1	11-4 2	11-5 1	11-5 2	11-6 1	11-6 2	11-7 1	11-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 12

Clinical sign	Group Name	Administration Week-day													
		12-1 1	12-1 2	12-2 1	12-2 2	12-3 1	12-3 2	12-4 1	12-4 2	12-5 1	12-5 2	12-6 1	12-6 2	12-7 1	12-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 13

Clinical sign	Group Name	Administration Week-day													
		13-1 1	13-1 2	13-2 1	13-2 2	13-3 1	13-3 2	13-4 1	13-4 2	13-5 1	13-5 2	13-6 1	13-6 2	13-7 1	13-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 14

Clinical sign	Group Name	Administration Week-day													
		14-1 1	14-1 2	14-2 1	14-2 2	14-3 1	14-3 2	14-4 1	14-4 2	14-5 1	14-5 2	14-6 1	14-6 2	14-7 1	14-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 15

Clinical sign	Group Name	Administration Week-day													
		15-1 1	15-1 2	15-2 1	15-2 2	15-3 1	15-3 2	15-4 1	15-4 2	15-5 1	15-5 2	15-6 1	15-6 2	15-7 1	15-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 16

Clinical sign	Group Name	Administration Week-day													
		16-1 1	16-1 2	16-2 1	16-2 2	16-3 1	16-3 2	16-4 1	16-4 2	16-5 1	16-5 2	16-6 1	16-6 2	16-7 1	16-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 17

Clinical sign	Group Name	Administration Week-day													
		17-1 1	17-1 2	17-2 1	17-2 2	17-3 1	17-3 2	17-4 1	17-4 2	17-5 1	17-5 2	17-6 1	17-6 2	17-7 1	17-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	1	1	2	2	2	2	2	2	2	2	2	2
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	0	0	0	0	0	0	0	1	1	1	1	1
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	1	1	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 18

Clinical sign	Group Name	Administration Week-day													
		18-1 1	18-1 2	18-2 1	18-2 2	18-3 1	18-3 2	18-4 1	18-4 2	18-5 1	18-5 2	18-6 1	18-6 2	18-7 1	18-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	2	2	2	2	2	2	2	4	4	4
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	1	1	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	3	3	3	3	2	2	2	2	2	2	1	1	1	1
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	3	3	3	2	2	2	2	2	2	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 19

Clinical sign	Group Name	Administration Week-day													
		19-1 1	19-1 2	19-2 1	19-2 2	19-3 1	19-3 2	19-4 1	19-4 2	19-5 1	19-5 2	19-6 1	19-6 2	19-7 1	19-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	2	2	2	2	2	2	3	3
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	1	1	1	1	1	1	1	1	1	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	1	1	1	1	1	1	1	1	1	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 20

Clinical sign	Group Name	Administration Week-day			20-2		20-3		20-4		20-5		20-6		20-7	
		20-1 1	20-1 2	20-2 1	20-2 2	20-3 1	20-3 2	20-4 1	20-4 2	20-5 1	20-5 2	20-6 1	20-6 2	20-7 1	20-7 2	
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1	
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
A LOT OF SPILLED FOOD	Control	1	1	1	1	1	1	1	1	1	1	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 21

Clinical sign	Group Name	Administration Week-day													
		21-1 1	21-1 2	21-2 1	21-2 2	21-3 1	21-3 2	21-4 1	21-4 2	21-5 1	21-5 2	21-6 1	21-6 2	21-7 1	21-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	3	3	3	3	3	3	3	3	3	3	4	4	4	4
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTON	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 22

Clinical sign	Group Name	Administration Week-day													
		22-1 1	22-1 2	22-2 1	22-2 2	22-3 1	22-3 2	22-4 1	22-4 2	22-5 1	22-5 2	22-6 1	22-6 2	22-7 1	22-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	4	4	4	4	5	5	5	5	5	5	5	5	5	5
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 23

Clinical sign	Group Name	Administration Week-day													
		23-1 1	23-1 2	23-2 1	23-2 2	23-3 1	23-3 2	23-4 1	23-4 2	23-5 1	23-5 2	23-6 1	23-6 2	23-7 1	23-7 2
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	5	5	5	5	5	5	5	5	5	5	5	5	6	6
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 24

Clinical sign	Group Name	Administration Week-day			24-2 2	24-3 1	24-3 2	24-4 1	24-4 2	24-5 1	24-5 2	24-6 1	24-6 2	24-7 1	24-7 2
		24-1 1	24-1 2	24-2 1											
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	6	6	6	6	6	6	6	6	6	6	6	6	6	6
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
ANEMIA	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 25

Clinical sign	Group Name	Administration Week-day													
		25-1 1	25-1 2	25-2 1	25-2 2	25-3 1	25-3 2	25-4 1	25-4 2	25-5 1	25-5 2	25-6 1	25-6 2	25-7 1	25-7 2
DEATH	Control	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	6	6	6	6	6	6	6	6	6	6	6	6	6	6
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	2
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
ANEMIA	Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 26

Clinical sign	Group Name	Administration Week-day													
		26-1 1	26-1 2	26-2 1	26-2 2	26-3 1	26-3 2	26-4 1	26-4 2	26-5 1	26-5 2	26-6 1	26-6 2	26-7 1	26-7 2
DEATH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	5	5
MORIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	6	6	6	6	6	6	6	6	6	6	6	6	6	6
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
A LOT OF SPILLED FOOD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	1	1	1
PILORECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWELLING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEEP BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 27

Clinical sign	Group Name	Administration Week-day	
		27-1 1	27-1 2
DEATH	Control	1	1
	Posi. Control	5	5
MORIBUND SACRIFICE	Control	1	1
	Posi. Control	6	6
HUNCHBACK POSITION	Control	0	0
	Posi. Control	0	0
PARALYTIC GAIT	Control	0	0
	Posi. Control	0	0
A LOT OF SPILLED FOOD	Control	0	0
	Posi. Control	1	1
PILORECTION	Control	0	0
	Posi. Control	0	0
FROG BELLY	Control	0	0
	Posi. Control	0	0
EXTERNAL MASS	Control	0	0
	Posi. Control	2	2
INTERNAL MASS	Control	0	0
	Posi. Control	0	0
M. PERI-MOUTH	Control	0	0
	Posi. Control	0	0
M. GENITALIA	Control	0	0
	Posi. Control	2	2
ANEMIA	Control	0	0
	Posi. Control	0	0
SWELLING	Control	0	0
	Posi. Control	0	0
HEMORRHAGE	Control	0	0
	Posi. Control	0	0
DEEP BREATHING	Control	0	0
	Posi. Control	0	0

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 28

Clinical sign	Group Name	Administration Week-day													
		1-1 1	1-1 2	1-2 1	1-2 2	1-3 1	1-3 2	1-4 1	1-4 2	1-5 1	1-5 2	1-6 1	1-6 2	1-7 1	1-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 29

Clinical sign	Group Name	Administration Week-day													
		2-1 1	2-1 2	2-2 1	2-2 2	2-3 1	2-3 2	2-4 1	2-4 2	2-5 1	2-5 2	2-6 1	2-6 2	2-7 1	2-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day													
		3-1 1	3-1 2	3-2 1	3-2 2	3-3 1	3-3 2	3-4 1	3-4 2	3-5 1	3-5 2	3-6 1	3-6 2	3-7 1	3-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 31

Clinical sign	Group Name	Administration Week-day													
		4-1 1	4-1 2	4-2 1	4-2 2	4-3 1	4-3 2	4-4 1	4-4 2	4-5 1	4-5 2	4-6 1	4-6 2	4-7 1	4-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 32

Clinical sign	Group Name	Administration Week-day													
		5-1 1	5-1 2	5-2 1	5-2 2	5-3 1	5-3 2	5-4 1	5-4 2	5-5 1	5-5 2	5-6 1	5-6 2	5-7 1	5-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOW REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 33

Clinical sign	Group Name	Administration Week-day													
		6-1 1	6-1 2	6-2 1	6-2 2	6-3 1	6-3 2	6-4 1	6-4 2	6-5 1	6-5 2	6-6 1	6-6 2	6-7 1	6-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 34

Clinical sign	Group Name	Administration Week-day													
		7-1 1	7-1 2	7-2 1	7-2 2	7-3 1	7-3 2	7-4 1	7-4 2	7-5 1	7-5 2	7-6 1	7-6 2	7-7 1	7-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 35

Clinical sign	Group Name	Administration Week-day													
		8-1 1	8-1 2	8-2 1	8-2 2	8-3 1	8-3 2	8-4 1	8-4 2	8-5 1	8-5 2	8-6 1	8-6 2	8-7 1	8-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 36

Clinical sign	Group Name	Administration Week-day													
		9-1 1	9-1 2	9-2 1	9-2 2	9-3 1	9-3 2	9-4 1	9-4 2	9-5 1	9-5 2	9-6 1	9-6 2	9-7 1	9-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 37

Clinical sign	Group Name	Administration Week-day													
		10-1 1	10-1 2	10-2 1	10-2 2	10-3 1	10-3 2	10-4 1	10-4 2	10-5 1	10-5 2	10-6 1	10-6 2	10-7 1	10-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day													
		11-1 1	11-1 2	11-2 1	11-2 2	11-3 1	11-3 2	11-4 1	11-4 2	11-5 1	11-5 2	11-6 1	11-6 2	11-7 1	11-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 39

Clinical sign	Group Name	Administration Week-day													
		12-1 1	12-1 2	12-2 1	12-2 2	12-3 1	12-3 2	12-4 1	12-4 2	12-5 1	12-5 2	12-6 1	12-6 2	12-7 1	12-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 40

Clinical sign	Group Name	Administration Week-day													
		13-1 1	13-1 2	13-2 1	13-2 2	13-3 1	13-3 2	13-4 1	13-4 2	13-5 1	13-5 2	13-6 1	13-6 2	13-7 1	13-7 2
OLIGD-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 41

Clinical sign	Group Name	Administration Week-day													
		14-1 1	14-1 2	14-2 1	14-2 2	14-3 1	14-3 2	14-4 1	14-4 2	14-5 1	14-5 2	14-6 1	14-6 2	14-7 1	14-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	15	15	15	15

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 42

Clinical sign	Group Name	Administration Week-day													
		15-1 1	15-1 2	15-2 1	15-2 2	15-3 1	15-3 2	15-4 1	15-4 2	15-5 1	15-5 2	15-6 1	15-6 2	15-7 1	15-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	15	15	15	15	15	15	15	15	15	15	14	14	14	14

(HAN190)

BAIS5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jc1  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 43

Clinical sign	Group Name	Administration Week-day													
		16-1 1	16-1 2	16-2 1	16-2 2	16-3 1	16-3 2	16-4 1	16-4 2	16-5 1	16-5 2	16-6 1	16-6 2	16-7 1	16-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	14	14	14	14	14	14	14	14	14	14	14	14	14	14

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 44

Clinical sign	Group Name	Administration Week-day													
		17-1 1	17-1 2	17-2 1	17-2 2	17-3 1	17-3 2	17-4 1	17-4 2	17-5 1	17-5 2	17-6 1	17-6 2	17-7 1	17-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	1	1	1	1	1	1	2	2	2	2	2	2
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	13	12	12	12	12	12	12	12	11	11	11	11	11	11

(HAN190)

BAIS 5



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 45

Clinical sign	Group Name	Administration Week-day													
		18-1 1	18-1 2	18-2 1	18-2 2	18-3 1	18-3 2	18-4 1	18-4 2	18-5 1	18-5 2	18-6 1	18-6 2	18-7 1	18-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	1	1	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	10	9	9	9	9	9	9	9	9	9	9	9	9	9

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 46

Clinical sign	Group Name	Administration Week-day													
		19-1 1	19-1 2	19-2 1	19-2 2	19-3 1	19-3 2	19-4 1	19-4 2	19-5 1	19-5 2	19-6 1	19-6 2	19-7 1	19-7 2
OLIGO-STOOL	Control	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	Posi. Control	0	0	0	1	1	1	1	1	1	1	1	1	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	9	9	9	9	9	9	8	8	8	8	8	8	8	8

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 47

Clinical sign	Group Name	Administration Week-day													
		20-1 1	20-1 2	20-2 1	20-2 2	20-3 1	20-3 2	20-4 1	20-4 2	20-5 1	20-5 2	20-6 1	20-6 2	20-7 1	20-7 2
OLIGO-STOOL	Control	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	Posi. Control	0	0	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	8	8	7	7	7	7	7	7	7	7	7	7	7	7

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 48

Clinical sign	Group Name	Administration Week-day													
		21-1 1	21-1 2	21-2 1	21-2 2	21-3 1	21-3 2	21-4 1	21-4 2	21-5 1	21-5 2	21-6 1	21-6 2	21-7 1	21-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	6	6	6	6	6	6	6	6	6	6	6	5	5	5

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 49

Clinical sign	Group Name	Administration Week-day													
		22-1 1	22-1 2	22-2 1	22-2 2	22-3 1	22-3 2	22-4 1	22-4 2	22-5 1	22-5 2	22-6 1	22-6 2	22-7 1	22-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	5	5	5	5	5	5	5	5	5	5	5	5	5	5

(HANT90)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 50

Clinical sign	Group Name	Administration Week-day													
		23-1 1	23-1 2	23-2 1	23-2 2	23-3 1	23-3 2	23-4 1	23-4 2	23-5 1	23-5 2	23-6 1	23-6 2	23-7 1	23-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	Posi. Control	4	4	4	4	4	4	4	4	4	4	4	4	3	3

(HAN190)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 51

Clinical sign	Group Name	Administration Week-day													
		24-1 1	24-1 2	24-2 1	24-2 2	24-3 1	24-3 2	24-4 1	24-4 2	24-5 1	24-5 2	24-6 1	24-6 2	24-7 1	24-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	23	23	23	23	23	23	23	23	23	23	23	23	23	23
	Posi. Control	3	3	3	3	3	3	3	3	3	2	2	2	2	2

(HAN190)

BALS

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jct  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 52

Clinical sign	Group Name	Administration Week-day													
		25-1 1	25-1 2	25-2 1	25-2 2	25-3 1	25-3 2	25-4 1	25-4 2	25-5 1	25-5 2	25-6 1	25-6 2	25-7 1	25-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	23	23	23	23	23	23	23	23	23	23	23	23	23	23
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2

(HAN190)

BAIS 5



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 53

Clinical sign	Group Name	Administration Week-day													
		26-1 1	26-1 2	26-2 1	26-2 2	26-3 1	26-3 2	26-4 1	26-4 2	26-5 1	26-5 2	26-6 1	26-6 2	26-7 1	26-7 2
OLIGO-STOOL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Posi. Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	23	23	23	23	23	23	23	23	23	23	23	23	23	23
	Posi. Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2

(HAN190)

BAIS 5

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash20Jc1  
REPORT TYPE : A1 27

CLINICAL OBSERVATION (SUMMARY)  
ALL ANIMALS

SEX : FEMALE

PAGE : 54

Clinical sign	Group Name	Administration Week-day	
		27-1 1	27-1 2
OLIGO-STOOL	Control	0	0
	Posi. Control	0	0
NON REMARKABLE	Control	23	9
	Posi. Control	2	2

(HAN190)

BAIS 5

TABLE B 5

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL

NUMBERS : MALE

(Control and Positive control group)

STUDY NO. : 0900

## MEAN BODY WEIGHTS AND SURVIVAL

ANIMAL : Jic: CB6F1-Tg rasH2@Jcl

UNIT : g

SEX : MALE

Week-Day on Study	Control		Posi. Control		
	Av. Wt. <25>	No. of Surviv. <25>	Av. Wt. <15>	% of cont. <15>	No. of Surviv. <15>
0-0	24.7 (25)	25/25	24.7 (15)	100	15/15
1-1	24.8 (25)	25/25	24.6 (15)	99	15/15
2-1	25.2 (25)	25/25	25.0 (15)	99	15/15
3-1	25.3 (25)	25/25	25.6 (15)	101	15/15
4-1	25.7 (25)	25/25	26.4 (15)	103	15/15
5-1	25.9 (25)	25/25	27.3 (15)	105	15/15
6-1	26.4 (25)	25/25	27.9 (15)	106	15/15
7-1	26.8 (25)	25/25	28.4 (15)	106	15/15
8-1	26.9 (25)	25/25	28.7 (15)	107	15/15
9-1	27.4 (25)	25/25	28.6 (15)	104	15/15
10-1	27.8 (25)	25/25	29.2 (15)	105	15/15
11-1	27.5 (25)	25/25	29.3 (15)	107	15/15
12-1	27.7 (25)	25/25	29.8 (15)	108	15/15
13-1	28.0 (25)	25/25	30.2 (15)	108	15/15
14-1	28.3 (25)	25/25	30.5 (15)	108	15/15
15-1	28.4 (25)	25/25	30.3 (15)	107	15/15
16-1	28.5 (25)	25/25	30.7 (14)	108	14/15
17-1	28.7 (25)	25/25	30.5 (14)	106	14/15
18-1	28.8 (25)	25/25	29.8 (14)	103	14/15
19-1	28.6 (25)	25/25	30.3 (13)	106	13/15
20-1	28.7 (25)	25/25	30.3 (12)	106	12/15
21-1	28.5 (25)	25/25	30.4 (10)	107	10/15
22-1	28.7 (25)	25/25	29.9 (10)	104	10/15
23-1	28.8 (25)	25/25	29.4 (10)	102	10/15
24-1	29.1 (25)	25/25	30.9 ( 8)	106	8/15
25-1	29.0 (25)	25/25	31.0 ( 8)	107	8/15
26-1	29.2 (25)	25/25	30.7 ( 8)	105	8/15
26-7	29.3 (25)	25/25	30.6 ( 8)	104	8/15

< >: No. of effective animals, ( ): No. of measured animals Av. Wt. : g

TABLE B 6

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL

NUMBERS : FEMALE

(Control and Positive control group)

STUDY NO. : 0901

## MEAN BODY WEIGHTS AND SURVIVAL

ANIMAL : Jic: CB6F1-Tg rasH2@Jcl

UNIT : g

SEX : FEMALE

Week-Day on Study	Control		Posi. Control		
	Av. Wt. <25>	No. of Surviv. <25>	Av. Wt. <15>	% of cont. <15>	No. of Surviv. <15>
0-0	20.3 (25)	25/25	20.3 (15)	100	15/15
1-1	19.5 (25)	25/25	19.4 (15)	99	15/15
2-1	20.3 (25)	25/25	20.1 (15)	99	15/15
3-1	20.5 (25)	25/25	20.3 (15)	99	15/15
4-1	20.2 (25)	25/25	20.7 (15)	102	15/15
5-1	20.1 (25)	25/25	20.9 (15)	104	15/15
6-1	20.2 (25)	25/25	21.6 (15)	107	15/15
7-1	20.6 (25)	25/25	21.6 (15)	105	15/15
8-1	21.2 (25)	25/25	22.5 (15)	106	15/15
9-1	21.4 (25)	25/25	22.8 (15)	107	15/15
10-1	21.8 (25)	25/25	23.0 (15)	106	15/15
11-1	21.9 (25)	25/25	23.0 (15)	105	15/15
12-1	22.0 (25)	25/25	23.4 (15)	106	15/15
13-1	22.1 (25)	25/25	23.1 (15)	105	15/15
14-1	22.2 (25)	25/25	23.3 (15)	105	15/15
15-1	21.9 (25)	25/25	23.4 (15)	107	15/15
16-1	22.2 (25)	25/25	23.2 (15)	105	15/15
17-1	22.0 (25)	25/25	22.8 (15)	104	15/15
18-1	22.3 (25)	25/25	23.3 (13)	104	13/15
19-1	22.3 (25)	25/25	23.9 (10)	107	10/15
20-1	22.2 (25)	25/25	23.6 ( 8)	106	8/15
21-1	22.8 (24)	24/25	24.0 ( 8)	105	8/15
22-1	22.8 (24)	24/25	24.4 ( 7)	107	7/15
23-1	22.3 (24)	24/25	23.6 ( 6)	106	6/15
24-1	22.6 (24)	24/25	24.4 ( 5)	108	5/15
25-1	22.9 (24)	24/25	25.5 ( 5)	111	5/15
26-1	22.7 (23)	23/25	24.6 ( 5)	108	5/15
26-7	23.1 (23)	23/25	24.0 ( 4)	104	4/15

< >: No. of effective animals, ( ): No. of measured animals Av. Wt. : g

TABLE B 7

BODY WEIGHT CHANGES : MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	0-0	1-1	2-1	3-1	4-1	5-1	6-1
Control	24.7± 1.0	24.8± 1.0	25.2± 1.2	25.3± 1.2	25.7± 1.2	25.9± 1.5	26.4± 1.4
Posi. Control	24.7± 1.0	24.6± 1.0	25.0± 1.1	25.6± 1.2	26.4± 1.0	27.3± 1.1**	27.9± 1.1**

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of t



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	7-1	8-1	9-1	10-1	11-1	12-1	13-1
Control	26.8± 1.6	26.9± 1.6	27.4± 1.7	27.8± 1.7	27.5± 1.8	27.7± 1.8	28.0± 1.8
Posi. Control	28.4± 1.1**	28.7± 1.1**	28.6± 1.1*	29.2± 0.9**	29.3± 1.1**	29.8± 1.3**	30.2± 1.2**

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : D900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	14-1	15-1	16-1	17-1	18-1	19-1	20-1
Control	28.3± 1.5	28.4± 1.8	28.5± 1.9	28.7± 1.9	28.8± 1.8	28.6± 2.0	28.7± 2.1
Posi. Control	30.5± 1.5**	30.3± 1.5**	30.7± 1.7**	30.5± 1.9**	29.8± 2.9	30.3± 2.1*	30.3± 1.8*

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of t

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	21-1	22-1	23-1	24-1	25-1	26-1	26-7
Control	28.5± 1.9	28.7± 2.0	28.8± 1.9	29.1± 2.1	29.0± 2.0	29.2± 1.9	29.3± 2.1
Posi. Control	30.4± 1.8**	29.9± 2.9	29.4± 3.3	30.9± 1.6*	31.0± 1.8*	30.7± 2.7	30.6± 2.7

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

TABLE B 8

BODY WEIGHT CHANGES : FEMALE

(Control and Positive control group)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	0-0	1-1	2-1	3-1	4-1	5-1	6-1
Control	20.3± 1.2	19.5± 1.2	20.3± 1.5	20.5± 1.4	20.2± 1.2	20.1± 1.2	20.2± 1.1
Posi. Control	20.3± 1.2	19.4± 1.0	20.1± 1.1	20.3± 1.2	20.7± 1.2	20.9± 1.2*	21.6± 1.3**

Significant difference ; \* : P ≤ 0.05    \*\* : P ≤ 0.01                      Test of t

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day							
	7-1	8-1	9-1	10-1	11-1	12-1	13-1	
Control	20.6± 1.2	21.2± 1.1	21.4± 1.3	21.8± 1.3	21.9± 1.5	22.0± 1.4	22.1± 1.3	
Posi. Control	21.6± 1.2*	22.5± 1.3**	22.8± 1.2**	23.0± 1.2**	23.0± 1.5*	23.4± 1.6**	23.1± 1.3*	

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of t

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	14-1	15-1	16-1	17-1	18-1	19-1	20-1
Control	22.2± 1.6	21.9± 1.2	22.2± 1.5	22.0± 1.3	22.3± 1.3	22.3± 1.6	22.2± 1.5
Posi. Control	23.3± 1.2*	23.4± 1.7**	23.2± 1.3*	22.8± 1.6	23.3± 2.0	23.9± 2.5*	23.6± 1.2*

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day						
	21-1	22-1	23-1	24-1	25-1	26-1	26-7
Control	22.8± 1.5	22.8± 1.3	22.3± 1.2	22.6± 1.3	22.9± 1.3	22.7± 1.3	23.1± 1.5
Posi. Control	24.0± 1.7	24.4± 1.7*	23.6± 1.9*	24.4± 2.5	25.5± 3.1	24.6± 2.3*	24.0± 1.6

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t



TABLE B 9

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL

NUMBERS : MALE

(Control and Positive control group)

STUDY NO. : 0900

## MEAN FOOD CONSUMPTION AND SURVIVAL

ANIMAL : Jic: CB6F1-Tg rasH2@Jcl

UNIT : g

SEX : MALE

Week-Day on Study	Control		Posi. Control		
	Av. FC. <25>	No. of Surviv. <25>	Av. FC.	% of cont. <25>	No. of Surviv.
2-1	3.9 (25)	25/25	4.2 (15)	108	15/15
3-1	3.3 (25)	25/25	4.0 (15)	121	15/15
4-1	3.3 (25)	25/25	4.0 (15)	121	15/15
5-1	3.4 (25)	25/25	4.2 (15)	124	15/15
6-1	3.3 (25)	25/25	4.2 (15)	127	15/15
7-1	3.3 (25)	25/25	4.2 (15)	127	15/15
8-1	3.3 (25)	25/25	4.2 (15)	127	15/15
9-1	3.4 (25)	25/25	4.1 (15)	121	15/15
10-1	3.2 (25)	25/25	4.2 (15)	131	15/15
11-1	3.1 (25)	25/25	4.2 (15)	135	15/15
12-1	3.2 (25)	25/25	4.2 (15)	131	15/15
13-1	3.3 (25)	25/25	4.2 (15)	127	15/15
14-1	3.2 (25)	25/25	4.1 (15)	128	15/15
15-1	3.3 (25)	25/25	4.0 (15)	121	15/15
16-1	3.2 (25)	25/25	4.1 (14)	128	14/15
17-1	3.3 (25)	25/25	3.9 (14)	118	14/15
18-1	3.3 (25)	25/25	3.6 (14)	109	14/15
19-1	3.1 (25)	25/25	3.8 (13)	123	13/15
20-1	3.1 (25)	25/25	3.8 (12)	123	12/15
21-1	3.1 (25)	25/25	3.9 (10)	126	10/15
22-1	3.2 (25)	25/25	3.7 (10)	116	10/15
23-1	3.1 (25)	25/25	3.6 (10)	116	10/15
24-1	3.2 (25)	25/25	3.8 ( 8)	119	8/15
25-1	3.1 (25)	25/25	3.8 ( 8)	123	8/15
26-1	3.3 (25)	25/25	3.8 ( 8)	115	8/15
26-7	3.2 (25)	25/25	3.8 ( 8)	119	8/15

< >: No. of effective animals, ( ): No. of measured animals Av. FC. : g

TABLE B 10

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL

NUMBERS : FEMALE

(Control and Positive control group)

STUDY NO. : 0901

## MEAN FOOD CONSUMPTION AND SURVIVAL

ANIMAL : Jic: CB6F1-Tg rasH2@Jcl

UNIT : g

SEX : FEMALE

Week-Day on Study	Control		Posi. Control		
	Av. FC. <25>	No. of Surviv.	Av. FC.	% of cont. <15>	No. of Surviv.
2-1	3.3 (25)	25/25	3.4 (15)	103	15/15
3-1	3.0 (25)	25/25	3.4 (15)	113	15/15
4-1	2.7 (25)	25/25	3.3 (15)	122	15/15
5-1	2.8 (25)	25/25	3.4 (15)	121	15/15
6-1	2.9 (25)	25/25	3.7 (15)	128	15/15
7-1	3.0 (25)	25/25	3.6 (15)	120	15/15
8-1	3.0 (25)	25/25	3.8 (15)	127	15/15
9-1	3.0 (25)	25/25	3.7 (15)	123	15/15
10-1	3.0 (25)	25/25	3.7 (15)	123	15/15
11-1	3.0 (25)	25/25	3.7 (15)	123	15/15
12-1	3.0 (25)	25/25	3.7 (15)	123	15/15
13-1	2.9 (25)	25/25	3.4 (15)	117	15/15
14-1	3.0 (25)	25/25	3.6 (15)	120	15/15
15-1	2.9 (25)	25/25	3.6 (15)	124	15/15
16-1	2.9 (25)	25/25	3.5 (14)	121	15/15
17-1	2.9 (25)	25/25	3.8 (15)	131	15/15
18-1	2.9 (25)	25/25	3.9 (13)	134	13/15
19-1	2.8 (25)	25/25	3.6 (10)	129	10/15
20-1	2.9 (25)	25/25	3.3 ( 8)	114	8/15
21-1	2.8 (24)	24/25	3.6 ( 8)	129	8/15
22-1	2.8 (24)	24/25	3.6 ( 7)	129	7/15
23-1	2.8 (24)	24/25	3.5 ( 6)	125	6/15
24-1	2.8 (24)	24/25	3.6 ( 5)	129	5/15
25-1	3.0 (24)	24/25	4.3 ( 5)	143	5/15
26-1	2.8 (23)	23/25	3.8 ( 5)	136	5/15
26-7	2.8 (23)	23/25	4.2 ( 4)	150	4/15

< >: No. of effective animals, ( ): No. of measured animals Av. FC. : g

TABLE B 11

FOOD CONSUMPTION CHANGES : MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20JcI  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	2-1 (7)	3-1 (7)	4-1 (7)	5-1 (7)	6-1 (7)	7-1 (7)	8-1 (7)
Control	3.9± 0.4	3.3± 0.3	3.3± 0.3	3.4± 0.3	3.3± 0.3	3.3± 0.3	3.3± 0.3
Posi. Control	4.2± 0.2*	4.0± 0.3**	4.0± 0.2**	4.2± 0.3**	4.2± 0.3**	4.2± 0.2**	4.2± 0.3**

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	9-1 (7)	10-1 (7)	11-1 (7)	12-1 (7)	13-1 (7)	14-1 (7)	15-1 (7)
Control	3.4± 0.3	3.2± 0.3	3.1± 0.3	3.2± 0.3	3.3± 0.3	3.2± 0.3	3.3± 0.3
Posi. Control	4.1± 0.3**	4.2± 0.3**	4.2± 0.4**	4.2± 0.3**	4.2± 0.4**	4.1± 0.5**	4.0± 0.6**

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	16-1 (7)	17-1 (7)	18-1 (7)	19-1 (7)	20-1 (7)	21-1 (7)	22-1 (7)
Control	3.2± 0.3	3.3± 0.3	3.3± 0.3	3.1± 0.3	3.1± 0.4	3.1± 0.3	3.2± 0.4
Posi. Control	4.1± 0.4**	3.9± 0.5**	3.6± 0.9	3.8± 0.6**	3.8± 0.9*	3.9± 0.5**	3.7± 0.9

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t



STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jci  
UNIT : g  
REPORT TYPE : A1 26  
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
ALL ANIMALS

PAGE : 4

Group Name	Administration week-day (effective)				
	23-1 (7)	24-1 (7)	25-1 (7)	26-1 (7)	26-7 (6)
Control	3.1± 0.3	3.2± 0.4	3.1± 0.3	3.3± 0.3	3.2± 0.3
Posi. Control	3.6± 0.6*	3.8± 0.2**	3.8± 0.3**	3.8± 0.6**	3.8± 0.3**

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of t

(HAN260)

BAIS 5

TABLE B 12

FOOD CONSUMPTION CHANGES : FEMALE

(Control and Positive control group)

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash20JcI  
UNIT : g  
REPORT TYPE : A1 26  
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
ALL ANIMALS

PAGE : 1

Group Name	Administration week-day (effective)						
	2-1 (7)	3-1 (7)	4-1 (7)	5-1 (7)	6-1 (7)	7-1 (7)	8-1 (7)
Control	3.3± 0.4	3.0± 0.2	2.7± 0.2	2.8± 0.3	2.9± 0.3	3.0± 0.2	3.0± 0.2
Posi. Control	3.4± 0.3	3.4± 0.3**	3.3± 0.4**	3.4± 0.3**	3.7± 0.4**	3.6± 0.2**	3.8± 0.3**

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

(HAN260)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	9-1 (7)	10-1 (7)	11-1 (7)	12-1 (7)	13-1 (7)	14-1 (7)	15-1 (7)
Control	3.0± 0.3	3.0± 0.3	3.0± 0.4	3.0± 0.3	2.9± 0.3	3.0± 0.4	2.9± 0.2
Posi. Control	3.7± 0.3**	3.7± 0.2**	3.7± 0.3**	3.7± 0.4**	3.4± 0.3**	3.6± 0.2**	3.6± 0.4**

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day (effective)						
	16-1 (7)	17-1 (7)	18-1 (7)	19-1 (7)	20-1 (7)	21-1 (7)	22-1 (7)
Control	2.9± 0.3	2.9± 0.3	2.9± 0.2	2.8± 0.3	2.9± 0.3	2.8± 0.3	2.8± 0.3
Posi. Control	3.5± 0.4**	3.8± 1.8	3.9± 1.0**	3.6± 0.8*	3.3± 0.2**	3.6± 0.4**	3.6± 0.4**

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@JcI  
UNIT : g  
REPORT TYPE : A1 26  
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
ALL ANIMALS

PAGE : 4

Group Name	Administration week-day (effective)				
	23-1 (7)	24-1 (7)	25-1 (7)	26-1 (7)	26-7 (6)
Control	2.8± 0.3	2.8± 0.2	3.0± 0.3	2.8± 0.2	2.8± 0.3
Posi. Control	3.5± 0.5*	3.6± 0.8	4.3± 0.9*	3.8± 0.3**	4.2± 1.1

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

(HAN260)

BAIS5

TABLE B 13

URINALYSIS : MALE

(Control and Positive control group)

STUDY NO. : 0900

ANIMAL : Jic:CB6F1-Tg rash20JcI

MEASURE TIME : 1

SEX : MALE

REPORT TYPE : A1

URINALYSIS

PAGE : 1

Group Name	NO. of Animals	pH							CHI	Protein					CHI	Glucose					CHI	Ketone body					CHI	Occult blood					CHI	
		5.0	6.0	6.5	7.0	7.5	8.0	8.5		-	±	+	2+	3+		4+	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-	±		+
Control	20	0	0	0	0	0	1	19	0	2	14	4	0	0	20	0	0	0	0	0	0	0	0	0	5	10	5	0	0	20	0	0	0	0
Posi. Control	6	0	0	0	0	0	1	5	0	2	4	0	0	0	6	0	0	0	0	0	0	0	0	1	1	4	0	0	6	0	0	0	0	

Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01

Test of CHI SQUARE

(HCL101)

BAIS5



STUDY NO. : 0900

URINALYSIS

ANIMAL : Jic:CB6F1-Tg rash20Jcl

MEASURE TIME : 1

SEX : MALE

REPORT TYPE : A1

PAGE : 2

---

Group Name	NO. of Animals	Urobilinogen				CHI
		±	+	2+	3+	
Control	20	20	0	0	0	0
Posi. Control	6	6	0	0	0	0

---

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of CHI SQUARE

(HCL101)

BAIS5

TABLE B 14

URINALYSIS : FEMALE

(Control and Positive control group)

STUDY NO. : 0901

ANIMAL : Jic:CB6F1-Tg rash20Jc1

MEASURE TIME : 1

SEX : FEMALE

REPORT TYPE : A1

URINALYSIS

PAGE : 1

Group Name	NO. of Animals	pH						CHI	Protein					CHI	Glucose					CHI	Ketone body					CHI	Occult blood					CHI				
		5.0	6.0	6.5	7.0	7.5	8.0		8.5	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-	±		+	2+	3+	4+	-		±	+	2+	3+
Control	13	0	0	0	1	2	4	6	0	5	6	0	2	0	13	0	0	0	0	0	0	0	0	0	0	6	5	2	0	0	13	0	0	0	0	
Posi. Control	4	0	0	0	1	1	2	0	0	0	2	2	0	0	*	4	0	0	0	0	0	0	0	0	0	0	1	1	2	0	0	3	0	0	1	0

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of CHI SQUARE

(HCL101)

BAIS5

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
MEASURE TIME : 1  
SEX : FEMALE REPORT TYPE : A1

URINALYSIS

PAGE : 2

---

Group Name	NO. of Animals	Urobilinogen ± + 2+ 3+ 4+ CHI
Control	13	13 0 0 0 0
Posi. Control	4	4 0 0 0 0

---

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of CHI SQUARE

(HCL101)

BAIS5

TABLE B 15

HEMATOLOGY : MALE

(Control and Positive control group)

STUDY NO. : 0900

ANIMAL : Jic:CB6F1-Tg rash2@Jcl

MEASURE TIME : 1

SEX : MALE

REPORT TYPE : A1

HEMATOLOGY (SUMMARY)

ALL ANIMALS ( 27W)

PAGE : 1

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g/dl		PLATELET 10 <sup>9</sup> /μl	
Control	25	11.54±	0.57	16.6±	0.6	48.5±	1.7	42.0±	1.0	14.4±	0.3	34.3±	0.4	1534±	113
Posi. Control	8	9.80±	2.87	14.1±	4.6	42.2±	10.8	44.2±	4.3	14.0±	1.8	32.1±	5.8	1490±	319

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of t

(HCL070)

BAIS 5

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash20Jcl  
MEASURE. TIME : 1  
SEX : MALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

---

Group Name	NO. of Animals	RETICULOCYTE %
Control	25	3.5± 2.1
Posi. Control	8	11.6± 19.8

---

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of t

(HCL070)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20JcI  
 MEASURE TIME : 1  
 SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		$10^9/\mu\text{l}$		NEUTRO		LYMPHO							
Control	25	1.68±	0.92	30.3±	6.4	63.8±	6.7	3.4±	2.0	2.2±	2.4	0.3±	0.7
Posi. Control	8	4.24±	3.30	42.6±	11.0*	50.0±	9.1**	4.3±	3.8	2.8±	6.5	0.4±	0.3

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of t



TABLE B 16

HEMATOLOGY : FEMALE

(Control and Positive control group)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash20Jc1  
 MEASURE TIME : 1  
 SEX : FEMALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g/dl		PLATELET 10 <sup>9</sup> /μl	
Control	23	11.35±	0.33	16.6±	0.3	48.0±	1.1	42.3±	0.6	14.6±	0.3	34.6±	0.4	1382±	128
Posi. Control	4	8.71±	2.78	12.7±	5.3	39.4±	12.3	45.3±	1.9	14.1±	2.3	31.2±	5.2	897±	498

Significant difference ; \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of t

(HCL070)

BAIS 5

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash20JcI  
MEASURE TIME : 1  
SEX : FEMALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

Group Name	NO. of Animals	RETICULOCYTE %
Control	23	3.5± 0.5
Posi. Control	4	12.6± 16.6

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of t

(HCL070)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 MEASURE TIME : 1  
 SEX : FEMALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 3

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		$10^9/\mu l$		NEUTRO		LYMPHO							
Control	23	2.27±	1.32	30.1±	8.3	63.8±	7.0	4.1±	1.3	1.5±	1.2	0.5±	0.4
Posi. Control	4	19.42±	25.88	28.1±	2.3	51.7±	17.4*	9.3±	8.7	8.6±	12.8	2.3±	3.3

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of t

(HCL070)

BAIS 5

TABLE B 17

BIOCHEMISTRY : MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jc1  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	25	5.1±	0.2	2.8±	0.1	1.2±	0.1	0.06±	0.01	200±	19	94±	10	44±	15
Posi. Control	8	5.0±	0.5	2.7±	0.2	1.2±	0.1	0.05±	0.03	186±	27	98±	16	112±	142

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

(HCL074)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20JcI  
 MEASURE TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	25	188±	19	53±	14	16±	5	210±	48	227±	26	0.4±	0.4	60±	17
Posi. Control	8	202±	21	69±	12**	24±	5**	251±	50*	186±	21**	0.7±	0.5	70±	26

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

(HCL074)

BAIS 5

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 3

Group Name	NO. of Animals	UREA NITROGEN mg/dl		SODIUM mEq/l		POTASSIUM mEq/l		CHLORIDE mEq/l		CALCIUM mg/dl		INORGANIC PHOSPHORUS mg/dl	
Control	25	20.6±	3.2	153±	2	3.6±	0.2	118±	2	8.5±	0.3	5.1±	0.8
Posi. Control	8	27.0±	5.2**	154±	1	3.7±	0.4	120±	2	8.7±	0.3*	6.1±	1.1*

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of t

(HCL074)

BAIS 5



TABLE B 18

BIOCHEMISTRY : FEMALE

(Control and Positive control group)

STUDY NO. : 0901

ANIMAL : Jic:CB6F1-Tg rash2@Jcl

MEASURE TIME : 1

SEX : FEMALE

REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)

ALL ANIMALS ( 27W)

PAGE : 1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	23	5.2±	0.2	3.1±	0.1	1.4±	0.1	0.05±	0.01	180±	18	67±	7	34±	12
Posi. Control	4	5.4±	0.4	2.9±	0.4	1.2±	0.4*	0.05±	0.02	172±	40	72±	16	30±	12

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of t

(HCL074)

BAIS 5

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 MEASURE TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	23	137±	13	51±	7	16±	2	159±	30	310±	40	0.5±	0.6	47±	16
Posi. Control	4	124±	23	228±	326	57±	65	2252±	4023	251±	77±	0.8±	0.5	176±	127

Significant difference ; \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of t

(HCL074)

BAIS 5

STUDY NO. : 0901

ANIMAL : Jic:CB6F1-Tg rash2@JcI

MEASURE TIME : 1

SEX : FEMALE

REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)

ALL ANIMALS ( 27W)

PAGE : 3

Group Name	NO. of Animals	UREA NITROGEN mg/dℓ		SODIUM mEq/ℓ		POTASSIUM mEq/ℓ		CHLORIDE mEq/ℓ		CALCIUM mg/dℓ		INORGANIC PHOSPHORUS mg/dℓ	
Control	23	16.7±	3.9	152±	2	3.3±	0.2	118±	2	8.8±	0.3	4.6±	0.8
Posi. Control	4	24.0±	9.1	153±	1	3.9±	0.9	118±	1	8.9±	0.2	6.4±	1.1**

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of t

(HCL074)

BAIS 5

TABLE B 19

GROSS FINDINGS : MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@JcI  
 REPORT TYPE : A1  
 SEX : MALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0- 27W)

PAGE : 1

Organ	Findings	Group Name NO. of Animals	Control 25 (%)	Posi. Control 15 (%)
skin/app	nodule		0 ( 0)	3 ( 20)
subcutis	mass		0 ( 0)	1 ( 7)
lung	white zone		1 ( 4)	0 ( 0)
	red zone		0 ( 0)	1 ( 7)
	nodule		1 ( 4)	1 ( 7)
lymph node	enlarged		0 ( 0)	6 ( 40)
thymus	enlarged		0 ( 0)	2 ( 13)
spleen	enlarged		0 ( 0)	7 ( 47)
	black zone		2 ( 8)	0 ( 0)
	nodule		1 ( 4)	1 ( 7)
oral cavity	nodule		0 ( 0)	1 ( 7)
tongue	nodule		0 ( 0)	1 ( 7)
stomach	forestomach:nodule		0 ( 0)	14 ( 93)
	forestomach:white zone		0 ( 0)	1 ( 7)
liver	enlarged		0 ( 0)	1 ( 7)
	nodule		0 ( 0)	1 ( 7)
kidney	enlarged		0 ( 0)	2 ( 13)
mediastinum	mass		0 ( 0)	2 ( 13)
thoracic ca	pleural fluid		0 ( 0)	5 ( 33)
whole body	anemic		0 ( 0)	1 ( 7)

TABLE B 20

GROSS FINDINGS : FEMALE

(Control and Positive control group)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control		Posi. Control	
			25	(%)	15	(%)
skin/app	nodule		1	( 4)	2	( 13)
lung	white zone		2	( 8)	0	( 0)
	red zone		0	( 0)	3	( 20)
	nodule		0	( 0)	1	( 7)
lymph node	enlarged		0	( 0)	5	( 33)
	red		1	( 4)	0	( 0)
thymus	enlarged		0	( 0)	1	( 7)
spleen	enlarged		2	( 8)	9	( 60)
	black zone		3	( 12)	1	( 7)
heart	white zone		0	( 0)	1	( 7)
stomach	forestomach:nodule		0	( 0)	12	( 80)
liver	enlarged		0	( 0)	3	( 20)
kidney	enlarged		0	( 0)	1	( 7)
ovary	enlarged		1	( 4)	1	( 7)
uterus	nodule		0	( 0)	1	( 7)
brain	red zone		0	( 0)	1	( 7)
Harder gl	nodule		0	( 0)	1	( 7)
mediastinum	mass		0	( 0)	7	( 47)
peritoneum	nodule		0	( 0)	1	( 7)
thoracic ca	pleural fluid		0	( 0)	2	( 13)
other	hindlimb:swollen		1	( 4)	0	( 0)
whole body	anemic		0	( 0)	2	( 13)



TABLE B 21

ORGAN WEIGHT, ABSOLUTE : MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight	THYMUS	ADRENALS	TESTES	HEART	LUNGS
Control	25	26.3± 2.1	0.059± 0.023	0.016± 0.004	0.262± 0.029	0.156± 0.015	0.157± 0.019
Posi. Control	8	27.2± 2.3	0.056± 0.020	0.017± 0.003	0.263± 0.043	0.174± 0.009**	0.160± 0.020

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of t

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash20Jcl  
REPORT TYPE : A1  
SEX : MALE  
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 2

Group Name	NO. of Animals	KIDNEYS		SPLEEN		LIVER		BRAIN	
Control	25	0.519±	0.050	0.061±	0.017	1.069±	0.091	0.477±	0.015
Posi. Control	8	0.540±	0.051	0.156±	0.146	1.210±	0.140**	0.475±	0.012

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

(HCL040)

BAIS 5

TABLE B 22

ORGAN WEIGHT, ABSOLUTE : FEMALE

(Control and Positive control group)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight	THYMUS	ADRENALS	OVARIES	HEART	LUNGS
Control	23	20.4 ± 1.4	0.044 ± 0.019	0.015 ± 0.002	0.031 ± 0.008	0.117 ± 0.010	0.146 ± 0.014
Posi. Control	4	21.3 ± 1.9	0.065 ± 0.039	0.013 ± 0.002	0.032 ± 0.010	0.148 ± 0.022	0.185 ± 0.061

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of t

(HCL040)

BAIS5

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 2

Group Name	NO. of Animals	KIDNEYS		SPLEEN		LIVER		BRAIN	
Control	23	0.343±	0.026	0.068±	0.012	0.885±	0.085	0.481±	0.013
Posi. Control	4	0.386±	0.054	0.394±	0.485	1.480±	0.793	0.481±	0.012

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

(HCL040)

BAIS5

TABLE B 23

ORGAN WEIGHT, RELATIVE : MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight (g)	THYMUS	ADRENALS	TESTES	HEART	LUNGS
Control	25	26.3± 2.1	0.224± 0.080	0.060± 0.015	0.996± 0.101	0.592± 0.035	0.596± 0.068
Posi. Control	8	27.2± 2.3	0.202± 0.063	0.062± 0.009	0.968± 0.153	0.644± 0.088	0.591± 0.065

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t



STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash20JcI  
REPORT TYPE : A1  
SEX : MALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 2

Group Name	NO. of Animals	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	25	1.973 ± 0.121	0.231 ± 0.058	4.059 ± 0.165	1.819 ± 0.128
Posi. Control	8	1.985 ± 0.073	0.606 ± 0.637	4.437 ± 0.217**	1.755 ± 0.129

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of t

(HCL042)

BAIS 5

TABLE B 24

ORGAN WEIGHT, RELATIVE : FEMALE

(Control and Positive control group)

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 1

Group Name	NO. of Animals	Body Weight (g)	THYMUS	ADRENALS	OVARIES	HEART	LUNGS
Control	23	20.4 ± 1.4	0.216 ± 0.082	0.073 ± 0.010	0.151 ± 0.039	0.575 ± 0.046	0.713 ± 0.049
Posi. Control	4	21.3 ± 1.9	0.310 ± 0.184	0.063 ± 0.012	0.149 ± 0.047	0.690 ± 0.051**	0.853 ± 0.204

Significant difference ; \* : P ≤ 0.05    \*\* : P ≤ 0.01

Test of t

(HCL042)

BAIS5

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash20Jcl  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	KIDNEYS	SPLEEN	LIVER	BRAIN
Control	23	1.681 ± 0.103	0.332 ± 0.061	4.335 ± 0.296	2.364 ± 0.146
Posi. Control	4	1.805 ± 0.112*	1.726 ± 1.999	6.763 ± 3.051	2.271 ± 0.190

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of t

(HCL042)

BAIS5

TABLE B 25

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20JcI  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	Posi. Control 15
(Integumentary system/appandage)				
skin/app	squamous cell papilloma		<25> 0 ( 0%)	<15> 3 ( 20%)
subcutis	hemangiosarcoma		<25> 0 ( 0%)	<15> 1 ( 7%)
(Respiratory system)				
nasal cavit	adenoma		<25> 0 ( 0%)	<15> 1 ( 7%)
lung	bronchiolar-alveolar adenoma		<25> 1 ( 4%)	<15> 4 ( 27%)
	bronchiolar-alveolar carcinoma		0 ( 0%)	1 ( 7%)
(Hematopoietic system)				
thymus	malignant lymphoma		<25> 0 ( 0%)	<15> 8 ( 53%)
spleen	hemangioma		<25> 1 ( 4%)	<15> 0 ( 0%)
	hemangiosarcoma		0 ( 0%)	1 ( 7%)
(Digestive system)				
tongue	squamous cell papilloma		<25> 0 ( 0%)	<15> 1 ( 7%)
stomach	squamous cell papilloma		<25> 0 ( 0%)	<15> 15 (100%)

< a > a : Number of animals examined at the site  
 b ( c) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rasH2@JcI  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
ALL ANIMALS (0- 27W)

PAGE : 2

---

Organ	Findings	Group Name No. of animals on Study	Control 25	Posi. Control 15
-------	----------	---------------------------------------	---------------	---------------------

---

(Digestive system)

stomach	squamous cell carcinoma		<25> 0 ( 0%)	<15> 4 ( 27%)
---------	-------------------------	--	-----------------	------------------

---

< a > a : Number of animals examined at the site  
b ( c ) b : Number of animals with neoplasm c : b / a \* 100

---

(HPT085)

BA1S6

TABLE B 26

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

(Control and Positive control group)



STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@JcI  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	Posi. Control 15
(Integumentary system/appandage)				
skin/app	squamous cell papilloma		<25> 0 ( 0%)	<15> 1 ( 7%)
	schwannoma:malignant		1 ( 4%)	0 ( 0%)
(Respiratory system)				
trachea	papillary adenoma		<25> 0 ( 0%)	<15> 1 ( 7%)
		lung		
	bronchiolar-alveolar adenoma		<25> 3 ( 12%)	<15> 3 ( 20%)
(Hematopoietic system)				
lymph node	malignant lymphoma		<25> 0 ( 0%)	<15> 2 ( 13%)
		thymus		
	malignant lymphoma		<25> 0 ( 0%)	<15> 6 ( 40%)
spleen	malignant lymphoma		<25> 0 ( 0%)	<15> 3 ( 20%)
		(Digestive system)		
salivary gl	hemangioma		<25> 1 ( 4%)	<15> 0 ( 0%)
		stomach		
	squamous cell papilloma		<25> 0 ( 0%)	<15> 13 ( 87%)
	squamous cell carcinoma		0 ( 0%)	2 ( 13%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@JcI  
REPORT TYPE : A1  
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
ALL ANIMALS (0- 27W)

PAGE : 2

Organ	Findings	Group Name No. of animals on Study	Control 25	Posi. Control 15
(Urinary system)				
urethra	transitional cell carcinoma		<25> 0 ( 0%)	<15> 1 ( 7%)
(Reproductive system)				
uterus	hemangiosarcoma		<25> 0 ( 0%)	<15> 1 ( 7%)
	endometrial stromal sarcoma		0 ( 0%)	1 ( 7%)
vagina	squamous cell papilloma		<25> 0 ( 0%)	<15> 1 ( 7%)

< a > a : Number of animals examined at the site  
b ( c ) b : Number of animals with neoplasm c : b / a \* 100

(HPT085)

BA1S6

TABLE B 27

NEOPLASTIC LESIONS-INCIDENCE  
AND STATISTICAL ANALYSIS : MALE  
(Control and Positive control group)

NEOPLASTIC LESIONS – INCIDENCE AND STATISTICAL ANALYSIS

STUDY NO.: 0900  
 ANIMAL : Jic: CB6F1-Tg rasH2@Jcl  
 SEX : MALE

Group Name	Control	Posi. Control
	SITE : skin/appendage TUMOR : squamous cell papilloma	
Tumor rate (a)	0/25 ( 0.0 )	3/15 ( 20.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0461*
	SITE : subcutis TUMOR : hemangiosarcoma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : nasal cavity TUMOR : adenoma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : lung TUMOR : bronchiolar-alveolar adenoma	
Tumor rate (a)	1/25 ( 4.0 )	4/15 ( 26.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0564
	SITE : lung TUMOR : bronchiolar-alveolar carcinoma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : lung TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma	
Tumor rate (a)	1/25 ( 4.0 )	5/15 ( 33.3 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0209*
	SITE : thymus TUMOR : malignant lymphoma	
Tumor rate (a)	0/25 ( 0.0 )	8/15 ( 53.3 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0001**

NEOPLASTIC LESIONS – INCIDENCE AND STATISTICAL ANALYSIS

STUDY NO.: 0900  
 ANIMAL : Jic: CB6F1-Tg rasH2@Jcl  
 SEX : MALE

Group Name	Control	Posi. Control
	SITE : spleen TUMOR : hemangiosarcoma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : tongue TUMOR : squamous cell papilloma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : stomach TUMOR : squamous cell papilloma	
Tumor rate (a)	0/25 ( 0.0 )	15/15 ( 100.0 )
Statistical analysis		
Fisher Exact test (b)		P < 0.0001**
	SITE : stomach TUMOR : squamous cell carcinoma	
Tumor rate (a)	0/25 ( 0.0 )	4/15 ( 26.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0149*
	SITE : stomach TUMOR : squamous cell papilloma, squamous cell carcinoma	
Tumor rate (a)	0/25 ( 0.0 )	15/15 ( 100.0 )
Statistical analysis		
Fisher Exact test (b)		P < 0.0001**
	SITE : ALL SITE TUMOR : hemangiosarcoma	
Tumor rate (a)	0/25 ( 0.0 )	2/15 ( 13.3 )
Statistical analysis		
Fisher Exact test (b)		P = 0.1346

(a): Number of tumor-bearing animals/number of animals examined at the site.

(b): Fisher exact test compare directly the overall incidence rates.

Significant difference: \* : P ≤ 0.05 \*\* : P ≤ 0.01

TABLE B 28

NEOPLASTIC LESIONS-INCIDENCE  
AND STATISTICAL ANALYSIS : FEMALE  
(Control and Positive control group)

NEOPLASTIC LESIONS – INCIDENCE AND STATISTICAL ANALYSIS

STUDY NO.: 0901

ANIMAL : Jic: CB6F1-Tg rash2@Jcl

SEX : FEMALE

PAGE: 1

Group Name	Control	Posi. Control
	SITE : skin/appendage	
	TUMOR : squamous cell papilloma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : trachea	
	TUMOR : papillary adenoma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : lung	
	TUMOR : bronchiolar-alveolar adenoma	
Tumor rate (a)	3/25 ( 12.0 )	3/15 ( 20.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.4002
	SITE : lymph node	
	TUMOR : malignant lymphoma	
Tumor rate (a)	0/25 ( 0.0 )	2/15 ( 13.3 )
Statistical analysis		
Fisher Exact test (b)		P = 0.1346
	SITE : thymus	
	TUMOR : malignant lymphoma	
Tumor rate (a)	0/25 ( 0.0 )	6/15 ( 40.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0013**

NEOPLASTIC LESIONS – INCIDENCE AND STATISTICAL ANALYSIS

STUDY NO.: 0901

ANIMAL : Jic: CB6F1-Tg rash2@Jcl

SEX : FEMALE

PAGE: 2

Group Name	Control	Posi. Control
	SITE : spleen	
	TUMOR : malignant lymphoma	
Tumor rate (a)	0/25 ( 0.0 )	3/15 ( 20.0 )
Statistical analysis		
Fisher Exact test (b)		P = 0.0461*
	SITE : stomach	
	TUMOR : squamous cell papilloma	
Tumor rate (a)	0/25 ( 0.0 )	13/15 ( 86.7 )
Statistical analysis		
Fisher Exact test (b)		P < 0.0001**
	SITE : stomach	
	TUMOR : squamous cell carcinoma	
Tumor rate (a)	0/25 ( 0.0 )	2/15 ( 13.3 )
Statistical analysis		
Fisher Exact test (b)		P = 0.1346
	SITE : stomach	
	TUMOR : squamous cell papilloma, squamous cell carcinoma	
Tumor rate (a)	0/25 ( 0.0 )	13/15 ( 86.7 )
Statistical analysis		
Fisher Exact test (b)		P < 0.0001**
	SITE : urethra	
	TUMOR : transitional cell carcinoma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750



NEOPLASTIC LESIONS – INCIDENCE AND STATISTICAL ANALYSIS

STUDY NO.: 0901

ANIMAL : Jic: CB6F1-Tg rasH2@Jcl

SEX : FEMALE

PAGE: 3

Group Name	Control	Posi. Control
	SITE : uterus	
	TUMOR : hemangiosarcoma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : uterus	
	TUMOR : endometrial stromal sarcoma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : vagina	
	TUMOR : squamous cell papilloma	
Tumor rate (a)	0/25 ( 0.0 )	1/15 ( 6.7 )
Statistical analysis		
Fisher Exact test (b)		P = 0.3750
	SITE : ALL SITE	
	TUMOR : malignant lymphoma	
Tumor rate (a)	0/25 ( 0.0 )	11/15 ( 73.3 )
Statistical analysis		
Fisher Exact test (b)		P < 0.0001**

(a): Number of tumor-bearing animals/number of animals examined at the site.

(b): Fisher exact test compare directly the overall incidence rates.

Significant difference: \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

TABLE B 29

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF  
TUMORS - TIME RELATED: MALE  
(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jc1  
 REPORT TYPE : A1  
 SEX : MALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

Time-related Weeks	Items	Group Name	Control	Posi. Control
0 - 20	NO. OF EXAMINED ANIMALS		0	5
	NO. OF ANIMALS WITH TUMORS		0	5
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	5
	NO. OF BENIGN TUMORS		0	5
	NO. OF MALIGNANT TUMORS		0	5
	NO. OF TOTAL TUMORS		0	10
21 - 26	NO. OF EXAMINED ANIMALS		0	2
	NO. OF ANIMALS WITH TUMORS		0	2
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	2
	NO. OF BENIGN TUMORS		0	3
	NO. OF MALIGNANT TUMORS		0	4
	NO. OF TOTAL TUMORS		0	7
27 - 27	NO. OF EXAMINED ANIMALS		25	8
	NO. OF ANIMALS WITH TUMORS		2	8
	NO. OF ANIMALS WITH SINGLE TUMORS		2	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	8
	NO. OF BENIGN TUMORS		2	16
	NO. OF MALIGNANT TUMORS		0	6
	NO. OF TOTAL TUMORS		2	22
0 - 27	NO. OF EXAMINED ANIMALS		25	15
	NO. OF ANIMALS WITH TUMORS		2	15
	NO. OF ANIMALS WITH SINGLE TUMORS		2	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	15
	NO. OF BENIGN TUMORS		2	24
	NO. OF MALIGNANT TUMORS		0	15
	NO. OF TOTAL TUMORS		2	39

TABLE B 30

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF  
TUMORS - TIME RELATED: FEMALE  
(Control and Positive control group)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1  
 SEX : FEMALE

NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

PAGE : 2

Time-related Weeks	Items	Group Name	Control	Posi. Control
0 - 20	NO. OF EXAMINED ANIMALS		1	7
	NO. OF ANIMALS WITH TUMORS		1	7
	NO. OF ANIMALS WITH SINGLE TUMORS		1	2
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	5
	NO. OF BENIGN TUMORS		0	6
	NO. OF MALIGNANT TUMORS		1	8
	NO. OF TOTAL TUMORS		1	14
21 - 26	NO. OF EXAMINED ANIMALS		1	4
	NO. OF ANIMALS WITH TUMORS		0	4
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	4
	NO. OF BENIGN TUMORS		0	6
	NO. OF MALIGNANT TUMORS		0	5
	NO. OF TOTAL TUMORS		0	11
27 - 27	NO. OF EXAMINED ANIMALS		23	4
	NO. OF ANIMALS WITH TUMORS		4	4
	NO. OF ANIMALS WITH SINGLE TUMORS		4	1
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	3
	NO. OF BENIGN TUMORS		4	7
	NO. OF MALIGNANT TUMORS		0	3
	NO. OF TOTAL TUMORS		4	10
0 - 27	NO. OF EXAMINED ANIMALS		25	15
	NO. OF ANIMALS WITH TUMORS		5	15
	NO. OF ANIMALS WITH SINGLE TUMORS		5	3
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	12
	NO. OF BENIGN TUMORS		4	19
	NO. OF MALIGNANT TUMORS		1	16
	NO. OF TOTAL TUMORS		5	35

TABLE B 31

HISTOPATHOLOGICAL FINDINGS:

METASTASIS OF TUMOR:MALE

(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study	Control 25	Posi. Control 15
<b>(Respiratory system)</b>				
nasal cavit	leukemic cell infiltration		<25> 0	<15> 4
nasopharynx	leukemic cell infiltration		<25> 0	<15> 1
lung	leukemic cell infiltration		<25> 0	<15> 7
<b>(Hematopoietic system)</b>				
bone marrow	leukemic cell infiltration		<25> 0	<15> 6
lymph node	leukemic cell infiltration		<25> 0	<15> 6
spleen	leukemic cell infiltration		<25> 0	<15> 6
<b>(Circulatory system)</b>				
heart	leukemic cell infiltration		<25> 0	<15> 3
<b>(Digestive system)</b>				
salivary gl	leukemic cell infiltration		<25> 0	<15> 1
liver	leukemic cell infiltration		<25> 0	<15> 6

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 27#)

Organ	Findings	Group Name No. of Animals on Study	Control 25	Posi. Control 15
<b>(Digestive system)</b>				
gall bladd	leukemic cell infiltration		<25> 0	<15> 1
<b>(Urinary system)</b>				
kidney	leukemic cell infiltration		<25> 0	<15> 6
urin bladd	leukemic cell infiltration		<25> 0	<15> 1
<b>(Endocrine system)</b>				
adrenal	leukemic cell infiltration		<25> 0	<15> 2
<b>(Reproductive system)</b>				
testis	leukemic cell infiltration		<25> 0	<15> 3
epididymis	leukemic cell infiltration		<25> 0	<15> 4
prostate	leukemic cell infiltration		<25> 0	<15> 1
<b>(Special sense organs/appendage)</b>				
Harder gl	leukemic cell infiltration		<25> 0	<15> 1

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion



STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
REPORT TYPE : A1  
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
ALL ANIMALS (0- 27W)

PAGE : 3

---

Organ	Findings	Group Name No. of Animals on Study	Control 25	Posi. Control 15
[Musculoskeletal system]				
muscle	leukemic cell infiltration		<25> 0	<15> 6

---

< a > a : Number of animals examined at the site  
b b : Number of animals with lesion

(JPT150)

BA1S6

TABLE B 32

HISTOPATHOLOGICAL FINDINGS:  
METASTASIS OF TUMOR: FEMALE  
(Control and Positive control group)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study	Control 25	Posi. Control 15
<b>(Respiratory system)</b>				
nasal cavit	leukemic cell infiltration		<25> 0	<15> 5
lung	leukemic cell infiltration		<25> 0	<15> 10
	metastasis:skin/appendage tumor		1	0
<b>(Hematopoietic system)</b>				
bone marrow	leukemic cell infiltration		<25> 0	<15> 8
lymph node	leukemic cell infiltration		<25> 0	<15> 8
	metastasis:stomach tumor		0	1
spleen	leukemic cell infiltration		<25> 0	<15> 8
<b>(Circulatory system)</b>				
heart	leukemic cell infiltration		<25> 0	<15> 6
<b>(Digestive system)</b>				
stomach	leukemic cell infiltration		<25> 0	<15> 1
small intes	leukemic cell infiltration		<25> 0	<15> 1

< a > a : Number of animals examined at the site  
 b : Number of animals with lesion

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH20Jc1  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study	Control 25	Posi. Control 15
(Digestive system)				
liver			<25>	<15>
	leukemic cell infiltration		0	11
gall bladd			<25>	<15>
	leukemic cell infiltration		0	1
(Urinary system)				
kidney			<25>	<15>
	leukemic cell infiltration		0	10
urin bladd			<25>	<15>
	leukemic cell infiltration		0	1
(Endocrine system)				
pituitary			<24>	<15>
	leukemic cell infiltration		0	1
(Reproductive system)				
ovary			<25>	<15>
	leukemic cell infiltration		0	10
	metastasis:stomach tumor		0	1
uterus			<25>	<15>
	leukemic cell infiltration		0	3
vagina			<25>	<15>
	leukemic cell infiltration		0	4
(Nervous system)				
brain			<25>	<15>
	leukemic cell infiltration		0	1

< a > a : Number of animals examined at the site  
 b b : Number of animals with lesion

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash2@JcI  
REPORT TYPE : A1  
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
ALL ANIMALS (0- 27W)

PAGE : 3

Organ	Findings	Group Name No. of Animals on Study	Control 25	Posi. Control 15
(Special sense organs/appendage)				
Harder gl	leukemic cell infiltration		<25> 0	<15> 2
(Musculoskeletal system)				
muscle	leukemic cell infiltration		<25> 0	<15> 10
(Body cavities)				
mediastinum	leukemic cell infiltration		<25> 0	<15> 3
peritoneum	metastasis:stomach tumor		<25> 0	<15> 1

< a > a : Number of animals examined at the site  
b : Number of animals with lesion

(JPT150)

BAIS6

TABLE B 33

HISTOPATHOLOGICAL FINDINGS:  
NON-NEOPLASTIC LESIONS: MALE  
(Control and Positive control group)

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash20Jcl  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study Grade				Posi. Control 15			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
(Respiratory system)									
nasal cavit	eosinophilic change:respiratory epithelium	<25> 1 0 0 0 ( 4) ( 0) ( 0) ( 0)				<15> 1 0 0 0 ( 7) ( 0) ( 0) ( 0)			
	respiratory metaplasia:gland	20 ( 80)	0 ( 0)	0 ( 0)	0 ( 0)	10 ( 67)	0 ( 0)	0 ( 0)	0 ( 0)
lung	bronchiolar-alveolar cell hyperplasia	<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)				<15> 1 0 0 0 ( 7) ( 0) ( 0) ( 0)			
	(Hematopoietic system)								
thymus	granulation	<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)				<15> 1 0 0 0 ( 7) ( 0) ( 0) ( 0)			
	spleen	atrophy	<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)				<15> 0 0 1 0 ( 0) ( 0) ( 7) ( 0)		
deposit of melanin		2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study Grade				Posi. Control 15			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
(Hematopoietic system)									
spleen	extramedullary hematopoiesis	<25> 2 0 0 0 ( 8) ( 0) ( 0) ( 0)				<15> 3 0 1 0 ( 20) ( 0) ( 7) ( 0)			
(Digestive system)									
stomach	squamous cell hyperplasia:forestomach	<25> 1 0 0 0 ( 4) ( 0) ( 0) ( 0)				<15> 4 0 0 0 ( 27) ( 0) ( 0) ( 0)			
liver	necrosis:focal	<25> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)				<15> 2 0 0 0 ( 13) ( 0) ( 0) ( 0)			
	fatty change:central	0 0 0 0 ( 0) ( 0) ( 0) ( 0)				1 0 0 0 ( 7) ( 0) ( 0) ( 0)			
	focus of cellular alteration	0 1 0 0 ( 0) ( 4) ( 0) ( 0)				1 0 0 0 ( 7) ( 0) ( 0) ( 0)			
(Endocrine system)									
pituitary	cystic degeneration:anterior lobe	<25> 3 0 0 0 ( 12) ( 0) ( 0) ( 0)				<15> 1 0 0 0 ( 7) ( 0) ( 0) ( 0)			

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



STUDY NO. : 0900  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Posi. Control			
		Control 25	Control 25	Control 25	Control 25	Posi. Control 15	Posi. Control 15	Posi. Control 15	Posi. Control 15
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
<b>(Endocrine system)</b>									
thyroid	cyst	<25>				<15>			
		1	0	0	0	0	0	0	0
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
adrenal	spindle-cell hyperplasia	<25>				<15>			
		14	0	0	0	3	0	0	0
		( 56)	( 0)	( 0)	( 0)	( 20)	( 0)	( 0)	( 0)
<b>(Reproductive system)</b>									
testis	tubular atrophy	<25>				<15>			
		0	0	0	0	1	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 7)	( 7)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

TABLE B 34

HISTOPATHOLOGICAL FINDINGS:  
NON-NEOPLASTIC LESIONS: FEMALE  
(Control and Positive control group)

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Control				Posi. Control			
		1+ Grade (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
(Integumentary system/appandage)									
skin/app	inflammatory infiltration	<25>				<15>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)	0 ( 0)
subcutis	inflammation	<25>				<15>			
		0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
(Respiratory system)									
nasal cavit	eosinophilic change:olfactory epithelium	<25>				<15>			
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)	0 ( 0)
		5 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)
nasopharynx	eosinophilic change	<25>				<15>			
		23 ( 92)	0 ( 0)	0 ( 0)	0 ( 0)	13 ( 87)	0 ( 0)	0 ( 0)	0 ( 0)
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@JcI  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name Control No. of Animals on Study Grade				Posi. Control 15			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
<b>(Respiratory system)</b>									
lung	hemorrhage	<25>				<15>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)	0 ( 0)
	inflammatory infiltration	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)
<b>(Hematopoietic system)</b>									
bone marrow	atrophy	<25>				<15>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)
	increased hematopoiesis	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	1 ( 7)	0 ( 0)	0 ( 0)
lymph node	inflammatory infiltration	<25>				<15>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)
spleen	deposit of melanin	<25>				<15>			
		3 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name Control No. of Animals on Study 25				Posi. Control 15			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)
(Hematopoietic system)									
spleen	extramedullary hematopoiesis		<25>			<15>			
		0	2	0	0	2	0	1	0
		( 0)	( 8)	( 0)	( 0)	( 13)	( 0)	( 7)	( 0)
(Circulatory system)									
heart	inflammatory infiltration		<25>			<15>			
		0	1	0	0	0	0	0	0
		( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
(Digestive system)									
stomach	squamous cell hyperplasia:forestomach		<25>			<15>			
		0	0	0	0	6	0	0	0 **
		( 0)	( 0)	( 0)	( 0)	( 40)	( 0)	( 0)	( 0)
liver	inflammatory infiltration		<25>			<15>			
		0	0	0	0	1	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 7)	( 7)	( 0)	( 0)
(Urinary system)									
urin bladd	inflammation		<25>			<15>			
		0	0	0	0	0	1	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 7)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rasH2@JcI  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study Grade				Posi. Control 15			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Endocrine system]									
pituitary	cystic degeneration:anterior lobe	<24>				<15>			
		3 ( 13)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
thyroid	cystic thyroid follicle	<25>				<15>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)	0 ( 0)
adrenal	spindle-cell hyperplasia	<25>				<15>			
		15 ( 60)	10 ( 40)	0 ( 0)	0 ( 0)	10 ( 67)	2 ( 13)	0 ( 0)	0 ( 0) *
[Reproductive system]									
ovary	granuloma	<25>				<15>			
		0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
uterus	atrophy	<25>				<15>			
		1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 7)	0 ( 0)	0 ( 0)	0 ( 0)
		<25>				<15>			
	cystic endometrial hyperplasia	10 ( 40)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 13)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0901  
 ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study				Posi. Control			
		Control 25				15			
		1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
<b>(Reproductive system)</b>									
vagina		<25>				<15>			
	inflammatory polyp	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	vascular anomaly	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
<b>(Nervous system)</b>									
brain		<25>				<15>			
	epidermal cyst	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

TABLE B 35

CAUSE OF DEATH: MALE

(Control and Positive control group)



STUDY NO. : 0900  
ANIMAL : Jic:CB6F1-Tg rash2@Jcl  
SEX : MALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

PAGE : 1

Group Name	Control	Posi. Control
Number of Dead and Moribund Animal	0	7
tumor d:leukemia	0	7
tumor d:spleen	0	0
tumor d:stomach	0	0
tumor d:pleura	0	0

(B10120)

BA1S6

TABLE B 36

CAUSE OF DEATH: FEMALE

(Control and Positive control group)

STUDY NO. : 0901  
ANIMAL : Jic:CB6F1-Tg rash20Jcl  
SEX : FEMALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

Group Name	Control	Posi. Control
Number of Dead and Moribund Animal	2	11
no microscop confirm	1	0
tumor d:leukemia	0	10
tumor d:skin/app	1	0
tumor d:stomach	0	1
tumor d:muscle	0	0
tumor d:peritoneum	0	0

(B10120)

BA1S6

4-(1,1,3,3-テトラメチルブチル)フェノールの rasH2 マウスを用いた  
強制経口投与による中期がん原性試験報告書

試験番号 : 0900, 0901

## FIGURES

## FIGURES

(Test substance-treated group)

FIGURE A 1 SURVIVAL ANIMAL RATE OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)

FIGURE A 2 SURVIVAL ANIMAL RATE OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)

FIGURE A 3 BODY WEIGHT CHANGES OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)

FIGURE A 4 BODY WEIGHT CHANGES OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)

FIGURE A 5 FOOD CONSUMPTION CHANGES OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)

FIGURE A 6 FOOD CONSUMPTION CHANGES OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)

## FIGURES (Positive control group)

FIGURE B 1 SURVIVAL ANIMAL RATE OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)

FIGURE B 2 SURVIVAL ANIMAL RATE OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)

FIGURE B 3 BODY WEIGHT CHANGES OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)

FIGURE B 4 BODY WEIGHT CHANGES OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)

FIGURE B 5 FOOD CONSUMPTION CHANGES OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)

FIGURE B 6 FOOD CONSUMPTION CHANGES OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)




FIGURE A 1 SURVIVAL ANIMAL RATE OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)




FIGURE A 2 SURVIVAL ANIMAL RATE OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)




FIGURE A 3 BODY WEIGHT CHANGES OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)




FIGURE A 4 BODY WEIGHT CHANGES OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)






FIGURE A 5 FOOD CONSUMPTION CHANGES OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)




FIGURE A 6 FOOD CONSUMPTION CHANGES OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL (GAVAGE STUDY)




FIGURE B 1 SURVIVAL ANIMAL RATE OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)




FIGURE B 2 SURVIVAL ANIMAL RATE OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)




FIGURE B 3 BODY WEIGHT CHANGES OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)




FIGURE B 4 BODY WEIGHT CHANGES OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)




FIGURE B 5 FOOD CONSUMPTION CHANGES OF MALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)




FIGURE B 6 FOOD CONSUMPTION CHANGES OF FEMALE *rasH2* MICE IN THE 26-WEEK CARCINOGENICITY STUDY OF *N*-NITRSO-*N*-METHYLUREA (GAVAGE STUDY)


4-(1,1,3,3-テトラメチルブチル)フェノールの rasH2 マウスを用いた  
強制経口投与による中期がん原性試験報告書

試験番号 : 0900, 0901


# PHOTOGRAPHS




Photograph 1  
Forestomach: Squamous cell papilloma  
Mouse, Male, 200 mg/kg, Animal No. 0900-1325 (H&E)  
Bar: 1000  $\mu$ m




Photograph 2  
High magnification of photograph 1  
Bar: 100  $\mu$ m




Photograph 3  
Forestomach: Squamous cell carcinoma  
Mouse, Male, 200 mg/kg, Animal No. 0900-1323 (H&E)  
Bar: 1000  $\mu$ m




Photograph 4  
High magnification of photograph 3  
Bar: 100  $\mu$ m




Photograph 5  
Liver: Hepatocellular hypertrophy: central  
Mouse, Male, 200 mg/kg, Animal No. 0900-1310 (H&E)  
Bar: 100  $\mu$ m




Photograph 6  
Kidney: Chronic nephritis  
Mouse, Female, 200 mg/kg, Animal No. 0901-2302 (H&E)  
Bar: 100  $\mu$ m




Photograph 7  
Thymus: Malignant lymphoma  
Mouse, Male, Positive control, Animal No. 0900-1401 (H&E)  
Bar: 1000  $\mu$ m




Photograph 8  
High magnification of photograph 7  
Bar: 50  $\mu$ m




Photograph 9  
Lung: Bronchiolar-alveolar adenoma  
Mouse, Male, Positive control, Animal No. 0900-1412 (H&E)  
Bar: 200  $\mu$ m



Photograph 10  
High magnification of photograph 9  
Bar: 50  $\mu$ m



Photograph 11  
Skin: Squamous cell papilloma  
Mouse, Male, Positive control, Animal No. 0900-1411 (H&E)  
Bar: 500  $\mu$ m



Photograph 12  
High magnification of photograph 11  
Bar: 100  $\mu$ m

4-(1,1,3,3-テトラメチルブチル)フェノールの rasH2 マウスを用いた  
強制経口投与による中期がん原性試験報告書

試験番号 : 0900, 0901

# APPENDICES



## APPENDICES

- APPENDIX 1-1 IDENTITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL
- APPENDIX 1-2 STABILITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL
- APPENDIX 2-1 IDENTITY OF *N*-NITROSO-*N*-METHYLUREA
- APPENDIX 2-2 STABILITY OF *N*-NITROSO-*N*-METHYLUREA
- APPENDIX 3-1 CONCENTRATION OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL
- APPENDIX 3-2 HOMOGENEITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL
- APPENDIX 4 CONCENTRATION OF *N*-NITROSO-*N*-METHYLUREA
- APPENDIX 5 STABILITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL IN THE OLIVE OIL (STUDY NO. 8042)
- APPENDIX 6 METHODS, UNITS AND DECIMAL PLACE FOR HEMATOLOGY AND BIOCHEMISTRY

## APPENDIX 1-1

### IDENTITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL

## IDENTITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL

Test Substance : 4-(1,1,3,3-Tetramethylbutyl) phenol (Tokyo Chemical Industry Co., Ltd.)

Lot No. : Y8LQL


## 1. Spectral Data

Infrared Spectrometry


Instrument : Shimadzu IRAffinity-1

Cell : KBr

Resolution : 4  $\text{cm}^{-1}$



Infrared Spectrum of Test Substance



Infrared Spectrum of Literature Data\*

Result: The infrared spectrum was consistent with literature spectrum.

\* Performed by National Institute of Advanced Industrial Science and Technology. Spectra Database for Organic Compounds, SDDBS.

[http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/cre\\_index.cgi](http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/cre_index.cgi) [accessed 2017/4/26]

2. Conclusion: The test substance was identified as 4-(1,1,3,3-tetramethylbutyl) phenol by infrared spectrum.

## APPENDIX 1-2

### STABILITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL

## STABILITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL

Test Substance : 4-(1,1,3,3-Tetramethylbutyl) phenol (Tokyo Chemical Industry Co., Ltd.)

Lot No. : Y8LQL


## 1. Spectral Data

Infrared Spectrometry


Instrument : Shimadzu IRAffinity-1

Cell : KBr

Resolution : 4 cm<sup>-1</sup>



Infrared Spectrum of Test Substance (before use)



Infrared Spectrum of Test Substance (after use)

Result: The infrared spectra were not changed before used on 2017.9.20 and after used on 2018.4.3.

2. Conclusion: The test substance was stable for the period that the test substance had been used for the study.

APPENDIX 2-1

IDENTITY OF *N*-NITROSO-*N*-METHYLUREA

IDENTITY OF *N*-NITROSO-*N*-METHYLUREATest Substance : *N*-Nitroso-*N*-Methylurea (Sigma-Aldrich Co. LLC.)


Lot No. : MKBQ7120V

## 1. Spectral Data


Infrared Spectrometry

Instrument : Shimadzu IRAffinity-1

Cell : KBr


Resolution : 4 cm<sup>-1</sup>

Infrared Spectrum of Test Substance



Infrared Spectrum of Literature\*1

\*1 Performed by National Institute of Advanced Industrial Science and Technology(AIST).  
Spectra Database for Organic Compounds, SDDBS.  
[http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/cre\\_index.cgi](http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/cre_index.cgi) [accessed 2017/8/7]



Infrared Spectrum of Additional Literature\*2

\*2 Performed by National Institute of Standards and Technology(NIST).  
NIST Chemistry WebBook, SRD 69  
<https://webbook.nist.gov/cgi/cbook.cgi?Name=684-93-5&Units=SI&cIR=on#IR-Spec>  
[accessed 2017/9/20]

Result: The infrared spectrum pattern and main absorption bands of structure bonds were consistent with literature spectrum(literature\*1) at C=O peaks (1750,1630,1230  $\text{cm}^{-1}$ ), N-NO peaks(1420,1380  $\text{cm}^{-1}$ ) and  $\text{NH}_2$  peaks(3300,1750  $\text{cm}^{-1}$ ). In addition, the infrared spectrum was consistent with literature spectrum(literature\*2)

2. Conclusion: The test substance was identified as *N*-nitroso-*N*-methylurea by infrared spectrum.



APPENDIX 2-2

STABILITY OF *N*-NITROSO-*N*-METHYLUREA

STABILITY OF *N*-NITROSO-*N*-METHYLUREA

Test Substance : *N*-Nitroso-*N*-Methylurea (Sigma-Aldrich Co. LLC.)

Lot No. : MKBQ7120V


## 1. Spectral Data

Infrared Spectrometry


Instrument : Shimadzu IRAffinity-1

Cell : KBr

Resolution : 4 cm<sup>-1</sup>



Infrared Spectrum of Test Substance (before use)



Infrared Spectrum of Test Substance (after use)

Result: The infrared spectra were not changed before used on 2017.9.20 and after used on 2018.4.3.

2. Conclusion: The test substance was stable for the period that the test substance had been used for the study.

APPENDIX 3-1

CONCENTRATION OF  
4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL

## CONCENTRATION OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL

Analytical Method : The samples were analyzed by high performance liquid chromatography.

Instrument : Shimadzu LC-10 High Performance Liquid Chromatograph

Column : Kinetex® 5 µm C18 100 Å (4.6 mm φ × 15 cm)

Column Temperature: 40 °C

Mobile Phase : Acetonitrile : Distilled Water = 75 : 25

Flow Rate : 1 mL/min

Detector : UV (294 nm)

Injection Volume : 10 µL

Date Analyzed	Target Concentration		
	10 <sup>a</sup>	20	40
2017.09.25	10.0 <sup>b</sup> (100) <sup>c</sup>	19.6 (98.0)	38.3 (95.8)
2017.12.20	9.75 <sup>b</sup> (97.5) <sup>c</sup>	19.7 (98.5)	39.2 (98.0)

<sup>a</sup> mg/mL

<sup>b</sup> mg/mL (Mean measured concentration)

<sup>c</sup> % (Mean measured concentration/target concentration × 100)

APPENDIX 3-2

HOMOGENEITY OF  
4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL

## HOMOGENEITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL

Analytical Method : The samples were analyzed by high performance liquid chromatography.

Instrument : Shimadzu LC-10 High Performance Liquid Chromatograph

Column : Kinetex® 5 µm C18 100 Å (4.6 mm φ × 15 cm)

Column Temperature: 40 °C

Mobile Phase : Acetonitrile : Distilled Water = 75 : 25

Flow Rate : 1 mL/min

Detector : UV (294 nm)

Injection Volume : 10 µL

Date Analyzed	Target Concentration		
	10 <sup>a</sup>	20	40
2017.09.25	1.00 <sup>b</sup>	1.53	1.57
2017.12.20	1.44 <sup>b</sup>	1.02	0.765

<sup>a</sup> mg/mL

<sup>b</sup> Coefficient of Variation (%), (n=7)

## APPENDIX 4

### CONCENTRATION OF *N*-NITROSO-*N*-METHYLUREA

CONCENTRATION OF *N*-NITROSO-*N*-METHYLUREA

Analytical Method : The samples were analyzed by high performance liquid chromatography.

Instrument : Shimadzu LC-10 High Performance Liquid Chromatograph

Column : L-ColumnODS 5  $\mu\text{m}$  (4.6 mm  $\phi$   $\times$  15 cm)

Column Temperature: 40  $^{\circ}\text{C}$

Mobile Phase : Distilled Water : Methanol = 95 : 5

Flow Rate : 1 mL/min

Detector : UV (210 nm)

Injection Volume : 10  $\mu\text{L}$

Study No.	Date Analyzed	Target Concentration
		7.5 <sup>a</sup>
0900	2017.09.26	7.97 <sup>b</sup> (106 ) <sup>c</sup>
0901	2017.09.28	7.49 ( 99.9)

<sup>a</sup> mg/mL

<sup>b</sup> mg/mL (Mean measured concentration)

<sup>c</sup> % (Mean measured concentration/target concentration  $\times$  100)



## APPENDIX 5

STABILITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL  
IN THE OLIVE OIL (STUDY NO. 8042)

STABILITY OF 4-(1,1,3,3-TETRAMETHYLBUTYL) PHENOL IN THE OLIVE OIL  
(STUDY NO. 8042)

Analytical Method : The samples were analyzed by high performance liquid chromatography.  
 Instrument : Shimadzu LC-10 High Performance Liquid Chromatograph  
 Column : Kinetex® 5 µm C18 100 Å (4.6 mm φ × 15 cm)  
 Column Temperature: 40 °C  
 Mobile Phase : Acetonitrile : Distilled Water = 75 : 25  
 Flow Rate : 1 mL/min  
 Detector : UV (294 nm)  
 Injection Volume : 10 µL

Date Analyzed	Target Concentration	
	0.6 <sup>a</sup>	60
2017.06.08	0.576 (100) <sup>b</sup>	56.7 (100)
2017.06.16 <sup>c</sup>	0.603 (105)	59.0 (104)

<sup>a</sup> mg/mL

<sup>b</sup> % (Percentage was based on the concentration at the date of preparation)

<sup>c</sup> The samples were stored in a dark place at refrigerated.

The data of stability of the test sample referred with the result of study No. 8042 on Japan Bioassay Research Center.

## APPENDIX 6

### METHODS, UNITS AND DECIMAL PLACE FOR HEMATOLOGY AND BIOCHEMISTRY

## METHODS, UNITS AND DECIMAL PLACE FOR HEMATOLOGY AND BIOCHEMISTRY

Item	Method	Unit	Decimal place
<b>Hematology</b>			
Red blood cell (RBC)	Hydrodynamically focussed DC detection method <sup>1)</sup>	$\times 10^6/\mu\text{L}$	2
Hemoglobin(Hgb)	SLS-Hemoglobin method <sup>1)</sup>	g/dL	1
Hematocrit(Hct)	Hydrodynamically focussed DC detection method <sup>1)</sup>	%	1
Mean corpuscular volume(MCV)	Calculated as $\text{Hct}/\text{RBC} \times 10$ <sup>1)</sup>	fL	1
Mean corpuscular hemoglobin(MCH)	Calculated as $\text{Hgb}/\text{RBC} \times 10$ <sup>1)</sup>	pg	1
Mean corpuscular hemoglobin concentration (MCHC)	Calculated as $\text{Hgb}/\text{Hct} \times 100$ <sup>1)</sup>	g/dL	1
Platelet	Hydrodynamically focussed DC detection method <sup>1)</sup>	$\times 10^3/\mu\text{L}$	0
Reticulocyte	Flow cytometry method using semiconductor laser <sup>1)</sup>	%	1
White blood cell(WBC)	Flow cytometry method using semiconductor laser <sup>1)</sup>	$\times 10^3/\mu\text{L}$	2
Differential WBC	Flow cytometry method using semiconductor laser <sup>1)</sup>	%	1
<b>Biochemistry</b>			
Total protein(TP)	Biuret method <sup>2)</sup>	g/dL	1
Albumin (Alb)	BCG method <sup>2)</sup>	g/dL	1
A/G ratio	Calculated as $\text{Alb}/(\text{TP}-\text{Alb})$ <sup>2)</sup>	—	1
T-bilirubin	BOD method <sup>2)</sup>	mg/dL	2
Glucose	GlcK·G-6-PDH method <sup>2)</sup>	mg/dL	0
T-cholesterol	CE·COD·POD method <sup>2)</sup>	mg/dL	0
Triglyceride	MGLP·GK·GPO·POD method <sup>2)</sup>	mg/dL	0
Phospholipid	PLD·ChOD·POD method <sup>2)</sup>	mg/dL	0
Aspartate aminotransferase (AST)	JSCC method <sup>2)</sup>	U/L	0
Alanine aminotransferase (ALT)	JSCC method <sup>2)</sup>	U/L	0
Lactate dehydrogenase (LDH)	JSCC method <sup>2)</sup>	U/L	0
Alkaline phosphatase (ALP)	JSCC method <sup>2)</sup>	U/L	0
$\gamma$ -Glutamyl transpeptidase ( $\gamma$ -GTP)	JSCC method <sup>2)</sup>	U/L	1
Creatine kinase (CK)	JSCC method <sup>2)</sup>	U/L	0
Urea nitrogen	Urease·GLDH method <sup>2)</sup>	mg/dL	1
Sodium	Ion selective electrode method <sup>2)</sup>	mEq/L	0
Potassium	Ion selective electrode method <sup>2)</sup>	mEq/L	1
Chloride	Ion selective electrode method <sup>2)</sup>	mEq/L	0
Calcium	OCPC method <sup>2)</sup>	mg/dL	1
Inorganic phosphorus	PNP·XOD·POD method <sup>2)</sup>	mg/dL	1

1) Automated Hematology Analyzer (XN-2000V : Sysmex Corporation)

2) Automatic analyzer (Hitachi 7080 : Hitachi,Ltd.)

## 4-(1, 1, 3, 3-テトラメチルブチル)フェノールの rasH2 マウスを用いた 強制経口投与による中期がん原性試験結果概要

日本バイオアッセイ研究センター

### 1 被験物質

#### 1-1 名称等


名 称：4-(1, 1, 3, 3-テトラメチルブチル)フェノール

別 名：4-*tert*-Octylphenol

CAS 番号：140-66-9

#### 1-2 構造式及び分子量（文献1）

構 造 式：



分 子 量：206.33

#### 1-3 物理化学的性状等（文献1, 2）

性 状：白色～ほとんど白色、結晶～粉末

融 点：83°C

沸 点：279°C

溶 解 性：水にほとんど溶けない、エタノール及びアセトンに溶けやすい

保管条件：室温、暗所に保管

#### 1-4 製造量等（文献3）

製造、輸入量：23,364 t（平成29年度）

#### 1-5 用途（文献1）

樹脂、非イオン界面活性剤及びゴム添加剤の製造の中間体

#### 1-6 許容濃度等

管理濃度：未設定

日本産業衛生学会：未設定

米国産業衛生専門家会議（ACGIH）：未設定

国際がん研究機関（IARC）：情報なし

ドイツ研究振興協会（DFG）：MAK value 0.5ml/m<sup>3</sup>(ppm) (4.3mg/m<sup>3</sup>)（文献4）

#### 1-7 遺伝毒性

微生物を用いる変異原性試験（Ames試験）：陰性（文献1, 5）

CHL/IU 細胞を用いる染色体異常試験：陽性（文献6）

## 2 目的

4-(1,1,3,3-テトラメチルブチル)フェノールを遺伝子改変マウス (rasH2 マウス) に 26 週間強制経口投与し、そのがん原性を検索した。

## 3 方法

媒体対照群、被験物質投与群 3 群及び陽性対照群 (*N*-Nitroso-*N*-methylurea, MNU) の計 5 群の構成で、媒体対照群と被験物質投与群は雌雄とも各 25 匹/群、陽性対照群は 15 匹/群とした。投与は毎日 1 回の強制経口投与 (26 週間)、陽性対照物質は単回腹腔内投与とした。投与用量は、雌雄とも、0 (オリブ油)、50、100 及び 200 mg/kg BW とし、陽性対照物質は、雌雄とも 75 mg/kg BW とした。観察、検査として、一般状態の観察、体重及び摂餌量の測定、血液学的検査、血液生化学的検査、尿検査、解剖時の肉眼的観察、臓器重量測定及び病理組織学的検査を行った。

## 4 26 週間試験の用量設定理由

本試験の投与用量は、4 週間 (28 日間) 用量設定試験の結果を基に設定した。雌雄の rasH2 マウス (non-Tg) を用いて、1 群当たり各 10 匹の動物に 0 (オリブ油)、30、100、200 及び 300 mg/kg BW の用量で、毎日、4 週間強制経口投与した。

その結果、雌雄とも全群で動物の死亡及び一般状態に毒性症状はみられなかった。体重は雌雄とも投与群でやや高値傾向で推移した。

被験物質の毒性標的器官は主に腎臓 (重量増加、近位尿細管の再生、顆粒状円柱、尿素窒素の高値等)、肝臓 (重量増加、小葉中心性の肝細胞肥大及び単細胞壊死、総コレステロール、トリグリセライド、リン脂質及び $\gamma$ -GTP の高値等) 及び造血系 (網赤血球比の高値、脾臓重量高値等) であると考えられた。この中で腎臓の雌雄 300 mg/kg に認められた近位尿細管の再生像は広範囲に認められ、尿細管への傷害も広範囲に起きたと判断できることから、300 mg/kg は 26 週間の投与には耐えられないと考えられる。一方、近位尿細管の再生像は 200 mg/kg でも全例にみられるものの、その程度は減弱していることから、200 mg/kg は 26 週間の投与に耐えうる用量であると判断した。したがって、本試験では、高用量を 200 mg/kg BW に設定し、公比 2 で除して中用量を 100 mg/kg BW、低用量を 50 mg/kg BW とした。

陽性対照物質の投与用量は、国際共同検証試験 (ILSI/HESI) (文献 7) の方法を参考に、雌雄ともに 75 mg/kg BW とした。

## 5 結果

動物の生存率は、雌雄とも媒体対照群と比較して差を認めなかった (生存率: 図 1)。一般状態では、雌雄とも被験物質投与の影響と考えられる異常所見は認められず、体重及び摂餌量も投与期間を通して媒体対照群との間に顕著な差は認めなかった (体重推移: 図 2)。

## 病理組織学的検査の結果

—雄—

### ① 腫瘍性病変 (表 1)

本試験は rasH2 マウスを用いた 26 週間がん原性試験の初回報告であり、当センターで行った対照群の蓄積データがないため、rasH2 マウスの背景データを取得する目的で、本試験に先立って実施した無処置動物 50 匹のデータをがん原性評価の参考とした。また、文献 (文献 8, 9, 10) のヒストリカルコントロールデータ (雌雄 rasH2 マウス) もがん原性評価の参考とした。

#### <胃 (前胃) >

雄では胃 (前胃) の扁平上皮乳頭腫の発生が、媒体対照群、50 mg/kg 群及び 100 mg/kg 群で 0 匹 (0 %) に対し、200 mg/kg 群で 2 匹 (8 %) みられ、Peto 検定 (有病率法) と Cochran-Armitage 検定で有意な増加を示した。扁平上皮癌の発生 (200 mg/kg 群 1 匹、4 %) は有意な増加は示さなかったが、扁平上皮乳頭腫と扁平上皮癌を合わせた発生 (200 mg/kg 群 3 匹、12 %) は、Peto 検定 (有病率法、死亡率法+有病率法) と Cochran-Armitage 検定で有意な増加を示した。

雄の胃の扁平上皮乳頭腫は、発生が極めて稀な腫瘍であり、当センターの雄 rasH2 マウス (無処置動物) 50 匹の発生率は 2 % (1/50 匹) であった。また、文献のヒストリカルコントロールデータでは、Paranjpe ら (文献 8) は平均 0.28 %、Nambiar ら (文献 9) は平均 0.6 %、Takaoka ら (文献 10) は平均 0.6 %と報告されている。これらの報告の試験単位での最大発生率は 6.7 %であり、本試験の 200 mg/kg 群の扁平上皮乳頭腫の発生 (2/25 匹、8 %) は、試験単位での最大発生率を超えていることから、被験物質投与による影響と考えた。

扁平上皮癌も発生が極めて稀な腫瘍であり、当センターの背景データの発生率は 2 % (1/50 匹) であった。文献データでは、Paranjpe らは平均 0.56 %、Nambiar らは平均 0.3 %、Takaoka らは平均 0.6 %と報告されている。これらの報告の試験単位での最大発生率は 6.7 %であり、本試験の 200 mg/kg 群の扁平上皮癌の発生 (1/25 匹、4 %) は、この範囲内であるものの試験単位での上限に近い発生率であった。これらのことを考慮し、扁平上皮乳頭腫と扁平上皮癌を合わせた発生 (3/25 匹、12 %) も被験物質投与による影響と考えた。

従って、雄に認められた胃の扁平上皮乳頭腫、及び扁平上皮乳頭腫と扁平上皮癌を合わせた発生増加は、rasH2 マウスに対するがん原性を示す証拠と考えられた。

### ② 非腫瘍性病変

#### <腎臓>

慢性腎炎の発生増加が 200 mg/kg 群で認められ、病変の程度は軽度から中等度であった。なお、100 mg/kg 群でも 1 匹に発生がみられた。慢性腎炎は、ネフロン単位で変性・壊死が認められ、尿細管の再生や線維化が認められた。

#### <肝臓>

小葉中心性の肝細胞肥大の発生増加が 200 mg/kg 群で認められ、病変の程度はいずれも軽度であった。なお、100 mg/kg 群でも 1 匹に発生がみられた。

—雌—

#### ① 腫瘍性病変（表 2）

被験物質投与による腫瘍の発生増加は認められなかった。

#### ② 非腫瘍性病変

#### <腎臓>

慢性腎炎の発生増加と程度の増強が 100 mg/kg 群と 200 mg/kg 群で認められ、病変の程度は 100 mg/kg 群が軽度から中等度、200 mg/kg 群が中等度から重度であった。慢性腎炎は、ネフロン単位で変性・壊死が認められ、尿細管の再生や線維化が認められた。

### 6 まとめ

rasH2 マウスを用いて、4-(1, 1, 3, 3-テトラメチルブチル)フェノールの 26 週間にわたる強制経口投与によるがん原性試験を行った結果、

- 1) 雄 rasH2 マウスに対するがん原性を示す証拠が得られた (some evidence of carcinogenic activity) と結論された。
- 2) 雌 rasH2 マウスに対するがん原性を示す証拠は得られなかった (no evidence of carcinogenic activity) と結論された。

### 7 陽性対照物質 (*N*-Nitroso-*N*-methylurea: MNU) の評価（表 3, 4）

陽性対照物質として、MNU を単回腹腔内投与（雌雄 15 匹、75 mg/kg BW）し、26 週間飼育した。

腫瘍性病変の発生は、雄では皮膚の扁平上皮乳頭腫、肺の細気管支-肺胞上皮腺腫と細気管支-肺胞上皮癌を合わせた発生、胸腺の悪性リンパ腫、胃の扁平上皮乳頭腫、及び扁平上皮癌の発生が、それぞれ Fisher 検定で有意な増加を示した。7 匹の途中死亡動物の死因は全て悪性リンパ腫であり、担腫瘍動物数は、媒体対照群 2 匹（8 %）に対し、陽性対照群 15 匹（100 %）であった。

雌では、胃の扁平上皮乳頭腫、及び扁平上皮乳頭腫と扁平上皮癌を合わせた発生、胸腺、脾臓及び全臓器の悪性リンパ腫の発生が Fisher 検定で有意な増加を示した。11 匹の途中死亡動物の死因は 10 匹が悪性リンパ腫、1 匹が胃の腫瘍であり、担腫瘍動物数は、媒体対照群 5 匹（20 %）に対し、陽性対照群 15 匹（100 %）であった。

以上の結果より、雌雄とも陽性対照物質（MNU）投与による明らかな腫瘍の発生増加が認められ、本試験系の有効性が確認された。



表1 4-(1,1,3,3-テトラメチルブチル)フェノールの中期がん原性試験における腫瘍発生 (rasH2 マウス 雄)

投与用量 (mg/kg)		0	50	100	200	Peto 検定	Cochran- Armitage 検定
検査動物数		25	25	25	25		
肺 胃 (前胃)	細気管支-肺胞上皮腺腫	1	4	1	1		
	扁平上皮乳頭腫	0	0	0	2	↑	↑
	扁平上皮癌 <sup>#</sup>	0	0	0	1		
	扁平上皮乳頭腫	0	0	0	3	↑↑	↑↑
	+扁平上皮癌 <sup>#</sup>						
鼻腔 脾臓	血管腫	0	1	0	0		
	血管腫	1	0	0	0		
	血管肉腫 <sup>#</sup>	0	1	0	2		
	血管腫+血管肉腫 <sup>#</sup>	1	1	0	2		
小腸	血管肉腫 <sup>#</sup>	0	0	0	1		
	膀胱	0	1	0	0		
胸膜	血管腫	0	0	0	1		
	血管肉腫 <sup>#</sup>	0	1	0	0		
	血管腫+血管肉腫 <sup>#</sup>	0	1	0	1		
全臓器	血管腫	1	2	0	1		
	血管肉腫 <sup>#</sup>	0	2	0	3		

上段：上皮系腫瘍 下段：非上皮系腫瘍

#：悪性腫瘍

\*： $p \leq 0.05$  で有意

\*\*： $p \leq 0.01$  で有意

(Fisher 検定)

↑： $p \leq 0.05$  で有意増加

↑↑： $p \leq 0.01$  で有意増加

(Peto, Cochran-Armitage 検定)

↓： $p \leq 0.05$  で有意減少

↓↓： $p \leq 0.01$  で有意減少

(Cochran-Armitage 検定)

表2 4-(1,1,3,3-テトラメチルブチル)フェノールの中期がん原性試験における腫瘍発生 (rasH2 マウス 雌)

投与用量 (mg/kg)		0	50	100	200	Peto 検定	Cochran- Armitage 検定
検査動物数		25	25	25	25		
肺	細気管支-肺胞上皮腺腫	3	3	2	0		
	細気管支-肺胞上皮癌 <sup>#</sup>	0	0	1	0		
	細気管支-肺胞上皮腺腫 +細気管支-肺胞上皮癌 <sup>#</sup>	3	3	3	0		
	胃 (前胃)						
	扁平上皮癌 <sup>#</sup>	0	0	0	1		
鼻腔	血管腫	0	0	1	0		
脾臓	血管肉腫 <sup>#</sup>	0	0	1	0		
唾液腺	血管腫	1	0	0	0		
子宮	血管腫	0	0	1	0		
筋肉	血管腫	0	0	0	1		
腹膜	血管肉腫 <sup>#</sup>	0	1	0	0		
全臓器	血管腫	1	0	2	1		
	血管肉腫 <sup>#</sup>	0	1	1	0		

上段：上皮系腫瘍 下段：非上皮系腫瘍

#：悪性腫瘍

\*： $p \leq 0.05$  で有意

\*\*： $p \leq 0.01$  で有意

(Fisher 検定)

↑： $p \leq 0.05$  で有意増加

↑↑： $p \leq 0.01$  で有意増加

(Peto, Cochran-Armitage 検定)

↓： $p \leq 0.05$  で有意減少

↓↓： $p \leq 0.01$  で有意減少

(Cochran-Armitage 検定)





図1 4-(1, 1, 3, 3-テトラメチルブチル)フェノールの中期がん原性試験における生存率 (rasH2 マウス)





図2 4-(1, 1, 3, 3-テトラメチルブチル)フェノールの中期がん原性試験における体重推移 (rasH2 マウス)

表3 陽性対照 (*N*-Nitroso-*N*-methylurea) の中期がん原性試験における腫瘍発生 (rasH2 マウス 雄)

投与用量 (mg/kg)		媒体対照	陽性対照
		0	75
検査動物数		25	15
皮膚	扁平上皮乳頭腫	0	3 *
	肺		
	細気管支-肺胞上皮腺腫	1	4
	細気管支-肺胞上皮癌 <sup>#</sup>	0	1
	細気管支-肺胞上皮腺腫	1	5 *
	+細気管支-肺胞上皮癌 <sup>#</sup>		
胃 (前胃)	扁平上皮乳頭腫	0	15 **
	扁平上皮癌 <sup>#</sup>	0	4 *
	扁平上皮乳頭腫	0	15 **
	+扁平上皮癌 <sup>#</sup>		
胸腺	悪性リンパ腫 <sup>#</sup>	0	8 **

表4 陽性対照 (*N*-Nitroso-*N*-methylurea) の中期がん原性試験における腫瘍発生 (rasH2 マウス 雌)

投与用量 (mg/kg)		媒体対照	陽性対照
		0	75
検査動物数		25	15
胃 (前胃)	扁平上皮乳頭腫	0	13 **
	扁平上皮癌 <sup>#</sup>	0	2
	扁平上皮乳頭腫	0	13 **
	+扁平上皮癌 <sup>#</sup>		
リンパ節	悪性リンパ腫 <sup>#</sup>	0	2
胸腺	悪性リンパ腫 <sup>#</sup>	0	6 **
脾臓	悪性リンパ腫 <sup>#</sup>	0	3 *
全臓器	悪性リンパ腫 <sup>#</sup>	0	11 **

上段：上皮系腫瘍 下段：非上皮系腫瘍

#：悪性腫瘍

\*： $p \leq 0.05$  で有意 \*\*： $p \leq 0.01$  で有意 (Fisher 検定)

## 文献

1. Organisation for Economic Co-operation and Development (OECD). 1995. OECD SIDS. PHENOL, 4-(1,1,3,3-TETRAMETHYLBUTYL)-. SIDS Initial Assessment Report for SIAM3.
2. 東京化成工業(株). 2017. 4-(1,1,3,3-Tetramethylbutyl)phenol 安全データシート.
3. 経済産業省. 2019. 優先評価化学物質の製造・輸入数量 (29年度実績)
4. Deutsche Forschungsgemeinschaft (DFG) 2018. 4-tert-Octylphenol: MAK Value Documentation. The MAK Collection for Occupational Health and Safety 2018, Vol 3, No 3 pp1137-1150.
5. 日本化学物質安全・情報センター編. 2000. 労働安全衛生法有害性調査制度に基づく既存化学物質変異原性試験データ集, 東京: 日本化学物質安全・情報センター, 補遺2版. 95-98.
6. 日本化学物質安全・情報センター編. 2008. 労働安全衛生法有害性調査制度に基づく既存化学物質変異原性試験データ集, 東京: 日本化学物質安全・情報センター, 補遺4版. 190-191.
7. Robinson DE, MacDonald JS. 2001. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. *Toxicol Pathol* 29 (Suppl.): 13-19.
8. Paranjpe MG, Elbekaei RH, Shah SA, Hickman M, Wenk ML, Zahalka EA. 2013. Historical control data of spontaneous tumors in transgenic CByB6F1-Tg (HRAS)2Jic (Tg. rash2) mice. *Int J Toxicol* 32: 48-57.
9. Nambiar PR, Turnquist SE, Morton D. 2012. Spontaneous tumor incidence in rash2 mice: review of internal data and published literature. *Toxicol Pathol* 40: 614-623.
10. Takaoka M, Sehata S, Maejima, T, Imai T, Torii M, Satoh H, et al. 2003. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rash2 transgenic mice. *Toxicol Pathol* 31: 191-199.